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This thesis investigates whether the formation of ion-pairs can influence the delivery of 
salbutamol to the airways of the lung. Presenting a drug with an excess of oppositely 
charged ion can force it to form an ion-pair complex, and this complex can modify a drug’s 
dissolution or transport across epithelia without chemically altering the drug. The binding of 
salbutamol with pharmaceutically relevant counter ions was studied. It was found that the 
larger more hydrophobic counter ions bound more tightly to the drug. Only 2 of the 
investigated counter ions had a significant effect on the LogD7.4 of salbutamol. Phytic acid 
was investigated as a novel counter ion. Generation of phytic acid derivatives was 
attempted via chemical synthesis however this method did not yield a pure sample. The 
binding of phytic acid was studied and was found to be stronger than the other 
investigated counter ions, although no change in the logD7.4 of salbutamol was observed. 
Salbutamol ion-pair dry powders with particle size < 5 μm were generated via spray drying. 
Impactor testing found that the powders were in the respirable range. Stability testing after 
4 weeks found that the powders containing both PVP and l-leucine were the most stable 
after this time. The biocompatibility of the counter ions with Calu-3 human bronchial 
epithelial cells was assessed and all counter ions were shown to be well tolerated. The 
effect of the ion-pairs on the transport of salbutamol across a monolayer of Calu-3 cells 
found a significant difference in the transport of the sulfate, gluconate and phytate ion-
pairs when compared with salbutamol base. There was no significant difference in the 
dissolution of the phytate or octanoate powders when compared with the base. An in vivo 
bronchoprotection study of salbutamol base and phytate was performed. The work in this 
thesis suggests that an ion-pairing strategy is suitable for use to prolong drug action in the 
lung. 
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1.1 Background 
The pulmonary system is an attractive route of administration for both locally and 
systemically acting agents for several reasons. The lungs have an incredibly large surface 
area, up to 100 m2 in the average human adult, and because the primary function of the 
lungs is gas exchange, the absorptive barrier a systemically acting drug would face in the 
deep lung is extremely thin in comparison with other routes of administration: the 
epithelium of the alveoli is only around 0.2 μm in thickness (Patton, 1996, Patton et al., 
2004). Furthermore, delivering systemic drugs via the lung has the benefit of bypassing 
the hepatic first pass effect (Labiris and Dolovich, 2003a). For drugs that act in the lung, 
delivery directly to the site of action allows for a smaller dose to be given to achieve the 
same therapeutic effect as if the drug was dosed systemically which minimizes side-effects 
(Pilcer and Amighi, 2010b). Finally, both locally and systemically acting drugs benefit from 
a rapid onset of action when delivered via the lungs (Patton and Byron, 2007).  
However, formulating an effective inhaled medicine also poses several problems. The 
lungs are well adapted to prevent unwanted and potentially harmful airborne particles from 
entering the body. The structure of the lungs encourages impaction of particles high in the 
airways where the barriers to drug absorption are more extreme and the lung contains 
many effective clearance mechanisms (Chow et al., 2007). Even the rapid absorption of 
medicines in to the blood can be thought of as a clearance mechanism (Patton and Byron, 
2007). The result of this is that many inhaled drugs are only therapeutically effective for a 
very short amount of time, meaning that frequent dosing is required (Zeng et al., 1995). An 
ideal inhaled formulation should successfully navigate the anatomy of the lung and avoid 
the rapid clearance mechanisms to provide an extended period of action of the therapeutic 
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agent at an appropriate concentration, thus reducing the frequency of doses, minimizing 
fluctuations in drug concentration and increasing patient compliance (Beck-Broichsitter et 
al., 2012). To achieve this, an effective strategy to prolong drug action in the lungs is 
needed. 
Extending the therapeutic action of a drug can be achieved by controlling the delivery in a 
number of ways including: decreasing the rate of dissolution; decreasing the absorption 
rate in to tissues; or increasing tissue retention time. Each of these changes would 
effectively create a drug reservoir to be drawn upon for an extended period of time.  A 
number of strategies have been employed in an attempt to prolong drug action in the 
lungs. These include the use of liposomes, nanoparticles and prodrugs (Elhissi, 2017, 
Vaughn et al., 2006, Zeng et al., 1995). However, all of these methods face problems of 
their own, including poor stability and toxicity (De Jong and Borm, 2008, Loira-Pastoriza et 
al., 2014b) and therefore the need for an inhaled formulation with prolonged drug action 
has not yet been met. One strategy that has been used to control the delivery of drugs via 
other routes of administration is the use of ion-pairs (ElShaer et al., 2014, Megwa et al., 
2000), though this method has not yet been fully explored for inhaled medicines (Patel et 
al., 2016). This thesis aims to explore the feasibility of using an ion-pair formulation to 
prolong drug action in the lungs. However, first there is a need to understand the 
processes which all inhaled medicines undergo upon administration.   
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1.2 Drug delivery to the lungs 
1.2.1 Pulmonary physiology 
The first barrier any inhaled formulation faces is the structure of the lung, therefore 
understanding of the organ’s structure is vital when considering design of a new medicine. 
The airways of the lung are classically divided in to two sections: the conducting zone and 
the respiratory zone (figure 1.1). The conducting zone is made up of the nose, mouth, 
trachea, bronchi, and bronchioles up to the terminal bronchioles and the function of this 
zone is to slow and humidify the air before it reaches the respiratory zone (Smyth and 
Hickey, 2011). To do this the branching system undergoes 17 bifurcations, becoming 
increasing thinner as the respiratory zone is reached (Patton, 1996). The respiratory zone 
begins at the respiratory bronchioles, the first to have alveoli, and finishes at the alveolar 
ducts which consist of alveolar sacs (West, 2008). The function of the respiratory zone is 
gas exchange, and due to this the alveoli have an extremely large surface area, an 
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Figure 1.1 - Diagram of the branching of the conducting and respiratory zones of the airways. From 
Patton (1996) 
 
As the two zones of the respiratory system have different functions, the cells that line the 
epithelia of these zones are physically and biologically diverse. The differences in these 
cells can drastically affect how they interact with a pharmaceutical agent. The upper 
airways are lined with columnar ciliated epithelial cells which get gradually thinner as you 
progress further down the bifurcations (Patton and Byron, 2007). Amongst the ciliated cells 
are the mucus producing goblet cells, and these two types of cells together make up the 
mucociliary escalator, an important mechanism of clearance for the airways (figure 1.2) 
(Knight and Holgate, 2003). Basal cells are also present in this region. These cells provide 
structural support, anchoring other cells to the basement membrane, and are also thought 
to be progenitor cells for the ciliated and goblet cells (Knight and Holgate, 2003). The cells 
that make up the epithelium of the alveoli exist as a monolayer and are classified as either 
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Type I or Type II pneumocytes (Payne and Wellikoff, 2012). The surface area of the alveoli 
is predominantly Type I cells, making up around 95% of the alveolar epithelium, they are 
thin cells that provide a minimal barrier between the airspace and the pulmonary blood 
supply in order to maximize gas exchange (Castranova et al., 1988). The function of the 









Figure 1.2 - Sizes of cells and lung surfactant found in the airways. From Patton and Byron (2007) 
 
The composition of the lung lining fluid also changes between the conducting and 
respiratory zones of the lung. The conducting airways are lined with two layers: a mucus 
gel and periciliary sol that ranges from 5 – 100 μm in depth (Widdicombe and Widdicombe, 
1995, Ng et al., 2004). The mucus contains many glycoproteins, proteins and 
phospholipids, and its main function is to trap inhaled material while the sol allows the 
beating of the cilia on the epithelial cells to move the fluid towards the mouth (Widdicombe 
and Widdicombe, 1995, Widdicombe, 2002). In contrast, the alveolar regions of the lung 
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are lined with a very thin layer, 0.1 – 0.2 μm deep, of alveolar subphase fluid and 
surfactant (Ng et al., 2004). The composition of surfactant comprises primarily of 
phospholipids (~ 90%), as well as proteins and some carbohydrates (Van Golde et al., 
1988). The principal function of lung surfactant is to lower the surface tension of the air-
liquid interface and help prevent the alveoli from collapsing after expiration (Van Golde et 
al., 1988). Lung surfactant also plays a role in response to infection, aiding in the 
eradication of bacteria and enhancing phagocytosis by macrophages found in the alveoli 
(Castranova et al., 1988).  
1.2.2 Administration of medicines to the lung 
With an understanding of the structure of the lungs, the next thing to consider is how an 
inhaled medicine will be administered as this will fundamentally influence formulation 
design. The three main classifications of devices used to aerosolize medicines for 
inhalation are nebulizers, pressurized metered dose inhalers (pMDIs) and dry powder 
inhalers. Each of these requires a different approach to formulation and will present 
different advantages and challenges for formulating an inhaled medicine with prolonged 
drug action.  
1.2.2.1 Nebulization 
Nebulizers are devices that convert a solution or suspension of a drug in to inhalable 
droplets that target the lower respiratory tract (Dolovich and Dhand, 2011, Myers, 2013). 
There are 3 categories of nebulizer depending on how they achieve aerosolization. These 
are jet, ultrasonic and mesh. Jet nebulizers use compressed air or oxygen to create an 
area of low pressure that draws the solution of drug up and causes it to form droplets as it 
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joins the gas stream (Labiris and Dolovich, 2003b). Ultrasonic nebulizers use an ultrasonic 
wave generated by a piezoelectric crystal to break up a liquid into a vapor mist (Dolovich 
and Dhand, 2011). Mesh nebulizers use electricity to vibrate a piezo plate and force the 
liquid drug through a fine mesh generating an inhalable mist (Myers, 2013). Use of all 
types of nebulizers requires a power source and up until fairly recently were large pieces 
of equipment with limited portability and long treatment times which are all disadvantages 
for therapies which require frequent dosing (Dolovich and Dhand, 2011). Modern 
nebulizers, such as the Respimat®, were created to overcome these challenges (Stein and 
Thiel, 2017). Minimal patient cooperation is required for effective dosing from these 
devices and so they are ideal for delivery to infants, the elderly or critically ill patients 
(Myers, 2013).  
1.2.2.2 Pressurized Metered Dose Inhalers 
Pressurized Metered Dose inhalers (pMDIs) are portable, cheap aerosolization devices 
that contain multiple doses of a medicine (Labiris and Dolovich, 2003b, Dolovich and 
Dhand, 2011). pMDIs use a propellant under pressure to force a reproducible dose 
through an atomization nozzle to achieve aerosolization (Dolovich and Dhand, 2011). 
Traditionally chlorofluorocarbons (CFCs) were used as propellants, until they were banned 
by the United Nations due to their deleterious effect on the ozone layer (Labiris and 
Dolovich, 2003b). They were replaced by hydrofluoralkanes (HFAs), which are non-toxic 
and do not affect the ozone layer, though they do have a nominal contributution to global 
warming (Dolovich and Dhand, 2011, Cripps et al., 2000). Although pMDIs are commonly 
used they are typically inefficient, only depositing between 10 – 20% of the given dose in 
to the lung (Lavorini and Corbetta, 2008). pMDIs dose larger particles at a high velocity 
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which causes a large amount of the dose to impact in the oropharyngeal region (Labiris 
and Dolovich, 2003b, Myers, 2013). Furthermore, they require a high degree of hand-
breath coordination from the patient (Fink et al., 2013). The best technique is to release 
the dose at the start of a deep, slow breath and then to hold the breath for 10 seconds to 
allow any smaller particles to be deposited and not immediately exhaled. Accessories for 
pMDIs such as spacers and holding chambers can alleviate the problems associated with 
poor patient technique by slowing the aerosols velocity before it is inhaled, however these 
also reduce the portability of the devices (Labiris and Dolovich, 2003b, Myers, 2013).  
1.2.2.3 Dry Powder Inhalers 
Dry powder inhalers (DPI) deliver a powdered formulation, either pure drug or formed with 
a bulk excipient such as lactose, for inhalation (Myers, 2013). Typically DPIs are breath-
actuated, powered by the patient’s own inhalation, which directs air through a reservoir of 
particles of the drug and drives them into the airways of the patient by means of a 
turbulent flow that allows the particles to disperse in to a respirable size (Gac et al., 2008). 
There are many different types of DPI: some devices are single dose that must be 
reloaded by the user; some are multi-dose by the use of blister packs or a reservoir of 
powder. On top of the different methods of use each of the different DPI devices has a 
different air flow resistance, which means that they require a differing amount of inspiratory 
effort to achieve an optimal inhaled dose (Dekhuijzen et al., 2013). The downside of this is 
that an increased variability of devices and their methods of use could be confusing to 
patients. Furthermore, even though the higher resistance devices reportedly give greater 
lung deposition they might not be suitable for use with small children, the elderly, or 
patients with chronic obstructive pulmonary disease (COPD) due to the increased effort 
needed to deaggregate the powder for inhalation (Dekhuijzen et al., 2013). Depending on 
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the device and drug formulation DPIs can deliver anywhere between 10 – 40% of the 
medicine to the lungs (Islam and Cleary, 2012). Inefficiency with these devices is usually 
caused by the powder forming large aggregates which cannot be broken up by the 
turbulent air and this problem can be aggravated by increased humidity, i.e. from 
exhalation, in the device (Labiris and Dolovich, 2003b). The advantages of using a DPI are 
that they are very portable devices and because they are breath actuated they don’t 
require the same level of coordination as an MDI would (Sou et al., 2011).  
Although each of these delivery systems could be used to administer a formulation that 
prolongs drug action to the lungs, using a dry powder or pMDI solution could be more 
beneficial as the administered drug would need to dissolve in the lung lining fluid. Limiting 
the rate of dissolution could be a useful mechanism in creating an inhaled formulation with 
prolonged drug action and so administering the formulation as solid particles would be 
preferred. 
1.2.2.4 Aerosol deposition 
Regardless of the device used to administer aerosols to the lung, an understanding of the 
mechanisms by which particles or droplets are deposited in the lungs is essential to 
ensure a maximum deposition at the site of action. Factors such as the size, density, 
charge and morphology of particles are known to affect deposition in the lung (Heyder, 
2004) and so all of these things must be taken in to account when designing an inhaled 
formulation. There are 5 mechanisms by which particles can deposit in the lungs: 
impaction, diffusion, sedimentation, electrostatic precipitation and interception; however 
the first 3 mechanisms are the predominant means by which therapeutic aerosols deliver 
drugs to the lungs (Lippmann et al., 1980). The deposition profile for varying sizes of 
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spherical particles of density 1 g/cm3 is well understood and documented (figure 1.3). 
However drug particles for inhalation do not necessarily adhere to these characteristics 
and so calculation of their aerodynamic diameter is used to equate all particles (Edwards 








Figure 1.3 - Relationship between diameter of unit density spheres and their mechanism of deposition. 
From Heyder (2004) 
 
The aerodynamic diameter is defined as the diameter of a sphere of standard density that 
settles at the same terminal velocity as the particle of interest (DeCarlo et al., 2004). As 
sedimentation and inertial impaction of a particle depend on the aerodynamic diameter, 
this characteristic has been used for many years to analyse where a particle is deposited 
in the lungs (Edwards et al., 1998). The aerodynamic diameter of a particle is given by 
equation 1.1. 
da = d√ρ/ρo                                                                                    [Equation 1.1] 
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Where d is the geometric particle diameter, ρ is the density of the particle;                                                                       
ρo is the unit density (1 g/cm
3) 
Inertial impaction occurs for particles that are travelling at a high velocity. Inhaled air 
changes direction with the branching of the airways, however high velocity particles tend 
not to be able to follow this change in direction, remaining instead on their predetermined 
path and impinging on the airway walls (Lippmann et al., 1980, Hickey, 2003). The 
occurrence of impaction increases with particle size and density, and is mainly seen in the 
upper airway (Bisgaard et al., 2001, Lippmann et al., 1980). Sedimentation occurs 
primarily in the smaller airways: the smaller bronchi; the bronchioles and alveolar spaces 
(Lippmann et al., 1980). This mechanism of deposition is governed by gravitational forces 
upon the particles when the air velocity is low (Newman, 1985). Deposition via diffusion 
occurs in the small airways and alveoli for particles that have a terminal velocity less than 
~ 0.001 cm/s, which equates to a particle size of around 0.5 μm (Lippmann et al., 1980). 
Particles this small are subject to Brownian motion, collision with gas molecules in the air 
causing random directional changes (Bisgaard et al., 2001). However, particles of this size 
may also not be deposited at all and instead can be exhaled (Newman, 1985).  
Control over the properties of an aerosol formulation, such as size, shape and density, is 
therefore essential to allow adequate deposition to the site of action for both locally 
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Figure 1.4 - Mechanisms of pulmonary particle deposition. From (Stellman and Office, 1998) 
 
1.2.2.5 Dissolution 
Following deposition in the lung, an inhaled particle must then be dissolved in the lung 
lining fluid before it can reach the pulmonary epithelium or be subject to the lungs’ 
clearance mechanisms. The definition of dissolution is the process by which a solid 
substrate enters in to a solvent to yield a solution and there are many factors in the lung 
which could influence this (Davies and Feddah, 2003). The solubility of any drug is 
dependent on the structure of the drug, its formulation and physical properties, as well as 
the solvent in which it is to be dissolved (Olsson et al., 2011). In the lungs the site of 
deposition can also impact the dissolution of the drug due to the differences in the lung 
lining fluid (Olsson et al., 2011). The composition of the epithelial lining fluid is mainly 
water (96%) and so hydrophilic drugs will have rapid dissolution, the alveolar region, on 
the other hand, is lined with a surfactant with a high concentration of phospholipids and 
proteins that can increase the solubility of more hydrophobic molecules. Furthermore, 
smaller particles will present a greater surface area to the lung fluid, allowing for enhanced 
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dissolution, as will presenting the drug in a more disordered, amorphous, state (Khadka et 
al., 2014).  
The primary reason that dissolution is thought to be rate-limiting in the lung is due to the 
very small volume of fluid that a particle will deposit in (Patton et al., 2010). The total 
volume of fluid in the lung ranges from 10 – 30 mL and at any one point its thickness can 
range from ~ 0.1 μm in the alveoli to a maximum of  100 μm in the upper airways (Olsson 
et al., 2011, Widdicombe and Widdicombe, 1995). Therefore some particles deposited in 
the lower airways could potentially be in fluid with a much thinner depth than their diameter 
(Olsson et al., 2011). There have been multiple studies that have shown the effect that 
altering dissolution profiles of inhaled drugs can have both in vitro and in vivo (Davies and 
Feddah, 2003, Yang et al., 2008a, Freiwald et al., 2005), however there have yet to be any 
studies that highlight the importance of dissolution in the clinic (Patton et al., 2010). 
Furthermore there is still discussion around an appropriate method to assess dissolution in 
a way that could be predictive of the situation in vivo (Arora et al., 2010). Pulmonary 
dissolution has been shown to be a rate-limiting step for some inhaled medicines 
(Borghardt et al., 2015), and so it is very possible that control over the rate of dissolution of 
an inhaled medicine could be used in a therapy that extends drug action.   
1.2.2.6 Absorption 
The subsequent barrier an inhaled drug particle faces is absorption across the pulmonary 
epithelium. The desired effect of absorption will differ depending on if the drug molecule is 
intended for local or systemic therapy. For systemic medicines administered via the lungs 
the absorption profile will regulate the onset and duration of action, however rapid 
absorption in to the blood can lead to a short duration of action for locally acting 
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medicines, and so for these drugs lung tissue retention may be ideal (Ehrhardt and Kim, 
2007).  The mechanisms by which drug molecules are absorbed are classified as either 
passive or active. Small hydrophobic molecules are thought to absorb in to the respiratory 
epithelium by transcellular diffusion, whereas hydrophilic compounds travel paracellularly, 
through intercellular spaces (Loira-Pastoriza et al., 2014a). Due to the difference in 
mechanisms, hydrophobic molecules are known to be absorbed much more rapidly than 
hydrophilic molecules and the absorption rate of hydrophilic compounds is inversely 
related to their molecular weight for molecules in the range of 60 – 75 kDa (Liu et al., 
2013, Ehrhardt and Kim, 2007). It is also thought that less ionized molecules have a faster 
absorption rate due to having fewer interactions with proteins and lipids surrounding the 
intercellular pores (Liu et al., 2013). In addition to this the site of deposition of the drug 
affects its absorption rate. Absorption will occur much more readily in the alveolar space 
where the surface area is much greater and the epithelial cells are very thin (0.1 – 0.4 μm) 
in comparison with the tracheobronchial airways that have a smaller surface areas and 
columnar epithelial cells that can be up to 60 μm thick (Yang et al., 2008b). For drug 
molecules that are actively transported across the epithelial layers by way of transporters 
the absorption rate will differ depending on the expression, functionality and competition 
for the relevant transporters at the site of deposition (Liu et al., 2013). Macromolecules are 
thought to be transported across the epithelium via more than one route. They are thought 
to be able to travel through the intercellular junctions as well as being transported by 
transcytosis (Patton, 1996).  
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1.2.3 Clearance of drugs from the lung 
The previous sections described an ideal situation for the administration of pulmonary 
medicines, in which the formulation is deposited at the correct site, dissolved if necessary 
and absorbed across the lung epithelium. The reality is that after deposition any inhaled 
particle faces one of several efficient removal mechanisms meant to protect the lungs from 
harmful substances (Oberdörster, 1988). In the conducting airways particles can be 
cleared rapidly via mucociliary clearance (Section 1.2.3.1) whereas in the lower airways 
clearance is slower and the work of macrophages (Section 1.2.3.2) (Stuart, 1984, 
Lippmann et al., 1980). Even the rapid absorption of drug molecules in to the blood can be 
thought of as a clearance, leading to short residence times in the lung (Section 1.2.3.4) 
(Patton and Byron, 2007). 
1.2.3.1 Mucociliary clearance 
Mucociliary clearance occurs from the trachea until the terminal bronchioles, where ciliated 
cells are found (Clarke and Pavia, 2015). Particles that cannot penetrate the mucus layer, 
and drugs that associate with mucus, that are deposited in this region are trapped and 
removed from the lung by the action of these cells (Edsbäcker et al., 2008). The cilia of the 
airways beat in a metachronal rhythm, optimizing the transport of mucus towards the 
mouth where it will be either swallowed or expectorated (Houtmeyers et al., 1999). The 
rate at which the cilia beat, and therefore the rate at which mucus is moved, increases 
from the distal to the proximal airways. In healthy individuals mucus moves at around 1 
mm/min in the small airways, but can move as much as 2 cm/min in the trachea (Olsson et 
al., 2011, Edsbäcker et al., 2008). Therefore the site of deposition of particles in the 
conducting zone will affect their residence times in the airways. The rate of mucociliary 
Using Ion-pairs to Control Salbutamol Delivery to the Lungs 
 
 
Chapter 1 - Introduction 
47 
clearance decreases with age and can be greatly affected by diseases such as asthma, 
immotile cilia syndrome, bronchiectasis, and cystic fibrosis (Edsbäcker et al., 2008, Yeates 
et al., 1976). In diseases such as immotile cilia syndrome or bronchiectasis the reduced 
clearance is as a result of impaired cilia function, whereas in cystic fibrosis the increased 
amount and composition of the mucous impairs its removal (Houtmeyers et al., 1999). 
When the mucociliary escalator is damaged, cough becomes an increasingly important 
mechanism of clearance from the lungs. Studies have shown that in patients with COPD a 
significantly greater percentage of centrally deposited particles are cleared by cough in 
comparison with healthy individuals (60% vs 8%) (Olsson et al., 2011).  An inhaled 
formulation that is delivered as a powder or suspension to the conducting zones of the 
airways would have to avoid premature removal via the mucociliary escalator in order to 
successfully extend the duration of action of the therapeutic agent. 
1.2.3.2 Phagocytosis 
Another mechanism by which particles are removed from the lung is phagocytic uptake by 
pulmonary macrophages. Macrophages are found on the alveolar surface and are able to 
move and engulf or lyse unwanted organisms, particles or toxic agents (Stuart, 1984). The 
clearance of insoluble particles via pulmonary macrophages is an overall slow process 
comprised of 2 parts. The first part is the uptake of the particle in to the cell, phagocytosis. 
This is a relatively rapid process, with 50 – 75% of deposited particles being phagocytosed 
within 2 – 3 hours and almost all within 24 hours (Geiser, 2010). Particle-bearing 
macrophages then move to the ciliated airways to be cleared via the mucociliary escalator, 
which can take anywhere from 24 hours to over a month to complete depending on the 
initial site of phagocytosis (Geiser, 2010). Alternatively, macrophages can break down 
endocytosed material via the mechanism of internal lysosomes or clearance can occur via 
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the lymphatic system (Stuart, 1984). This mechanism of clearance would be most 
important when designing an inhaled formulation for systemic delivery as the clearance of 
particles by phagocytosis could reduce the duration of action of the inhaled drug. 
1.2.3.3     Pulmonary metabolism  
The cytochrome P450 enzymes, known for their ability to metabolize drug molecules, are 
also found in the lung but at a much lower concentration than in the liver (Olsson et al., 
2011). Because of this the drug metabolizing capability of the lungs is minimal for most 
small molecules. There are however several drug molecules that are known to be 
substrates for pulmonary metabolic enzymes, namely: budesonide, salmeterol, fluticasone 
propionate and theophylline (Olsson et al., 2011). Furthermore, due to the presence of 
proteases in the lung, inhaled doses of proteins and peptides could be affected by 
metabolism (Labiris and Dolovich, 2003a). Although local metabolism could cause short 
residence times for therapeutics in the lung, it can also be taken advantage of, for example 
by the use of prodrugs (Section 1.3.1) (Olsson et al., 2011).  
1.2.3.4 Drug absorption 
Soluble particles that are not cleared by any of the processes described above will be 
absorbed across the pulmonary epithelium. The mechanisms by which this occurs has 
been described in detail in Section 1.2.2.6, however it is crucial to highlight absorption 
again as a mechanism of drug clearance from the lungs. Rapid absorption of drug 
molecules and metabolism elsewhere in the body can lead to a short duration of action for 
therapeutic agents and necessitate frequent dosing (Patton and Byron, 2007). This 
highlights the problems faced when attempting to create an inhaled formulation for 
prolonged therapeutic action, as a balance between avoiding the clearance mechanisms 
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of the lungs and limiting the rate of drug absorption to create a reservoir of drug that can 
continue to act over a prolonged period of time is essential. The methods that have been 
previously used in an attempt to overcome this problem and create a formulation that 
prolongs drug action will be discussed in the next section.  
1.3 Methods of prolonging drug action in the lung 
Despite the routine use of aerosols in the clinic, many inhaled medicines suffer from the 
same limitations: a short duration of action owing to the drug’s rapid clearance from the 
lungs. Sufferers of chronic respiratory diseases, such as asthma, are often required to take 
their inhaled medication up to four times daily (Loira-Pastoriza et al., 2014b). This 
inconvenience increases the risk of poor patient compliance, as well as the potential for 
fluctuating drug levels in the blood causing more unwanted side effects (Liang et al., 
2015). There are a number of strategies that are being investigated as prospective 
methods of extending drug action in the lungs including the use of liposomes as drug 
carriers (Section 1.3.3) or chemical modification of the active compound (Section 1.3.1). 
Despite this, there are currently no controlled delivery aerosol formulations on the market 
(Cook et al., 2005). It is clear that the development of a formulation for inhalation with 
prolonged drug action could improve the therapeutic efficacy of many drugs as well as the 
safety profile.  
1.3.1 Microparticles 
Modifications to formulations on the micro scale can be used as a strategy for achieving 
prolonged drug action in the lungs. Large porous particles (LPP) are particles with a large 
geometric diameter (> 5 μm) but low density (< 0.4 g/cm3), and as such their aerodynamic 
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diameter is low (Loira-Pastoriza et al., 2014b). This allows the particles to penetrate deep 
in to the lung on inhalation, bypassing much of the mucociliary escalator to prolong 
retention in the airways. Furthermore, due to their large geometric size they may be able to 
escape phagocytosis by alveolar macrophages (Loira-Pastoriza et al., 2014b). They are 
commonly made from polymer carriers such as PLGA and are prepared with porogen 
agent such as ammonium bicarbonate, which give the particles their porous structure 
(Liang et al., 2015). Recently rifampicin has been loaded into an LPP formulation and 
administration via inhalation achieved a higher systemic concentration than oral 
administration, and sustained a high local concentration in guinea pigs (Garcia Contreras 
et al., 2015). Despite the promising nature of LPPs there are still many limitations. Mainly, 
there is not yet a method for their fabrication that achieves high drug loading and 
predictable release profiles for all drug molecules and the porous nature of these particles 
calls in to question their physical stability and the potential difficulty for large scale 
manufacture (Liang et al., 2015).   
Swellable microparticles are another aerosol formulation strategy that has the potential to 
achieve prolonged drug action. These particles are in the inhalable size range when dry, 
but after deposition and contact with the fluid in the lungs they swell to a larger size (Ni et 
al., 2017). The swelling of the particles limits the amount of phagocytosis by macrophages, 
and so the particles have a longer lung retention time to release the active agent (Liang et 
al., 2015). Furthermore, natural polymers such as chitosan are often used to generate the 
swelling particles, and so they are biocompatible and biodegradable (Ni et al., 2017). 
Gaspar et al. produced chitosan microspheres crosslinked with glutaraldehyde and 
containing levofloxacin. He showed that the microparticles had a high drug loading 
efficiency, acceptable drug release profile, and equivalent antibacterial properties to the 
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free drug (Gaspar et al., 2015). However, there is still an issue of how to incorporate 
hydrophobic drug molecules in to these microspheres, especially if chitosan is used as the 
swelling polymer. Low drug loading, and uneven drug distribution are problems that must 
be overcome if swellable microparticles are to become a suitable delivery system for all 
inhaled medicines (Ni et al., 2017). 
1.3.2 Nanoparticles 
Nanoparticles can be used as drug carriers by either adsorbing the active agent to the 
surface of the particle, or by encapsulating the agent within (Sung et al., 2007). A 
nanoparticle refers to a solid particle in the size range of 1 to 1000 nm, however the term 
can sometimes be used to refer to particles in the 1 – 200 nm size range (Sung et al., 
2007).  
Several studies have shown that nanoparticle formulations can provide a method of 
extending drug action in the lungs. Yamamoto et al. created PLGA nanoparticles of 
elcatonin, modified with chitosan to give them mucoadhesive properties. They showed that 
the elimination of the particles compared with regular nanoparticles was prolonged and 
this resulted in an extended therapeutic effect in guinea pigs (Yamamoto et al., 2005). Das 
et al. showed that delivering a dry powder formulation of voriconazole loaded poly(lactic-
co-glycolic acid) (PLGA) nanoparticles to mice generated a sustained release profile in 
comparison with the intravenous (IV) route of administration (Das et al., 2015). Vaughn et 
al. explored delivering itraconazole in a formulation of nanoparticles made from 
polysorbate 80 and poloxamer 407 for the treatment of Aspergillus fumigatus fungal 
infections in mice, he found that the nano-formulation was able to generate and sustain 
the high lung concentration required compared to oral administration (Vaughn et al., 2006).  
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Although there have been numerous studies highlighting the potential use of nanoparticles 
in delivering drugs to the lungs, there are also potential shortcomings that require further 
investigation. A major concern when administering nanomaterials to the body is their 
potential for increased toxicity. Nanoparticles are developed for their surface functionalities 
which enhance their utility, however with such a small particle size there is a greatly 
increased surface area between these functional groups and the body’s tissue (De Jong 
and Borm, 2008). Furthermore, nanoparticles can migrate from the lung into systemic 
circulation and their bodily distribution  and ability to cross biological barriers such as the 
blood-brain barrier is unknown (De Jong and Borm, 2008, Bailey and Berkland, 2009). 
Various in vivo and in vitro studies have shown that nanoparticles can cause pulmonary 
inflammation, cause platelet aggregation or accelerate vascular thrombosis (De Jong and 
Borm, 2008, Bailey and Berkland, 2009).  Additionally, nanoparticles can be unstable in 
storage. Solutions of nanoparticles for nebulization have been shown to lose the 
encapsulated drug over time due to polymer hydrolysis, and agglomeration can lead to 
poor aerosolization (Sung et al., 2007). Dry powders of nanoparticles will also be 
susceptible to agglomeration during storage, or conversely, particles that do not 
agglomerate run the risk of not being deposited into the lung at all, and instead being 
exhaled. As a result of this microparticle formulations that release the nanoparticle upon 
administration are being investigated, however this might be considered to be adding 
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1.3.3 Liposomes 
Liposomes have also been investigated as carriers for drug delivery to the lungs. 
Liposomes are self-assembling colloidal structures that are formed from phospholipids and 
can be in the size range of 20 nm to 10 μm (Taylor and Newton, 1992, Willis et al., 2012). 
They can be unilamellar or multilamellar: containing many lipid bilayers separated by an 
aqueous core (Taylor and Newton, 1992). Due to their nature liposomes are capable of 
encapsulating a wide range of drug molecules. Hydrophilic drugs can be trapped within the 
aqueous regions of the structure, whilst hydrophobic molecules can associate with the lipid 






Figure 1.5 - The structure of a unilamellar liposome. From (Swaminathan and Ehrhardt, 2011) 
 
Liposomes have been successfully incorporated in nebulized, pMDI and DPI formulations 
for inhalation and have been shown to be able to extend drug action. In animals liposomal 
formulations of compounds such as cytarabine and orciprenaline sulphate have been 
shown to possess a prolonged period of therapeutic activity and a minimized amount of 
distribution around other bodily tissues (Taylor and Newton, 1992). More recently, a 
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liposomal amikacin formulation (Arikace®) has been shown to enhance and sustain the 
activity of the aminoglycoside antibiotic against pseudomonas aeruginosa, and is currently 
in phase III clinical trials for treatment of infections in cystic fibrosis patients (Elhissi, 2017). 
Liposomes are attractive drug delivery systems as they are made from compounds that 
are endogenous to the lungs, such as the primary component of lung surfactant 
dipalmitoylphosphatidylcholine (DPPC) and therefore do not have any toxicity related side 
effects (Willis et al., 2012). There are, however, also some drawbacks with the use of 
liposomal formulations for pulmonary drug delivery.  Formulations of liposomes for 
nebulization can be unstable, and even the process of nebulization can result in premature 
release of the encapsulated drug (Loira-Pastoriza et al., 2014b).  
1.3.4 Chemical modification 
Modification of the chemical structure of therapeutic agents, conjugation with a polymer or 
the development of a prodrug are all strategies that could be employed to create a 
formulation with prolonged drug action. An example of this is the modification of the short 
acting β2- agonist salbutamol to give the long acting salmeterol. This modification 
increased the molecular weight and lipophilicity of the original molecule and as a result 
increased the duration of action from 4 to around 12 hours (Kips and Pauwels, 2001). 
Conjugation of drug molecules with polyethylene glycol (PEG) also has been investigated 
as a means of creating prolonged drug action. PEG has a high molecular weight and 
creates steric hindrance around the drug molecule that slows absorption and protects from 
metabolic enzymes and phagocytosis (Loira-Pastoriza et al., 2014b). PEGylated insulin 
and calcitonin have both been shown to have increased stability in rat lungs while retaining 
the ability to be absorbed in to systemic situation, and PEGylated small drug molecules 
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such as prednisolone have been shown to have a reduced absorption rate (Loira-Pastoriza 
et al., 2014b). Prodrugs have also been shown to have some efficacy in the lung. A 
prodrug approach involves modification of a drug molecule with a moiety that will be 
enzymatically cleaved in the lung giving the original drug molecule that can then act. An 
example of this is ibuterol, a prodrug of terbutaline, was absorbed more rapidly than the 
parent drug but created a reservoir, releasing the parent drug over time, and was three 
times as effective (Zeng et al., 1995). Although chemical modification provides a potential 
route for creating a medicine with prolonged drug action, it only does so for an individual 
drug molecule at a time, and can require a large investment of time and money to create 
an appropriate formulation and take it to market. As such, it would be preferable to create 
a formulation strategy that could be applied to a range of drug molecules.  One such form 
of chemical modification that could be applied to numerous inhaled drug molecules is the 
use of ion-pairs, this strategy will be discussed in the next section. 
1.4 Ion-pairs as a strategy for prolonging drug action of inhaled 
medicines 
1.4.1 Ion-pair definition 
Another formulation strategy that has the potential to create an inhaled medicine with 
prolonged drug action is the use of ion-pairs. An ion-pair is a pair of oppositely charged 
ionic molecules that is held together via non-covalent interactions, such as Coulombic 
attraction and hydrogen bonding (Samiei et al., 2013). The general energies of these types 
of non-covalent interactions is around – 20 kj/mol, although the strength of the bonds can 
change depending on the dielectric constant of the surrounding environment (Wermuth, 
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2011). As a result, these interactions more readily dissociate in water, as preferential 
binding to water occurs. Therefore, the aim of an ion-pair is to create a stronger binding 
interaction between the two charged molecules so that a greater proportion of the ion-pair 
remains whilst in solution. In the lab this concept is often used, for example in the 
separation of difficult molecules by high performance liquid chromatography (HPLC) (Qiao 
et al., 2016). However, in a pharmaceutical sense ion-pairing refers to the binding of a 
charged drug molecule and a counter ion. In order to promote binding of the species on 
administration the counter ion is often present as an excess. The ion-pair species behaves 
as a single unit on dissolution and absorption across the epithelium and then dissociates in 
to the separate ions when diluted in the blood (Samiei et al., 2013). This differs from active 
agents that are formulated as salts, as they are prepared in a stoichiometric ratio. Previous 
studies have shown that increasing the ratio of counter ion can increase the concentration 
of bound species in solution, whereas a salt formulation would immediately dissociate 
when dissolved (Patel et al., 2009a). It is therefore important when creating a 
pharmaceutical ion-pair, to choose a biocompatible counter ion as it will be presented to 
the epithelium in a relatively high concentration.  
1.4.2 Use of ion-pairs in drug delivery 
The main advantage to forming ion-pairs is that it allows manipulation of a drug’s physical 
and biopharmaceutical properties without having to alter the chemical structure of the 
molecule. Depending on the counter ion used an ion-pair can be more hydrophilic or more 
lipophilic than the drug molecule alone, so processes such as dissolution or absorption 
across the epithelium can be modified. Previously, the ion-pairing strategy has been used 
to alter the properties of drugs for transdermal, ocular and oral administration.  
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Song et al. generated adhesive patches for the administration of bisoprolol ion-pairs. They 
found that a bisoprolol maleate ion-pair (figure 1.6) showed the most promise as it 
successfully controlled the drug’s flux through rabbit skin, the mechanism of action was 
proposed to be due to both the change in logP and molecular weight of the ion-pair when 
compared with the free drug (Song et al., 2012). Megwa et al. studied the effect of ion-
pairing salicylic acid with various quaternary ammonium compounds on the penetration of 
the drug across human skin. They found that the bioavailability of salicylic acid could be 
improved by ion-pairing when the complex formed was more hydrophobic than the drug 
molecule, but that the degree of effect was inconsistent depending on the counter ion 
chosen. They hypothesized that this was due to steric hindrance of some of the chosen 
counter ions increasing the distance between the two ions and therefore limiting the 
strength of the coulombic interaction (Megwa et al., 2000). This highlights the importance 






Figure 1.6 - Chemical structure of bisoprolol maleate ion-pair 
 
In ocular formulations ion-pairing with sorbic acid was shown to generate a 2-fold increase 
in timolol permeation across intact rabbit corneas in a study completed by Higashiyama et 
Using Ion-pairs to Control Salbutamol Delivery to the Lungs 
 
 
Chapter 1 - Introduction 
58 
al.. They found that the timolol – sorbic acid ion-pair did not affect the diffusion coefficient 
of the drug in to the epithelium, but that it did significantly increase the partition coefficient, 
and so proposed that the increased permeation was as a result of enhanced partitioning of 
the ion-pair in to the epithelium (Higashiyama et al., 2004). In a more recent study, Li et al. 
found that ion-pairing pirenzepine with sorbic acid greatly increased the drug’s absorption 
across the cornea, increased the drug’s loading in to a liposomal delivery system and 
improved the penetration of the liposomes across the cornea (Li et al., 2017).   
Oral absorption of amifostine was greatly improved by ion-pairing with succinic acid in a 
study by Samiei et al. in rats, reaching similar drug plasma levels after 20 minutes as an 
intravenous dose (Samiei et al., 2013).  
In all of these examples of the use of ion-pairs to modify a drug’s pharmacokinetic profile, 
permeation has been enhanced by creating a more hydrophobic complex. A formulation 
for the lungs could employ ion-pairs to create a more hydrophilic or a more hydrophobic 
complex. A hydrophilic complex could lower the rate of drug absorption in to the 
respiratory epithelium, slowing clearance by absorption. On the other hand, a more 
hydrophobic complex could lower the rate of dissolution, creating a drug reservoir in 
particle form which could be subject to clearance mechanisms, or could increase the 
tissue retention of the drug, creating a reservoir in the epithelial cells.  
1.5 Aims and scope of the PhD 
Despite the literature highlighting the potential of ion-pairs to modify a drug’s 
pharmacokinetic profile, there has been surprisingly little investigation into their 
incorporation in an inhaled formulation (Patel et al., 2016) . The lung could be an ideal site 
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for ion-pairs to act due to the relatively low volume of fluid, which could limit the 
dissociation of the drug molecule and counter ion. Reviewing the literature presented in 
the introduction there are several considerations that need to be made when developing 
an ion-pair formulation for inhalation. Charged, inhaled medicines would have to be able to 
form ion-pairs with suitable, biocompatible counter ions, and both species would have to 
be able to be incorporated into an aerosol formulation so that the ion-pair is intact at the 
site of action. The ion-pair would then modify either the dissolution of the drug or its 
absorption across the respiratory epithelium in order to avoid the lungs rapid clearance 
mechanisms to deliver a therapeutically effective dose of the drug molecule for a 
prolonged duration.  The desired effect of the ion-pair could change with the intended site 
of deposition. Locally acting drug molecules may benefit from rapid dissolution to avoid 
clearance via the mucociliary escalator, and therefore prolonged drug action would be a 
product of slow absorption of the ion-pair or tissue retention. Whereas for systemic drug 
delivery, ion-pairs could decrease the rate of dissolution of particles to limit the speed at 
which the drug enters circulation. Ion-pairs could potentially be formulated in to a 
nebulized, pMDI, or dry powder formulation. However, storing the drug and counter ion in 
a solution could increase the chances of complex dissociation and potential binding of the 
drug or counter ion to other excipients present in the formulation. 
The aim of this project, therefore, was to assess the feasibility of ion-pairs to be used in a 
formulation for inhalation intended to prolong drug action. It was hypothesized that a dry 
powder formulation containing an ion-pair could be delivered to the lungs and be used to 
generate a prolonged duration of therapeutic action.  
The following objectives were set in order to test this hypothesis: 
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- To assess the ion-pair formation of a charged inhaled model drug with a range of 
suitable counter ions 
- To investigate the effect of ion-pair formation on the physical and 
biopharmaceutical properties of the drug molecule 
- To create an inhalable dry powder formulation incorporating the ion-pairs 
- To study the ability of the ion-pair formulations to prolong drug efficacy in an 
animal model 
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2.1  Introduction 
There are many reasons why it might be desirable to temporarily alter a drug’s  
physicochemical characteristics during formulation and/or administration including: to 
increase solubility; to modify dissolution; or to control cell uptake of the drug molecule at 
the administration site (Desai et al., 2015, ElShaer et al., 2014, Lozoya-Agullo et al., 
2016). Forming ion-pairs could be an advantageous method to induce a temporary change 
in a drug’s physicochemical properties as it does not modify the chemical structure of the 
drug molecule itself, but can modify its properties (Lozoya-Agullo et al., 2016).  There have 
been a number of published studies that have shown forming ion-pairs between 
hydrophilic APIs and hydrophobic counter ions can improve permeability via oral, 
parenteral, ocular and transdermal routes (Lozoya-Agullo et al., 2016, Trotta et al., 2003, 
Tan et al., 2009). However, there are very few studies on how the fate of inhaled 
medicines can be changed by utilizing the ion-pairing strategy (Zhou et al., 2002, Patel et 
al., 2016).  
Ion-pairs are formed from 2 oppositely charged species which associate to behave as one 
unit prior to dissociating upon dilution in to a larger body of liquid such as the blood 
(Lozoya-Agullo et al., 2016). The airways of the lung are an ideal site for an ion-pairing 
approach to control drug delivery due to the very small volumes of fluid that line the lungs 
which will reduce the speed of dissociation (Forbes et al., 2000). Hence forming an inhaled 
medicine using a drug ion-pair could improve the uptake and duration of action of both 
topical and systemic medicines.  
In order to investigate the effect of ion-pairing on the behavior of drugs that could form 
inhaled medicines a model drug that is ionized at the correct (physiological) pH is needed. 
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For the purpose of the work in this thesis salbutamol was chosen as the model drug. 
Salbutamol is a β2-adrenergic receptor agonist used in the treatment of asthma as a 
bronchodilator (Imboden and Imanidis, 1999, Jashnani et al., 1993). At physiological pH its 
secondary amine is charged (figure 2.1). The structure of the drug also includes a benzene 
ring, and a primary, secondary and phenolic alcohol (figure 2.1).  
 
 
Figure 2.1 – Chemical structure of salbutamol at pH 7.4  
 
The duration of action of salbutamol following inhalation is relatively short, around 4 hours 
(Jashnani et al., 1993). The frequency and severity of the symptoms of asthma peak at 
around 4 am due to a circadian rhythm (Hetzel and Clark, 1980, Imboden and Imanidis, 
1999) and so a prolonged effect of the drug following an evening dose would be beneficial.  
In an attempt to prolong the action of salbutamol its chemical structure was altered to 
create salmeterol and formoterol (Santus et al., 2015). However, these agents can have 
serious side effects, in 1993 a study Castle et al. published a study showing there was a 
threefold increase in mortality in patients prescribed with salmeterol vs salbutamol (Castle 
et al., 1993). Previous work has shown that salbutamol does form an ion-pair species with 
the sulfate and 1-hydroxy-2-naphthoate counter ions and that the 1-hydroxy-2-naphthoate 
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ion-pair significantly increased the percentage reversal of airway obstruction in guinea pigs 
when compared to salbutamol base (Patel et al., 2016). However, in this study salbutamol 
and its ion-pairs were administered by way of an intravenous injection and so it is possible 
that the effects of the ion-pair had been reduced due to its dilution and dissociation in the 
blood. Furthermore, IV administration does not allow for an ion-pair to alter solubility or 
dissolution of the drug molecule which could have a large effect on the action of the drug. 
Therefore administering an ion-pair as a solid dosage form might allow for the maximum 
effect to be observed.  
The aim of the work presented in this chapter was to investigate whether salbutamol 
formed ion-pairs with counter ions at physiological pH, and if an ion-pair was formed to 
assess the strength of the complex. In order to achieve this Fourier Transform Infrared 
spectroscopy (FTIR) and high performance liquid chromatography (HPLC) methods were 
established. Other techniques can be used to analyze the binding of an ion-pair such as 
fluorescence spectroscopy and nuclear magnetic resonance (NMR) (Tan et al., 2009), 
however FTIR and HPLC were chosen due to ease of use and availability. Using results 
from these experiments, speciation software was used to predict the amount of drug 
bound in the form of an ion-pair at different ratios of drug to counter ion. Furthermore, the 
effect of ion-pairing on the lipophilicity and solubility of the drug was analyzed. Due to the 
surfactant nature of the octanoate counter ion, its ability to form micelles at the 
concentrations employed in other experiments was also examined using photon 
correlation spectroscopy.  
The choice of counter ion for an ion-pair formulation is extremely important as the 
behaviour of the complex in vitro and in vivo is likely to change depending on how strongly 
the drug and counter ion associate and what chemical groups are presented to the 
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environment (Patel et al., 2016). In order to achieve a greater understanding of the role the 
counter ion might play in the physicochemical properties of an ion-pair, a range of 
pharmaceutically relevant anionic counter ions were chosen for investigation. Typically, in 
the literature, only hydrophobic counter ions have been used in order to improve transport 
of drugs across membranes (Zhou et al., 2002, Trotta et al., 2003), however for the 
purpose of this study counter ions were chosen with a range of logP values. In addition the 
chemical groups of the counter ions were taken in to consideration. Salbutamol possesses 
hydroxyl groups which could from hydrogen bonds and a benzene ring which has the 
potential for a π-stacking interaction. The formation of multiple non-Coulombic interactions 
between the drug and chosen counter ion could improve ion-pair formation and the 
stability of the complex. The counter ions chosen for this study are shown in figure 2.2.  
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Figure 2.2 – Chemical structures (at pH 7.4), names and predicted logP values of all chosen counter 
ions. LogP values were predicted using ALOGPS software 
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2.2 Materials and Methods 
2.2.1  Materials 
Lactohale 300 (Friesland foods, Netherlands) was used as a source of lactose. Salbutamol 
base was from Cipla Ltd, India and used without further purification (BN. H80619). Sodium 
sulfate, sodium fumarate and sodium benzoate were purchased from Alfa Aesar, UK. 
Sodium octanoate, sodium maleate dibasic, deuterated water, PBS and HBSS were 
obtained from Sigma Aldrich (Dorset, UK). Sodium gluconate and sodium glucoheptonate 
were purchased from Santa Cruz Biotechnology (USA). For HPLC analysis, phosphate 
buffered saline was from Oxoid Ltd (Hampshire, UK), ammonium acetate was purchased 
from VWR (Leicestershire, UK). N-octanol, HPLC grade methanol and water were supplied 
by Fisher ltd (Leicestershire, UK).  
2.2.2 Fourier Transform Infrared Spectroscopy (FTIR) ion-pair 
binding assay 
A universal transmission cell system (Omni-Cell system, Specac Ltd., Orpington, Kent, 
U.K.) with CaF2 windows and Mylar spacer (25 µm path length) was used for the 
transmission measurements. All samples were made up in D2O and the pH adjusted to 7.4 
(± 0.2) with 1 M HCl or NaOH in D2O as needed. Blank solutions were prepared using the 
same amount of D2O and acid or base without the salbutamol. The spectra of 7 different 
concentrations of ionized salbutamol (ranging from 80 – 160 mM) were taken to assess if 
any changes in the transmission intensity of peaks occurred with increasing concentration. 
The spectra were recorded within the range of 4000 – 450 cm-1. The resolution was set at 
4 cm-1 and 32 scans were performed for each measurement. All spectra were baseline 
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corrected and differentially subtracted with the spectra of the baseline corrected blank 
solutions. Data was recorded using a Spectrum One spectrometer and analyzed with 
Spectrum software (Perkin Elmer Ltd., Beaconsfield, UK). A 100 mM concentration was 
chosen to investigate the effect of ion-pairing with salbutamol as this was the lowest 
concentration at which all peaks were clearly visible. Sodium sulfate, sodium gluconate, 
sodium glucoheptonate and sodium octanoate were the counter ions used. Blank solutions 
for these experiments consisted of an equal volume of D2O, acid and base and an equal 
weight of counter ion as in the sample. The FTIR spectra of 100 mM salbutamol with 
increasing concentrations of each of these counter ions were obtained as before.  
2.2.3 High Performance Liquid Chromatography (HPLC) ion-pair 
binding assay 
An HPLC machine (Agilent 1100, Agilent Technologies, California, USA) was used to 
determine the retention time of salbutamol in a pure H2O (pH 7.4 ± 0.2) mobile phase. The 
flow rate was set to 0.3 mLmin-1 and the UV detection wavelength was 278 nm. The 
stationary phase consisted of a biphenyl 100 A250 x 4.6 mm column (Phenomenex, UK). 
For each sample 2 injections of a 1 mM salbutamol solution were performed (n=3). Binding 
to counter ions was assessed by the change in retention time with increasing 
concentration of counter ions in the mobile phase. When the increase in counter ion 
concentration did not result in a difference in retention time 100% salbutamol was thought 
to be bound.  
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2.2.4 Calculation of salbutamol – counter ion speciation curves 
The Hyperquad Simulation and Speciation software (Hyss 2009, Protonic Software, UK)  
(Alderighi et al., 1999) was used to predict the percentage of salbutamol ion-pair species. 
The concentration of salbutamol was set to 0.00209 M (corresponding with the 
concentration used in cell transport experiments in Chapter 5). The binding was calculated 
for each counter ion at a 20:1 and 10:1 ratio assuming 1:1 binding occurred between drug 
and counter ion. 
2.2.5 Distribution coefficient assay 
PBS and octanol were equilibrated for 48 hours before use. Salbutamol base was 
dissolved in PBS saturated with n-octanol at a concentration of 0.2 mM for use. Counter 
ion was added to the drug solution at a ratio of 20:1. The drug containing PBS was pH 
adjusted to 7.4 (± 0.2) before an equal volume of n-octanol was added to the sample. The 
sample was shaken at 37oC for 48 hours. After this time the aqueous layer was taken to 
be analyzed by UV/VIS spectroscopy using a wavelength of 278 nm (Lambda 2 UV/VIS 
spectrometer) and data was analyzed using Lambda 25 software (Perkin Elmer Ltd., 
Beaconsfield, UK). The values obtained were compared to a calibration curve of 
salbutamol base made up in the PBS saturated with n-octanol and any difference in the 
concentration found to the initial concentration was assumed to be in the octanol layer. 
LogD7.4 was calculated using the following equation: 
LogD7.4 = log [octanol] /[aqueous]                                                    [Equation 2.1] 
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2.2.6 Photon correlation spectroscopy 
The potential for self-assembly of sodium octanoate in to micelles was investigated using 
PCS (Zetasizer Nano, Malvern Instruments, Worcestershire, UK). Serial dilutions of 
solutions of 20:1 salbutamol sulfate (control) and salbutamol octanoate in PBS were pH 
adjusted to 7.4 (± 0.2) before analysis. Concentrations of the samples ranged from 0.042 – 
21 mM. The derived count rate was analyzed for each concentration and where the value 
of the count rate was greater than 1000 the particle size was obtained from the size-
intensity distribution. All measurements were carried out using a scattering angle of 173 o 
using water as the dispersant (refractive index 1.33, viscosity 0.8872 cP at 25°C) and at 
room temperature.  
2.2.7 Spray drying of salbutamol ion-pair powders 
Spray drying was performed on a B-191 spray dryer (Buchi, Switzerland). The optimized 
conditions were as follows: a total concentration of 3 g/100 mL water was used, with an 
inlet temperature of 180oC. The aspirator was set at 80% (machine setting), the pump 
speed was 5 mL/min and the air flow rate was 800 l/h. A salbutamol lactose powder was 
generated using 1% w/w drug concentration. Ion-pair powders were generated for all 
counter ions in a 20:1 ratio.  
2.2.8 Ion-pair solubility 
HBSS (0.5 mL) was warmed to 37oC using a shaking water bath. After 1 hour salbutamol 
spray-dried powder was added (200 mg). The pH of the suspension was measured at the 
beginning of the experiment and adjusted to pH 7.4 (± 0.2) with 1 M HCl/NaOH as needed. 
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The suspension was shaken at 150 strokes per minute and 37oC for 24 hours. The pH was 
recorded once more at the end of the experiment. The solid material was separated from 
the liquid via centrifugation (Biofuge pico, Heraeus, Germany) at 2000 rpm for 5 min and 
an aliquot of the resulting clear solution was diluted (1:100) for HPLC analysis. 
2.2.9 High performance liquid chromatography (HPLC) 
An HPLC machine (Agilent 1100, Agilent Technologies, California, USA) was used to 
determine the concentration of salbutamol, separation was achieved using a 
SphereCloneTM ODS2 (250 x 4.6 mm, particle size: 5 µm) column (Phenomenex® Ltd., 
Cheshire, UK). The mobile phase for HPLC analysis was an 80:20 mixture of 1 g/L 
ammonium acetate solution: methanol, that had been adjusted to pH 4.5 using 1 M HCl, 
filtered through a 0.2 μm nylon membrane, and degassed by sonication. The run time was 
set at 8 min, with a flow rate of 1 mLmin-1 and 6 injections of 20 μL per vial. The UV 
detection was set at 226 nm. The amount of salbutamol in the samples was determined by 
comparison with a calibration curve. To generate a calibration curve an aliquot of 10 mg 
salbutamol was weighed out and added to a 100 mL volumetric flask and made up to 
volume with PBS to give a 100 μgmL-1 solution. A set of serial dilutions was performed 
using glass pipettes and volumetric flasks to prepare 7 standards (100, 80, 50, 20, 10, 5, 1 
μgmL-1). 
2.2.10 Data analysis 
Data was obtained from 3 experiments and have been expressed as a mean ± standard 
deviation, unless otherwise stated. Sigmoidal curves were fitted to the binding data in 
SigmaPlot and the value at 50% was taken as the ion-pair binding constant. One-way 
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Analysis of Variance (ANOVA) with a Shapiro-Wilkins normality test was performed with a 
probability limit of 0.05 set to indicate significant differences.  
2.3  Results 
2.3.1 The binding of salbutamol with negatively charged counter 
ions 
The full FTIR spectra of salbutamol base at a concentration range from 80 – 160 mM were 
analyzed in order to identify the main peaks associated with the drug (figure 2.3). It was 
found that the main peaks associated with salbutamol occurred in the range of 1350 – 
1650 cm-1.  The peaks found in this region were assigned to chemical groups in 
salbutamol based on the literature (Sharma, 2013, Paluch et al.). These peaks occurred at 
1385 cm-1 (CH3), 1413 cm
-1 (COH), 1507 cm-1 (CH2-N), 1596 cm
-1 (N-H), and 1617 cm-1 
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Figure 2.3 – Fourier transformed infrared spectrum of salbutamol base (120 mM, pH 7.4 (± 0.2)) in range 












Figure 2.4 – Fourier transformed infrared spectrum of salbutamol sulfate (120 mM, pH 7.4 (± 0.2)) in the 
region of 1330 – 1670 cm
-1 
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The changes in intensity were assessed for 3 main peaks in the spectra which were at 
1617, 1507 and 1385 cm-1. It was found that the absorption for these peaks increased 
linearly with concentration of salbutamol from 100 – 160 mM (figure 2.5) and so it was 
determined that changes in the ratio of one peak to another with added counter ion could 
be used to determine the amount of ion-pairing occurring in the system. 
FTIR was only used to assess the binding between salbutamol and the sulfate, gluconate, 
glucoheptonate, and octanoate counter ions as the remaining molecules exhibited a strong 










Figure 2.5 – Change in absorption of salbutamol base Fourier transformed infrared spectroscopy 
peaks found at 1617 cm
-1
 (C=C, red circle, R
2
 = 0.831), 1507 cm
-1
 (CH2-N, blue triangle, R
2
 = 0.905), and 
1385 cm
-1
 (CH3, green square, R
2
 = 0.984) over a concentration range of 100 – 160 mM. Data represents 
a mean ± standard deviation (n=3). 
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The addition of the sulfate, gluconate and glucoheptonate counter ions all resulted in an 
increase in the N-H peak at 1596 cm-1 in comparison to the inert peaks found at 1617 cm-1 
and 1385 cm-1 (C=C and CH3, respectively). On addition of the octanoate counter ion an 
increase in the methyl peak at 1385 cm-1 in relation to the benzene peak at 1617 cm-1 was 
observed. If increases in counter ion concentration no longer lead to a change in peak 
absorption it was assumed that 100% of salbutamol was bound in ion-pair form (figure 
2.6). This data was replotted as percentage salbutamol bound vs. – log free counter ion 
and fitted with a sigmoidal curve to give the ion-pair association constant at 50% 









Figure 2.6 - The relationship between the concentration of counter ion and percentage of salbutamol 
found in ion-pair form for the following ion-pairs: Salbutamol sulfate (black circle), salbutamol 
gluconate (red triangle), salbutamol octanoate (green square), and salbutamol glucoheptonate (yellow 
diamond) (n=1). 
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The association constants calculated from these plots were 1.57, 1.70, 2.27 and 2.56 for 











Figure 2.7 – Affinity binding plot for salbutamol sulfate (black circle), salbutamol gluconate (red 
triangle), salbutamol octanoate (green square) and salbutamol glucoheptonate (yellow diamond) ion-
pairs (n=1) 
 
The binding of salbutamol with anionic counter ions was also investigated using an HPLC 
technique. Samples of 1 mM salbutamol were analyzed by HPLC using a water mobile 
phase that had been pH corrected to 7.4 (± 0.2) with a flow of 0.3 mLmin-1 and a biphenyl 
column. It was found that in pure water salbutamol had a retention time of 5.47 min (± 
0.078). The mobile phase was then changed to a solution of counter ion at a known 
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concentration, corrected to pH 7.4. The change in retention time of salbutamol with 
increasing concentration was thought to indicate the percentage of ion-pair formation. The 
addition of all the counter ions studied resulted in an increase in the retention time of 










Figure 2.8 – Relationship between the retention time of salbutamol and the counter ion concentration 
for sulfate (black circle), maleate (red triangle) and gluconate (green square). Data represents a mean ± 
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Figure 2.9 – Relationship between the retention time of salbutamol and counter ion concentration for 
fumarate (black circle), octanoate (red triangle) and glucoheptonate (green square). Data represents a 









Figure 2.10 – Relationship between retention time of salbutamol and benzoate concentration. Data 
represents a mean ± standard deviation (n=3) 
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As with the FTIR data, salbutamol was assumed to be 100% in ion-pair form when an 
increase in counter ion concentration no longer resulted in a change in retention time. The 
data was used to plot percentage salbutamol bound vs. –log free counter ion 
concentration and fitted with a sigmoidal curve, with the 50% bound value giving the 
association constant for each ion-pair (figure 2.11 – 2.13, table 2.1). The association 
constants for the sulfate, gluconate, glucoheptonate and octanoate counter ions which 
were also analyzed via FTIR were 2.37, 2.62, 4.56 and 3.40, respectively (table 2.1). The 
exact values for association differ between the 2 techniques; however 3 of the counter ions 
(sulfate, gluconate and octanoate) show the same order of strength of binding. The 
calculated association constant for the glucoheptonate counter ion varied significantly 
between the 2 techniques used to calculate it. The association constants for the benzoate, 
fumarate and maleate counter ions were 3.82, 3.70 and 2.61 respectively (table 2.1). 
There was a significant increase in the association constant for salbutamol glucoheptonate 
ion-pair in comparison with the sulfate ion-pair (p <0.05), however there was no significant 
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- log free counter ion (M)
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Figure 2.11 – Affinity binding plot from HPLC data for salbutamol sulfate (black circle), salbutamol 










Figure 2.12 – Affinity binding plot from HPLC data for salbutamol fumarate (black circle), salbutamol 
octanoate (red triangle) and salbutamol glucoheptonate (green square). Data represents a mean ± 
standard deviation ± (n=3) 
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Figure 2.13 – Affinity binding plot from HPLC data for salbutamol benzoate. Data represents a mean ± 
standard deviation ± (n=3) 
 
The association constants calculated from the HPLC binding study were used in Hyss 
speciation software to predict the amount of salbutamol thought to be in ion-pair form at a 
concentration of 0.00209 M and a ratio of either 10:1 or 20:1 counter ion to drug. The 
values from the HPLC study were used rather than the FTIR as association constants 
were calculated for all counter ions using this method. The resultant plots show across a 
pH range of 1 – 14 which form salbutamol is likely to be found in. For each of these 
calculations a binding ratio of 1:1 was assumed as the excess of counter ion used would 
primarily facilitate this binding structure (figure 2.14). The speciation curve also shows the 
percentage of salbutamol H-1 and salbutamol H-2 which refer to the possible charged 
species of salbutamol base. At a 10:1 ratio the percentage of salbutamol found in ion-pair 
form at pH 7.4 ranges from around 80% for the sulfate counter ion, to around 100% for the 
- log free benzoate (M)
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glucoheptonate, octanoate, benzoate and fumarate molecules. At a ratio of 20:1 counter 
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Table 2.1 – Calculated pKa values from fourier transformed infrared spectroscopy (FTIR) and high 
performance liquid chromatography (HPLC) studies, and percentage of salbutamol found in ion-pair 
form at a concentration of 0.00209 M (pH 7.4) as calculated by speciation software for all counter ions. 
Where NA is shown a value could not be calculated. 
 
2.3.2 The effect of ion-pairing on the partitioning of salbutamol 
In order to investigate the effect of ion-pairing on the partitioning of salbutamol a PBS – 
octanol system was used. Salbutamol base was dissolved in PBS that had been saturated 
with octanol and the system was corrected to pH 7.4 (± 0.2). Initially, a series of 
salbutamol concentrations ranging from 0.01 – 1 mM was analyzed in an attempt to 
ascertain a suitable salbutamol concentration for further experiments. To achieve a true 
partitioning value it was important to establish that neither of the phases was saturated 
with drug to ensure free movement. It was found that in the concentration range used the 
Counter ion FTIR 
pKa 
HPLC pKa Salbutamol bound 





Sulfate 1.57 2.37 (± 0.025) 81.72 90.25 
Gluconate 2.27 2.62 (± 0.080) 88.72 94.23 
Glucoheptonate 1.70 4.56 (± 0.274) 99.83 99.92 
Octanoate 2.56 3.40 (± 0.047) 97.89 98.95 
Benzoate NA 3.82 (± 0.018) 99.15 99.58 
Fumarate NA 3.70 (± 0.106) 98.90 99.48 
Maleate NA 2.61 (± 0.039) 88.48 94.13 
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relationship between absorbance and concentration was linear, suggesting that the 
aqueous phase was not saturated (figure 2.15). Also, very little of the salbutamol in this 
system moved to the organic layer. 
This experiment was repeated using a 20:1 ratio of the hydrophobic counter ion octanoate, 
in an attempt to drive more drug in to the organic phase and determine the suitability of 
these concentrations of salbutamol in terms of the saturation of the octanol layer. It was 
found that more of the salbutamol was found in the octanol layer after shaking for 48 hours 
in the presence of the octanoate counter ion. Furthermore, at the concentration range 
tested, the relationship between the amount of salbutamol found in the organic phase and 








Figure 2.15 – Absorbance values of salbutamol found in aqueous layer after shaking for 48 hours with 
octanol at a concentration range of 0.01 – 1 mM. Data represents a mean ± standard deviation (n=3) 
Salbutamol concentration (mM)
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Figure 2.16 – Calculated concentration of salbutamol in octanol layer after shaking in presence of 20:1 
octanoate for 48 hours (pH 7.4 (±0.2)). Data represents a mean ± standard deviation (n = 3) 
 
In some systems the overall ionic strength of a solution can influence partitioning results. 
Differing amounts of acid and base were required to correct the pH of the systems to 
physiological pH so the ionic strength of the lowest concentration of salbutamol would 
greatly differ from the highest concentration. To test if the partitioning of salbutamol ion-
pairs would be affected by this the previous experiments were repeated for the lowest and 
highest concentrations of the drug and an amount of NaCl was added to the lowest 
concentration such that the ionic strength of the solution would be equal to the highest 
concentration. It was found that there were no significant differences in the results after 
correcting the ionic strength and so all further experiments were performed without 
correction (figure 2.17 and 2.18).  
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Figure 2.17 - Absorbance values of salbutamol found in aqueous layer after shaking for 48 hours with 
octanol at a concentration range of 0.01 – 1 mM when the solution had not been corrected for ionic 
strength (black circle) and when the lowest concentration was corrected with NaCl (red triangle). Data 
represents a mean ± standard deviation (n=3) 
Salbutamol concentration (mM)
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Figure 2.18 - Calculated concentration of salbutamol in octanol layer after shaking in presence of 20:1 
octanoate for 48 hours (pH 7.4 (±0.2)) without correction for ionic strength (black circle) and after 
correction with NaCl (red triangle). Data represents a mean ± standard deviation (n = 3) 
 
A salbutamol concentration of 0.2 mM was chosen to assess the partitioning of salbutamol 
ion-pairs in this system as this concentration allowed for accurate assaying of the drug and 
neither the aqueous or organic phase was near saturated at this concentration. Each of 
the counter ions were dissolved in the aqueous layer with salbutamol at a ratio of 20:1 
counter ion to drug and shaken for 48 hours with octanol. The subsequent concentration of 
salbutamol found in the aqueous phase by UV/vis spectroscopy was used to calculate the 
partitioning of the drug in ion-pair form between the phases.  
LogD7.4 values could not be calculated for the benzoate, fumarate or maleate ion-pairs due 
to a large UV absorption peak from the counter ions that overlapped and obscured the 
salbutamol peak. It may have been possible to separate these overlapping peaks using 
Salbutamol concentration (mM)







































Adjusted for ionic strength
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HPLC, however this was not performed as any octanol present in the sample could have 
been damaging for the column. For the remaining counter ions only 2 significantly changed 
the partitioning of salbutamol. The glucoheptonate counter ion resulted a significantly 
lower logD7.4 value for salbutamol (-1.845 vs -1.386 for glucoheptonate ion-pair and 
salbutamol base, respectively, p<0.05) and the octanoate counter ion caused a 
significantly higher logD7.4 value (-0.630 vs. -1.386 for octanoate ion-pair and base, 
respectively, p<0.05) (table 2.2).  
 
Table 2.2 – Calculated logD 7.4 values for salbutamol base and all ion-pairs after shaking for 48 hours 
with a phosphate buffered saline:octanol system, pH 7.4 (± 0.2). Values shown are a mean ± standard 








The salbutamol octanoate ion-pair was investigated using photon correlation spectroscopy 
to examine whether the surfactant counter ion was forming micelles. A concentration 
range of 0.042 – 20.90 mM 20:1 salbutamol octanoate in PBS (pH 7.4) was compared to 
the same concentrations of 20:1 salbutamol sulfate. The derived count rate was observed 
Counter ion Average calculated LogD7.4 
None -1.386 (± 0.036) 
Sulfate -1.405 (± 0.265) 
Gluconate -1.241 (± 0.228) 
Glucoheptonate -1.845 (± 0.118) 
Octanoate -0.630 (± 0.055) 
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Salbutamol concentration (mM)




























for each of the concentrations, and where this value was found to be over 1000, a size 
was generated.  
It was found that there was no difference between the derived count rate values for 
salbutamol octanoate and salbutamol sulfate solution up to 0.42 mM (p > 0.05). At 2.1 and 
4.2 mM concentration there was an increase in the derived count rate for salbutamol 
octanoate, with the highest values for 4.2 mM reaching around 2000 kcps (figure 2.19). 
However, a drop in the count rate was then observed for the 21 mM concentration and this 
value did not significantly differ from the salbutamol sulfate control. There was no 
significant difference between the results for salbutamol octanoate and salbutamol sulfate 









Figure 2.19 - Comparison of the derived count rates for 20:1 salbutamol sulfate (black circle) and 
salbutamol octanoate (red triangle). Data represents a mean ± standard deviation (n=3) 
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2.3.3 The effect of ion-pairing on the solubility of salbutamol 
It was found that the solubility of salbutamol in the majority of the ion-pair powders was 
lower than that of base alone. The solubility of salbutamol in the base powder was 5.37 
mg/mL. The solubility of salbutamol in the fumarate or sulfate ion-pair powders did not 
significantly differ from the base (p > 0.05). However there was a significant difference 
between all other ion-pair powders and the base (p < 0.05). The lowest concentration of 











Figure 2.20 – Solubility of salbutamol in base and ion-pair lactose formulations in Hanks balanced salt 
solution after stirring for 24 hours with a magnetic bar in a water bath at 37
o
C. Data represents a mean 
± standard deviation (n=3). * denotes a significant difference in comparison to the salbutamol base 
powder. 
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2.4  Discussion 
Both the FTIR and HPLC ion-pair binding analysis methods showed that salbutamol forms 
an ion-pair with each of the counter ions. The absolute values for association constants 
differed by up to 2.86 between the 2 methods. This is not surprising given the different 
methods by which the analytical methods act to determine the ion-pair association. FTIR 
spectroscopy works by passing infra-red radiation through a sample and determining the 
radiation that is absorbed at specific frequencies (Wartewig and Neubert, 2005). This 
allows the analysis of complex molecular vibrations and rotations within a molecule 
(Schmitt and Flemming, 1998). These vibrational bands are specific for the molecules 
involved in the bond and their orientation and so can be used to identify functional groups 
in a molecule (Schmitt and Flemming, 1998, Wartewig and Neubert, 2005). Thus changes 
in the FTIR spectrum of salbutamol on the addition of counter ion must result from a 
change to the conformation of that bond or its environment. Upon addition of the sulfate, 
gluconate and glucoheptonate counter ions to the salbutamol solution an increase in the 
peak assigned to the N-H functionality (1596 cm-1) of the drug was observed. This could 
indicate the presence of the electrostatic attraction between the 2 ions, as ionic bonding 
would potentially limit the movement of the N-H bond. Conversely, the addition of the 
octanoate counter ion to the salbutamol solution caused an increase in the absorption of 
the peak assigned to the methyl groups of salbutamol, found at 1385 cm-1. This would 
indicate that the binding between salbutamol and the octanoate counter ion occurred in a 
different way to the previous 3 counter ions or potentially that the conformation of the ion-
pair with this hydrophobic counter ion affected the movement of the methyl groups.  
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Chromatography entails the separation of components of a mixture by use of an adsorbent 
material. During the HPLC process a liquid mobile phase is pumped through a column 
containing a stationary phase to achieve this separation (Weston and Brown, 1997). In this 
study a biphenyl stationary phase was used, meaning that the functional group presented 
to any molecules from this phase were hydrophobic biphenyl and trimethylsilyl groups. As 
such it would be expected that more hydrophobic molecules have a longer retention time, 
due to the increased interactions with the stationary phase. The retention time of 
salbutamol base in this system was 5.47 min, and this was increased with the addition of 
each of the counter ions. This would suggest that each of the ion-pairs is more 
hydrophobic than the base itself but could also be caused by a conformational change of 
the salbutamol molecule or an overall reduction of the charge on the salbutamol in ion-pair 
form that favours these interactions, and this may not result in an overall increase in log P.   
The rank order of binding strength between ion-pairs was similar after analysis with the 
HPLC and FTIR techniques. The relatively small sulfate ion had the weakest binding with 
salbutamol, with a conditional association constant of 1.57 in the FTIR study and 2.37 in 
the HPLC study. Whereas the larger and more hydrophobic octanoate counter ion 
displayed stronger binding to salbutamol with association constants of 2.56 and 3.40 from 
FTIR and HPLC, respectively. The one counter ion that did not follow the same ranking of 
strength of binding between the two techniques was the glucoheptonate counter ion. The 
salbutamol glucoheptonate ion-pair had a dissociation constant of 1.70 when studied by 
FTIR, making it the second weakest. However when studied by HPLC the ion-pair 
displayed the strongest binding of all the counter ions investigated, with a dissociation 
constant of 4.56. This indicates the possibility of a large disparity in results between 
different techniques when attempting to quantify the binding of an ion-pair.  
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Out of the 2 techniques used in this study, the FTIR would provide the most accurate 
information about the binding between the drug and the counter ion as it provides 
information on the changes in specific functional groups of the drug on association. The 
FTIR method is observing the primary interaction between the 2 counter ions, whereas the 
HPLC method is measuring a secondary interaction after further binding to a stationary 
phase. However, the HPLC method was able to provide information on salbutamol binding 
to all of the counter ions and so it was also very useful. Further techniques that could be 
used to study the association of ion-pairs include UV/vis spectroscopy and nuclear 
magnetic resonance (NMR) spectroscopy (Nie et al., 2015, Dezhampanah and Chokami, 
2014). The counter ions chosen for this study had a range of log P values and functional 
groups that could bind to the salbutamol molecule, the results show that ion-pairs form 
with both lipophilic and hydrophilic molecules and that the strength of the interaction may 
increase with the amount of binding sites on the counter ion. 
Although the 2 methods of ion-pair binding analysis gave differing results for the same ion-
pair, they both showed that the binding of each ion-pair was sufficient for the purpose of an 
ion-pairing drug delivery system. All the association constants calculated were in the order 
of 1.5 – 5. To put this in to perspective, the association constant for the binding of the 2 
ions in LiOH is 0.36, whereas the binding between a hydroxide ion and proton to give 
water has an association constant of 13.98 (Smith and Martell, 1989). This shows that the 
association between ions in the ion-pairs is stronger than that of small inorganic ions, but 
is also likely to dissociate when diluted in larger volumes of liquid as expected.  
The partitioning of salbutamol base between PBS and octanol gave a partition coefficient 
of – 1.386. This differs from the reported values of water/octanol partition coefficients for 
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salbutamol base which range from -0.79 (Lin et al., 2005) to 0.11 (Forbes et al., 2003), but 
is very similar to the predicted value at pH 7.4 which is -1.32 (Patel et al., 2016). The 
calculated Log P from Lin et al was reached after experimentation at room temperature, 
whereas the experiment in this study was conducted at 37oC, and so it is difficult to 
conclude whether the ions present in PBS, the control of pH or the difference in 
temperature could have led to the dissimilarity in results. PBS was used in this study 
instead of water in an attempt to create an environment that is a better mimic of the liquid 
in the lungs than pure water due to the physiological level of ions present (Pelfrêne et al., 
2017). It has been shown in the literature that ion-pairing a drug molecule with a counter 
ion can significantly increase or decrease the logP of the drug molecule (ElShaer et al., 
2014, Samiei et al., 2014) however residual charges on the ion-pair species can minimize 
the change in partition coefficient (Hatanaka et al., 2000).  The partitioning study showed 
that the logD7.4 of the sulfate and gluconate ion-pairs did not significantly differ from that of 
salbutamol base. The partition coefficient found in this study (- 1.405) does not significantly 
differ from literature values for the hemisulfate (-1.58) (Lin et al., 2005). However the lack 
of difference in partitioning between the base and sulfate ion-pair was unexpected, as this 
is often hypothesized to be the cause of the difference in cellular transport rates between 
the base and hemisulfate (Haghi et al., 2012). The hydrophilic counter ion glucoheptonate 
caused a significant decrease in the logD7.4 value of the base, and the hydrophobic 
octanoate counter ion caused a significant increase. However, all ion-pairs still displayed a 
negative partitioning coefficient and all fall within a relatively narrow range, which could 
suggest that the differences in cell transport between these complexes would not be 
significant (Forbes et al., 2003, Foster et al., 2000).  
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The potential for the octanoate counter ion to form an organized structure, such as 
micelles, was investigated using PCS. The critical micellar concentration (CMC) of sodium 
octanoate is reported to be 300 mM (Stanley et al., 2009), however it was unknown 
whether ion-pairing or the presence of salbutamol would effect this. Therefore the effect of 
increasing octanoate concentration on the light intensity (derived count rate) was 
examined. In the concentration range studied there was not a significant enough increase 
in the derived count rate to assume that any form of micelle had been formed.  
The solubility of salbutamol base in a lactose formulation was calculated as 5.37 mg/mL. 
This was significantly reduced in each of the ion-pair formulations apart from salbutamol 
fumarate. The glucoheptonate ion-pair had the lowest solubility at 3.53 mg/mL; this is 
contradictory to what would be expected when looking at the partition coefficient as the 
significant decrease seen would indicate that the ion-pair is more hydrophilic than the base 
itself and therefore should be more soluble. Possible explanations for this include that 
hydrophilic functional groups that were previously involved in the dissolution of salbutamol 
are now preferentially involved in the ion-pairing and that the ion-pair species negates the 
charge of the salbutamol molecule (Song et al., 2016).  
2.5 Conclusion  
Salbutamol was shown to form ion-pair complexes with a range of counter ions at differing 
strengths. The binding constants gained from HPLC studies were used to predict the 
percentage of salbutamol found in ion-pair form at physiological pH. It was found that at a 
20:1 ratio of counter ion to drug that at least 90% of salbutamol (0.00209 M) would be in 
ion-pair form for each counter ion. The logD7.4 for salbutamol base and ion-pairs was 
examined with significant changes to logD7.4 being achieved for the glucoheptonate and 
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octanoate ion-pairs. The solubility of each of the ion-pairs except for salbutamol sulfate 
and salbutamol fumarate was found to be lower than salbutamol base in a lactose 
formulation after 24 hours. The sulfate, gluconate and octanoate counter ions were chosen 
to take forward to ion-pair formulation development in Chapter 4. The gluconate and 
octanoate counter ions were chosen because of their differences in functionalities, 
gluconate is a hydrophilic counter ion with multiple sites for hydrogen bonding whilst 
octanoate is hydrophobic, and their binding strength with salbutamol (2.27 and 2.56 
association constants for salbutamol gluconate and octanoate, respectively, in the FTIR 
assay). Salbutamol sulfate was chosen as a comparison as it is the most widely known 
form of salbutamol and yet appeared to be the most weakly bound ion-pair (association 
constant is 1.57 by FTIR). The next chapter will explore the potential of salbutamol to form 
ion-pairs with novel pharmaceutical counter ions derived from phytic acid.   
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3.1 Introduction 
Phytic acid, or myo-inositol hexakisphosphate (IP6), is a compound found abundantly in 
plants, it makes up between 1 and 5% of weight of many cereals, legumes, nuts and 
pollen (Graf et al., 1987, Graf and Eaton, 1990, Gupta et al., 2015). It accounts for around 
70% of the total phosphorous content of plants (Gupta et al., 2015, Zhou and Erdman Jr, 
1995) and is also found and synthesized in animal cells (Letcher et al., 2008). Its structure 
comprises a central cyclohexane with phosphoric ester linkages present from each carbon 
(figure 3.1). Phytic acid has been found to have many advantageous interactions with the 
body: it has been shown to reduce blood glucose levels and improve insulin sensitivity in 
normal and diabetic rats (Kim et al., 2014); it has antioxidant properties, binding to Fe3+  
and preventing the formation of hydroxyl radicals (Graf et al., 1987, Hawkins et al., 1993); 
and it has even been shown to have anticancer properties (Vucenik and Shamsuddin, 








Figure 3.1 - Chemical Structure of Phytic acid at pH 7.4 
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Despite the numerous beneficial properties of the molecule, Phytic acid is often thought of 
as an anti-nutrient due to its inhibitory effect on the bioavailability of minerals such as zinc 
(Zhou and Erdman Jr, 1995, Hurrell, 2003). Phytic acid has a strong chelating capacity 
and forms complexes with minerals when ingested which are often soluble in the acidic pH 
of the stomach, but insoluble in the higher pH of the intestines, preventing uptake of the 
mineral (Zhou and Erdman Jr, 1995).  
However, it is this strong chelating ability that could make phytic acid an ideal candidate 
for an ion-pairing strategy. As well as minerals, phytic acid has the potential to form strong 
complexes with organic drug compounds, and due to the presence of multiple phosphate 
groups present on the acid, it could also bind to several drug molecules at once. Coupled 
with the fact that phytic acid is known to be found in the body, and is therefore predicted to 
be biocompatible, it is an extremely interesting molecule and its use in an ion-pairing 
formulation deserves further investigation.  
The drawback of using phytic acid in an ion-pair formulation with salbutamol is the size of 
the molecule. Phytic acid has a molecular weight of 660.03 gmol-1. A complex with one or 
multiple salbutamol molecules would result in a complex with a much larger molecular 
weight than the salbutamol ion-pairs studied in Chapter 2, and also larger than the long 
acting β2-agonists formoterol and salmeterol, which have molecular weights of 344.41 and 
415.57 gmol-1, respectively. It is well known that smaller molecules are absorbed through 
epithelial layers more rapidly (Jitendra et al., 2011) and so it is crucial that the transport of 
the drug across the bronchial epithelium is not hindered in such a way as to lengthen the 
onset of action.  
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Phytic acid is metabolized by the phytase enzyme in to smaller inositol phosphates (IP1 – 
IP5) which are also found in plants and in the body (Steer and Gibson, 2002). Both phytic 
acid and its metabolites may be suitable to form an ion-pair with salbutamol to control its 
release as it could form a large hydrophilic complex that would slowly pass through 
respiratory epithelial cell. Of the metabolites, D-myo-inositol-1,4,5-trisphosphate (IP3) was 
chosen as a second suitable candidate for an ion-pairing strategy with salbutamol (figure 
3.2). The molecular weight of this compound is much lower than phytic acid, at 420.10 
gmol-1, but it retains multiple phosphate groups that could facilitate binding with the 








Figure 3.2 - Chemical structure of D-myo-inositol-1,4,5-trisphosphate (IP3) at pH 7.4 
 
IP3 is commercially available, however it is also extremely expensive, and so a new 
synthetic method to generate the molecule in situ was thought to be required for its use in 
an ion-pairing formulation to be viable. The aim of this chapter, therefore, was to establish 
a synthetic method to generate D-myo-inositol-1,4,5-trisphosphate in sufficient quantities 
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to investigate its binding with salbutamol. This molecule and phytic acid would then be 
investigated as counter ions for an ion-pairing strategy with salbutamol using the methods 
established in Chapter 2. The effect of these ion-pairs on the lipophilicity of salbutamol 
was analyzed. 
There are 2 potential ways in which to generate the IP3 molecule, from a top-down or a 
bottom-up approach. The top-down approach would involve hydrolyzing the phytic acid 
molecule with a phytase enzyme and purifying the IP3, whereas the bottom-up approach 
would be to chemically synthesize the molecule. Preliminary studies showed that the 
dephosphorylation process was long and resulted in a mixture of many different inositol 
phosphates that were difficult to identify and separate, this correlates with findings that the 
rate and order of hydrolysis of phosphate groups by phytase enzymes are inconsistent 
(Konietzny and Greiner, 2002).  It was therefore decided that a chemical synthesis method 
of IP3 from myo-inositol would be employed for the purpose of the work in this chapter.   
Synthesis of inositol phosphate compounds is reportedly very difficult due to the chiral 
nature of the molecules and the difficulties associated with phosphorylation (Meek et al., 
1988, Durantie et al., 2016). Chemical syntheses with expensive or difficult to produce 
chiral precursors would not be suitable for production of IP3 for a ion-pairing formulation. 
Therefore a synthetic route with a limited number of synthetic steps that utilized cheap, 
readily available starting materials was chosen. The method chosen reportedly produced 
IP3 in a high yield and so it was thought to be an ideal route to IP3 for ion-pairing (Meek et 
al., 1988).   
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3.2 Materials and Methods 
3.2.1  Materials 
Salbutamol base (BN. H80619) was from Cipla Ltd, India and used without further 
purification. Myo-inositol, silicone oil, p-toluenesulfonic acid (p-TSA), trimethylamine 
(Et3N), dimethyl chlorophosphate, pyridine, diethyl ether, acetone, N,N-dimethylformamide 
(DMF), N,N-diisopropylethylamine, deuterated chloroform, deuterated water, HPLC grade 
water and PBS were all purchased from Sigma Aldrich (Dorset, UK). 2,2-
dimethoxypropane, deuterated dimethyl sulfoxide (DMSO) and acetonitrile were 
purchased from Thermo Fisher Scientific (Geel, Belgium). N-octanol, hexane and ethyl 
acetate were from Fisher Scientific (Leicestershire, UK). Benzoyl chloride and phytic acid 
dipotassium salt were both from Santa Cruz Biotechnology (USA). Deuterated methanol 
and , hydrobromic acid 45% w/v solution in acetic acid were acquired from Cambridge 
Isotope laboratories (Massachusetts, USA) and 4-dimethylaminopyridine (4-DMAP) and 
acetyl chloride were purchased from Fluka Analytical (Durban Kwuzulu Natal, South 
Africa). 
3.2.2 Synthesis of D- myo-inositol-1,4,5-trisphosphate 
The synthesis of D-myo-inositol-1,4,5-trisphosphate (IP3, compound 5) was attempted by 
following protocols found in the literature (Khersonsky and Chang, 2002, Meek et al., 
1988). The complete synthetic route is shown in figure 3.3. The synthesis and analysis of 
products were completed by MPharm students Evgenia Kyriakopoulou and Amir Khosravi-
Nik under the careful supervision of Bridie Dutton.  
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Figure 3.3 - Planned synthetic route from myo-inositol to D- myo-inositol-1, 4, 5-trisphosphate 
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3.2.2.1 Synthesis of 1,2:4,5-di-O-isopropylidene-3,6-di-O-benzoyl-
inositol 
 
Figure 3.4 - Synthetic route for synthesis of 1,2:4,5-di-O-isopropylidene-3,6-di-O-benzoyl-inositol 
(compound 2) 
 
A mixture of myo-inositol (25 g, compound 1), p-TSA (0.5 g) and 2,2-dimethoxypropane 
(75 mL) in DMF (100 mL) was heated to 120oC for 3 hours before being rotary evaporated 
to dryness. To the residual oil was added Et3N (0.36 mL) and ethyl acetate (100 mL). The 
mixture was rotary evaporated with silica (40 g) to complete dryness. The silica powder 
was put in a column (5 x 9 cm) and washed thoroughly with ethyl acetate (700 mL). The 
solvent was removed in vacuo and the residual oil was cooled to 0oC before pyridine (70 
mL) and benzoyl chloride (50 mL) were added to it. The reaction mixture was stirred for 3 
hours at room temperature. The precipitate was filtered and washed with pyridine (50 mL), 
water (150 mL), acetone (40 mL) and diethyl ether (50 mL). After vacuum drying, 1,2:4,5-
di-O-isopropylidene-3,6-di-O-benzoyl-inositol (compound 2) was collected as a white solid 
(16.8 g, 27% yield).  
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A melting point test of the collected powder was performed by filling a capillary tube with a 
small amount of the product, placing the tube in a melting point apparatus (1A9000 Series; 
Electrothermal Cat, Bibby Scientific Limited, Staffordshire, UK) and recording the 
temperature at which the product melted. The product was dissolved in deuterated 
chloroform and analyzed by 1H NMR (Bruker Advance DRX 400 MHz NMR Spectrometer). 








Figure 3.5 - Synthetic route for synthesis of 1,4-Di-O-benzoyl-myo-inositol (compound 3) 
 
TFA (23 mL) and H2O (2.3 mL) were added to a suspension of 1,2:4,5-di-O-
isopropylidene-3,6-di-O-benzoyl-inositol (compound 2) (15 g) in boiling chloroform (210 
mL). The mixture was refluxed for 1 hour and then cooled to 0oC for 1 hour. A precipitate 
formed which was filtered and washed with diethyl ether (100 mL). After vacuum drying, 
1,4-Di-O-benzoyl-myo-inositol (compound 3) was collected as a white solid (9.3 g, 75% 
yield). Melting point analysis and 1H NMR were carried out as previously described, using 
DMSO-d6 as the NMR solvent. Thin layer chromatography (TLC) was performed using 
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chloroform-methanol (9:1) as the solvent. The retention factor (Rf) was calculated and 
compared to that in the literature (Meek et al., 1988).  
3.2.2.3 Synthesis of 2-O-Acetyl-3,6-di-O-benzoyl-myo-inositol-1,4,5-
triphosphate 
 
Figure 3.6 - Synthetic route for synthesis of 2-O-Acetyl-3,6-di-O-benzoyl-myo-inositol-1,4,5-
triphosphate (compound 4) 
 
Dry diisopropylethylamine (14 mL) was added to a solution of 1,4-Di-O-benzoyl-myo-
inositol (compound 3) (5.4 g) in dry DMF (54 mL) and the solution was cooled to -40oC. 
Dimethyl chlorophosphate (5 mL) was added dropwise to the solution, ensuring that the 
temperature stayed at -40oC and the mixture was stirred for 30 minutes before it was 
allowed to warm to room temperature. 4-DMAP (134 mg) and acetyl chloride (1.9 mL) 
were added and the solution was stirred for a further 30 minutes. Hydrogen peroxide 
27.5% (18 mL) was added dropwise and the solution was cooled to 0oC and left at this 
temperature overnight. The solution was dried in vacuo before the addition of DCM (50 
mL) and H2O (100 mL). The organic layer was collected using a separating funnel and to it 
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was added anhydrous sodium sulfate (40 g). This was filtered and the filtrate was rotary 
evaporated to dryness. The product was recrystallized by dissolution in DCM (5 mL) and 
addition of hexane (50 mL). The resulting crystals were filtered and dried under vacuum to 
give 2-O-Acetyl-3,6-di-O-benzoyl-myo-inositol-1,4,5-triphosphate (compound 4) as a white 
solid (1.8 g, 17% yield). This melting point and 1H NMR in CDCl3 of this product were 
performed as described previously.  
3.2.2.4 Synthesis of D- myo-inositol-1, 4, 5-trisphosphate 
 
Figure 3.7 - Synthetic route for D- myo-inositol-1, 4, 5-trisphosphate (compound 5) 
 
Hydrolysis of 2-O-Acetyl-3,6-di-O-benzoyl-myo-inositol-1,4,5-triphosphate (compound 4) 
(1.2 g) was attempted by heating a mixture with 30% HBr in acetic acid to 60oC for 1 hour 
as described by Meek et al (Meek et al., 1988). However, this produced a yellow oil 
instead of the white powder described and so the reaction was deemed to have failed. 1H 
NMR was performed on the oil in CDCl3 as described above. 
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3.2.3 Fourier Transform Infrared Spectroscopy (FTIR) ion-pair 
binding assay 
An FTIR binding study was performed for salbutamol and phytic acid as described in 
Chapter 2. Phytic acid concentrations of 0.1, 0.2, 0.5, 1, 5 and 100 mM were used to 
achieve this.  
3.2.4 High Performance Liquid Chromatography (HPLC) ion-pair 
binding assay 
An HPLC binding assay was completed for salbutamol (100 mM) and phytic acid as 
described in chapter 2. Phytic acid concentrations of 0.001, 0.005, 0.01, 0.025, 0.05, 0.1, 
0.4 and 0.5 mM in HPLC water were used to achieve this.  
3.2.5 Calculation of salbutamol – counter ion speciation curves 
A speciation curve and percentage bound drug levels at 20:1 and 10:1 counter ion to drug 
ratios were calculated for the salbutamol phytate ion-pair as described in Chapter 2. 
3.2.6 Distribution coefficient assay 
The partitioning of the salbutamol phytate ion-pair made by a 1:1 mixture of drug to 
counter ion was performed as described in Chapter 2.   
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3.2.7 Data Analysis 
Data was obtained from 3 experiments and have been expressed as a mean ± standard 
deviation, unless otherwise stated. Sigmoidal curves were fitted to the binding data in 
SigmaPlot and the value at 50% was taken as the ion-pair binding constant. One-way 
Analysis of Variance (ANOVA) with a Shapiro-Wilkins normality test was performed with a 
probability limit of 0.05 set to indicate significant differences.  
3.3  Results 
3.3.1 Synthesis of D- myo-inositol-1, 4, 5-trisphosphate (IP3) 
A white powder was collected at the end of the first reaction stage in 27% yield (16.8 g). Its 
identity as the reaction product 1,2:4,5-di-O-isopropylidene-3,6-di-O-benzoyl-inositol 
(compound 2), was confirmed with a melting point test and NMR analysis. The melting 
point of the powder was measured as 319 – 320oC, which is close to the reported value in 
the literature (322 – 324oC) (Khersonsky and Chang, 2002). 
Integration of the 1H NMR spectrum for the isolated compound gave a total of 29 protons 
being detected, compound 2 has 28 protons, however the extra detected proton could be 
due to an impurity and is found in the region of 1 – 2 ppm (figure 3.8). Assignments were 
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Figure 3.8 - 
1
H NMR spectrum of 1,2:4,5-di-O-isopropylidene-3,6-di-O-benzoyl-inositol. Numbers shown 
underneath each peak are the calculated integral values 
 
1H NMR (CDCl3): 1.32 (s, 3H, Me), 1.46 (s, 3H, Me), 1.53 (s, 3H, Me), 1.66 (s, 3H, Me), 
3.74 (dd, 1H, H2 or H3), 4.41 (m, 2H, H5 and H6), 4.81 (dd, 1H, H2 or H3), 5.45 (dd, 1H, 
H1 or H4), 5.63 (dd, 1H, H1 or H4), 7.48 (dd, 4H, H9 and H10), 7.61 (dd, 2H, H11), 8.15 
(m, 4H, H7 and H8). The chemical shifts found are similar to predicted at reported values 
(Khersonsky and Chang, 2002).   
1,4-Di-O-benzoyl-myo-inositol (compound 3)  was collected as a white powder in a 75% 
yield (9.3 g). The melting point of this powder was 219 – 224oC which is lower than the 
reported literature value for the product (251 – 253oC) (Meek et al., 1988). TLC analysis 
showed that the collected product has an Rf value of 0.55  which conformed with the 
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literature value for 1,4-Di-O-benzoyl-myo-inositol (Meek et al., 1988). Integration of the 1H 
NMR spectrum of compound 3 calculates the structure as having 24 protons, whereas the 
actual structure contains 20. The 4 extra protons are found in the integral of the broad 
hydroxyl peak, however, and so could be as a result of proton exchange with water in the 
sample. This could be investigated by addition of D2O to the NMR sample, to allow for 











Figure 3.9 - 1H NMR spectrum of 1,4-Di-O-benzoyl-myo-inositol. Numbers under each of the peaks 
correspond with calculated integral values 
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The peaks were assigned as follows: 3.48 (t, 1H, H2 or H3), 3.72 (dd, 1H, H5 or H6), 3.91 
(t, 1H, H5 or H6), 4.06 (t, 1H,  H2 or H3), 4.13 (broad, 8H, OH), 4.82, (dd, 1H, H1 or H4), 
5.28 (t, 1H, H1 or H4), 7.51 (m, 4H, H9 and H10), 7.64 (dd, 2H, H11), 8.02 (dd, 4H, H7 
and H8). These values are in partial agreement with the literature values (Meek et al., 
1988).  
2-O-Acetyl-3,6-di-O-benzoyl-myo-inositol-1,4,5-triphosphate (compound 4)  was isolated 
as crystals after the phosphorylation reaction in a 17% yield (1.8 g), however the 
properties of these crystals did not match those reported in the literature. The melting point 
recorded (127oC) was significantly lower than the literature value for 2-O-Acetyl-3,6-di-O-
benzoyl-myo-inositol-1,4,5-triphosphate (227 – 230oC) and the Rf value on a TLC plate 
was 0.83, which was higher than the literature value (0.73) (Meek et al., 1988).  
Furthermore, the weak signals found by 1H NMR make identification difficult (figure 1.10). 
Strong peaks at δ2.8 – 3.0 indicate that the dimethyl phosphate groups have been 
incorporated into the product (compound 4), however the uneven baseline indicates that 
the isolated compound is impure. Use of compound 4 in the final stage of the synthesis 
gave a yellow oil instead of the reported white powder and so the hydrolysis was deemed 
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Figure 3.10 - 1H NMR spectrum of isolated compound after treatment of compound 3 with dimethyl 
chlorophosphate 
 
3.3.2 The binding of salbutamol with phytic acid 
Addition of phytic acid (IP6) to solutions of salbutamol resulted in an increase in the N-H 
peak for the drug at 1596 cm-1 in comparison with the benzyl peak at 1616 cm-1. It was 
shown that 100% salbutamol was found in ion-pair form at a phytate concentration of 
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Figure 3.11 - Relationship between phytic acid concentration and percentage of salbutamol bound by 
FTIR (n=1) 
 
This data was used to plot a binding affinity curve as with the counter ions in Chapter 2 
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Figure 3.12 - Salbutamol phytate binding affinity curve calculated from FTIR binding data (n=1) 
 
Addition of phytic acid to an aqueous mobile phase resulted in an increase in the retention 
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Figure 3.13 - Relationship between salbutamol retention time and phytic acid concentration in mobile 
phase of HPLC binding assay. Data represents a mean ± standard deviation (n=3) 
 
This data was used to create a binding affinity curve as previously described, which gave 
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Figure 3.14 - Affinity binding plot for salbutamol phytate ion-pair calculated from HPLC binding assay 
data. Data represents a mean ± standard deviation (n=3) 
 
The association constant calculated from HPLC ion-pair binding studies was used to plot 
speciation curves for a 10:1 and 20:1 ratio of phytic acid:salbutamol with a salbutamol 
concentration of 0.00209 M (figure 3.15). A 1:1 binding ratio was assumed and the 
percentage of salbutamol found in ion-pair form at pH 7.4 was found to be 99.98% for both 
the 10:1 and 20:1 counter ion-drug ratios.    
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Figure 3.15 - Speciation curve for 10:1 salbutamol phytate from pH 1 - 14 
 
3.3.3 The effect of ion-pairing with phytic acid on the partitioning 
of salbutamol 
The octanol-water partitioning study showed that there was no significant difference in the 
partitioning of the salbutamol phytate ion-pair in comparison with salbutamol base alone (p 
> 0.05). The calculated logD7.4 value for salbutamol phytate was -1.211 (± 0.181) 
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3.4  Discussion 
Preparation of D-myo-inositol-1, 4, 5-trisphosphate from myo-inositol was a complicated 
procedure as it required reactions to occur selectively with specific hydroxyl groups on the 
starting molecule and/or precise purification of the correct stereoisomer. The first reaction 
step, preparation of 1,2:4,5-di-O-isopropylidene-3,6-di-O-benzoyl-inositol (compound 2), is 
known to generate 3 separate isomers with the correct isomer being preferentially isolated 
due to its highly crystalline nature in comparison with the other 2 (figure 3.16) (Khersonsky 
and Chang, 2002, Gigg et al., 1985). 1H NMR of the isolated compound 2 was in 
accordance with the literature, however the melting point obtained of the crystals was 
lower than the reported value, and so it is possible that the product still contained traces of 








Figure 3.16 - 3 stereoisomers generated after reaction of myo-inositol with 2,2-dimethoxypropane and 
benzoyl chloride 
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Deprotection of 1,2:4,5-di-O-isopropylidene-3,6-di-O-benzoyl-inositol (compound 2) gave 
1,4-Di-O-benzoyl-myo-inositol (compound 3) in good yield (75%). The TLC Rf corroborated 
that the correct compound had been isolated, and 1H NMR showed that it was the major 
product (Meek et al., 1988). However, there were also trace impurities visible in the NMR 
and there was a stark difference between the melting point of the generated product and 
that found in the literature for 1,4-Di-O-benzoyl-myo-inositol (compound 3), indicating that 
isolated product was not pure and the impurities were likely to be stereoisomers A or C 
(figure 3.16) without the acetonide protecting groups (Meek et al., 1988). 
Phosphorylation or phosphitylation of myo-inositol derivatives and isolation of an 
enantiomerically pure product also presented numerous difficulties. Under acidic 
conditions the phosphate groups have a tendency to migrate to other free hydroxyl groups 
on the molecule, and attempts to resolve this problem using chiral precursors or chiral 
resolution can be tedious and low-yielding (Meek et al., 1988, Durantie et al., 2016). Due 
to these problems and the trace impurities in the precursor, 1,4-Di-O-benzoyl-myo-inositol 
(compound 3), the isolated product of 2-O-Acetyl-3,6-di-O-benzoyl-myo-inositol-1,4,5-
triphosphate (compound 4) did not have a melting point or Rf value that matched the 
literature. The 1H NMR showed that although the phosphitylation had occurred, a mixture 
of compounds were present. The literature method that was followed for the preparation of 
D-myo-inositol-1, 4, 5-trisphosphate also reported a small quantity of a tetrakis(dimethyl 
phosphate) and an unknown tris(dimethyl phosphate) in the product after phosphitylation 
(Meek et al., 1988). In the previous work these did not negatively impact the final 
deprotection step however in the present work it seemed like there was a higher quantity 
of impurities from the earlier stages of the synthesis and this caused the final step to fail. 
Recently, studies have been published that employ chiral peptide catalysts or chiral 
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phosphorous sources that allow for synthesis of enantiomerically pure inositol phosphates 
(Durantie et al., 2016, Sculimbrene and Miller, 2001, Jordan et al., 2010, Duss et al., 
2015). However, these require expensive and difficult to synthesize reagents and so would 
not be suitable to create an inositol phosphate counter ion for ion-pairing, as a large 
quantity of pure compound would be required in any final ion-pair product.  
The larger, commercially available compound, phytic acid, was shown to form ion-pairs 
with salbutamol in both the FTIR and HPLC ion-pair binding studies. Furthermore, the 
concentration of phytic acid at which binding was detected was 100 fold lower than for any 
of the counter ions studied in Chapter 2, indicating that the binding between salbutamol 
and phytic acid was much stronger. The association constants generated from these 
studies were 4.15 M by FTIR, and 5.38 by HPLC which is significantly higher than the 
constants for any of the counter ions in Chapter 2 (p < 0.05). Previous studies quantifying 
the binding of phytic acid such as that by Graf  who investigated the binding to calcium via 
titration also found that at pH 7.2 the apparent association constants for phytate and 
calcium were relatively strong (22.7 mM-1) (Graf, 1983). Previous work has also found that 
maximum binding for phytic acid occurred at pH 8.4 when the phytic acid displayed a more 
negative charge (Graf, 1983, Heighton et al., 2008). Heighton et al. investigated the 
binding of phytic acid to iron via NMR spectroscopy in D2O. He found that ferrous phytate 
had a formation constant of 0.84 and a dissociation constant of 1.19, while ferric phytate 
had a formation constant of 0.90 and a dissociation constant of 1.11 (Heighton et al., 
2008). Comparison of these values with the association constants obtained in this study 
suggest that binding between phytic acid and salbutamol is stronger than that of phytic 
acid and mineral ions. This would be expected as salbutamol has functional groups that 
have the potential to interact with the phytic acid in addition to the electrostatic interaction.  
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There was no significant difference in the partitioning of salbutamol base and salbutamol 
phytate ion-pair. Both the base and ion-pair were very hydrophilic with calculated logD7.4 
values of -1.386 and -1.211, respectively. This is likely due to phytic acid having several 
negatively charged moieties at pH 7.4 (Heighton et al., 2008), so even though the charge 
of salbutamol is hidden, the ion-pair complex will still have an overall negative charge. This 
result could provide important information on the mechanism of action of the phytate ion-
pair, should it show any differences in vitro or in vivo these can likely be attributed to the 
size of the ion-pair complex compared to the salbutamol parent drug, as the lipophilicity of 
the complex doesn’t change upon ion-pairing (Ma and Hadzija, 2012).  
3.5 Conclusion 
Chemical synthesis of D-myo-inositol-1, 4, 5-trisphosphate was attempted from myo-
inositol, however this method was abandoned due to the difficulty in separating 
stereoisomers. Salbutamol was shown to form an ion-pair complex with phytic acid that 
had a significantly higher association constant in comparison with the ion-pairs studied in 
Chapter 2. Ion-pairing was shown to have no significant effect on the partitioning of 
salbutamol between octanol and water. The next chapter will explore the incorporation of 
salbutamol ion-pairs using phytate and the chosen counter ions from Chapter 2 in to a dry 
powder formulation. Phytic acid was chosen to take forward due to the strength of binding 
with salbutamol and also to assess how the ion-pairing to increase molecular weight might 
influence salbutamol delivery. The suitability of these formulations for inhalation and 
stability of the powders will also be investigated. 
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4.1 Introduction 
There are 3 main devices employed to administer drug formulations to the lung: 
nebulizers, pressurized metered dose inhalers (pMDI), and dry powder inhalers (DPI). For 
many years the pMDI was the most widely used type of inhaler due to its advantages such 
as ease of handling and reliability (Malcolmson and Embleton, 1998). However, the pMDI 
was also found to have shortfalls. One such shortfall is that many patients find the hand-
lung coordination necessary to achieve optimal actuation of the device difficult (Newman, 
2004). As such, DPIs are becoming more and more popular. They are breath-actuated, 
meaning that the patient’s breath is the driving force used to deliver the powder to the 
lungs. They also do not need to use a propellant and could be used to deliver locally or 
systemically acting proteins or peptides, which is becoming increasingly important in the 
pharmaceutical field (Malcolmson and Embleton, 1998, Uchenna Agu et al., 2001).  
The particle characteristics are a major factor in the delivery efficacy of a DPI. It is 
essential that the production method for creating the powders has tight control over 
particle size and particle size distribution as these properties determine the aerodynamic 
properties of the particles (Chapter 1). Many of the DPI products currently available 
commercially are produced by micronization, where the crystalline form of the drug is 
broken down via a milling technique, such as jet-milling, to a desirable particle size (Chow, 
2007). However, this process can be time-consuming and inefficient as well as producing 
particles that carry high amounts of electrostatic charge, meaning that they are highly 
cohesive (Chow, 2007, Malcolmson and Embleton, 1998). In order to combat this problem, 
micronized particles are usually blended with a coarse carrier particle such as lactose. 
Drug particles are distributed over the surface of the larger carrier molecules to allow 
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sufficient segregation of the particles, when the particles are delivered to the lungs the 
drug molecule releases from the carrier to deposit in the airways (Malcolmson and 
Embleton, 1998). 
An inhaled ion-pair formulation would need to contain the drug and counter ion in a 
heterogeneous, stable mixture of the correct particle size so that the majority of drug in the 
formulation is in ion-pair form upon deposition and dissolution. When attempting to deliver 
ion-pairs to the lung, the use of a DPI formulation is the most attractive option for a number 
of reasons. Primarily, delivery to the lung in powder form could allow the ion-pair to affect 
the dissolution of the drug in the lung fluid as a mechanism of prolonging drug action. In 
addition, although a pMDI formulation could theoretically be used to deliver ion-pairs, the 
storage of the drug, counter ion, and other excipients in a solution or suspension increases 
the likelihood of dissociation of the ion-pair before inhalation. Dissolution is a driving force 
for the dissociation of ion-pairs, and so a high concentration presented by a dry powder 
formulation would give the best chance for the drug to be presented to the lung in ion-pair 
form upon administration (Samiei et al., 2013). 
When creating a dry powder ion-pair formulation there are many things that need to be 
considered. Creating particles with an excess of ions present increases the likelihood of 
the particles having a charged surface, which can have great effects on the inhaler 
retention and aerosol performance of a powder (Wong et al., 2014). It has been found in 
previous studies that deposition of inhaled particles in the lung can be enhanced by an 
electrical surface charge (Yu et al., 2017). However there is also a link between the charge 
of particles and their hygroscopicity which could negatively affect the stability of the 
powder formulation (Kwok and Chan, 2008). 
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Therefore, the aim of this chapter was to understand the effect that the inclusion of excess 
ion has on a dry powder formulation that aims to deliver an ion-pair to the lung in terms of 
the physical characteristics, surface morphology and aerosolization.  
For the purpose of the work in this thesis, spray drying was chosen as the method of 
particle engineering. The spray drying process involves the spraying of a liquid feed 
solution in to a heated chamber where droplets are formed, quickly dried and separated 
from the air in a cyclone (Louey, 2004, Chow, 2007). This technique allows very precise 
control over the size of the particle generated compared with micronization and should 
also be able to create a heterogeneous mixture of drug, counter ion and excipients (Louey, 
2004).  
Lactose was used as the bulk of the powder due it being extremely well documented and 
widely accepted as a pharmaceutical excipient for inhaled formulations, as well as readily 
available and inexpensive (Pilcer and Amighi, 2010a). However, the issue with using 
lactose in a spray dried formulation is that the technique often results in an amorphous 
form of the sugar. Crystalline lactose is normally preferred in a formulation for inhalation 
due to its inherent stability. Amorphous lactose will undergo crystallization over time 
depending on the temperature and humidity of the storage conditions and this process can 
render a powder unsuitable for inhalation (Naini, 1998, Malcolmson and Embleton, 1998).  
Other excipients that were investigated as to their suitability in a dry powder ion-pair 
formulation were polyvinylpyrrolidone (PVP) and l-leucine. The most widely studied group 
of excipients used for stabilizing amorphous lactose is polymers, particularly PVP (Mahlin 
et al., 2006). PVP is a popular choice as it has already been approved by the Food and 
Drug Administration (FDA) for use in a variety of routes of drug administration, including 
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use in a pMDI (Sou et al., 2016, Berggren and Alderborn, 2003b). Amino acids, such as 
leucine, have been shown to reduce hygroscopicity and improve the in vitro deposition of 
powders, they can also be used as stabilizers for certain biomolecules (Pilcer and Amighi, 
2010a, Chen et al., 2016). Leucine is the most widely studied amino acid incorporated in to 
DPI formulations. Spray drying powders with leucine increases the dispersion of fine 
particles and may also have some protective ability against the crystallization of 
amorphous materials (Chen et al., 2016, Mangal et al., 2015).  
The powders formed were analyzed for particle size, drug uniformity, surface morphology 
and chemical stability. The in vitro deposition of the powders was also assessed. These 
experiments were repeated after one month in different storage conditions in order to 
assess the stability of the powders.  
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4.2 Materials and Methods 
4.2.1 Materials 
Lactohale 300 (Friesland foods, Netherlands) was used as a source of lactose. Salbutamol 
base (BN. H80619) was from Cipla Ltd, India and used without further purification. Sodium 
sulfate was purchased from Alfa Aesar, UK. Sodium octanoate, polyvinylpyrrolidone (10k) 
and l-leucine were obtained from Sigma Aldrich (Dorset, UK). Sodium gluconate and 
dipotassium phytate were purchased from Santa Cruz Biotechnology (USA). For HPLC 
analysis, phosphate buffered saline was from Oxoid Ltd (Hampshire, UK), ammonium 
acetate was purchased from VWR (Leicestershire, UK). HPLC grade methanol and water 
were supplied by Fisher ltd (Leicestershire, UK).  
4.2.2 Spray Drying 
The following formulations were generated via spray drying using the method described in 
Chapter 2:  
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Table 4.1 -Salbutamol ion-pair formulations generated via spray drying 
 
The generated powders were stored in a sealed container with phosphorous pentoxide 
dessicant at either room temperature or 4oC. 
 
Formulation 1 2 3 
Salbutamol base 






99% Lactose with 1% 
salbutamol 
20:1 counter ion to drug 
sulfate 
98.5% Lactose with 1% 
salbutamol 
20:1 counter ion to drug 
0.5% 10k PVP 
sulfateP 
93.5% Lactose with 1% 
salbutamol 
20:1 counter ion to drug 






99% Lactose with 1% 
salbutamol 
20:1 counter ion to drug 
gluconate 
98.5% Lactose with 1% 
salbutamol 
20:1 counter ion to drug 
0.5% 10k PVP 
gluconateP 
93.5% Lactose with 1% 
salbutamol 
20:1 counter ion to drug 






99% Lactose with 1% 
salbutamol 
20:1 counter ion to drug 
octanoate 
 
98.5% Lactose with 1% 
salbutamol 
20:1 counter ion to drug 
0.5% 10k PVP 
octanoateP 
 
93.5% Lactose with 1% 
salbutamol 
20:1 counter ion to drug 






99% Lactose with 1% 
salbutamol 
1:1 counter ion to drug 
phytate 
98.5% Lactose with 1% 
salbutamol 
1:1 counter ion to drug 
0.5% 10k PVP 
phytateP 
 
93.5% Lactose with 1% 
salbutamol 
1:1 counter ion to drug 
0.5% 10k PVP 
5% l-leucine 
phytatePL 
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4.2.3 Particle Sizing 
The spray dried powders were sized using a Helos/Rodos laser diffraction particle-size 
analyzer (Sympatec, Germany). The equipment was verified using a silicone carbonate 
P600 – 09 standard provided by the manufacturer. Approximately 100 mg of powder was 
used to obtain each size distribution. The R1 lens was used (size range 0.1 μm – 35 μm), 
the dispersion pressure was set at 6.00 bar and the vacuum was set at 30 - 32 mbar. 
Particle size distribution (PSD) was characterized using Fraunhofer theory and analyzed 
using WINDOX 4.0 software. The PSD was reported as x10, x50, x90 and volume mean 
diameter. x50 represents the median particle volume diameter and x10 and x90 are the 10
th 
and 90th percentile, respectively.  
4.2.4 Scanning Electron Microscopy (SEM) 
The spray dried particles were visualized within a week of being generated. The sample 
was deposited with a brush on a carbon disc stuck to an aluminum stub. The stub was 
then coated with platinum for 60 seconds. SEM images were obtained using a Zeiss Supra 
25 SEM (Carl Zeiss AG, Germany).  
4.2.5 High Performance Liquid Chromatography (HPLC) 
Concentrations of salbutamol were calculated using the HPLC method established in 
Chapter 2.  
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4.2.6 Content uniformity 
The spray dried powder (10 mg) was weighed out 5 times and dissolved in 80% (v/v) 
water-methanol (10 mL). The samples were analyzed by HPLC. Data were represented as 
a percentage of the loaded dose of 100 μg of salbutamol per 10 mg of powder. 
4.2.7 In Vitro Drug Deposition 
The in vitro drug deposition was analyzed using a Next Generation Impactor (NGI; Copley 
Scientific, UK) and a Phoenix Monodose dry powder inhaler (Plastiape, Italy). A total of 3 
assessments were carried out for each spray dried formulation and 5 capsules were used 
per assessment. Capsules were prepared by manually loading 12.5 (± 0.5) mg of spray 
dried powder in to a size 3 hard gelatin capsule (Meadow Laboratories Ltd, Essex, UK). 
The NGI was set up according to the USP (Pharmacopeia). The NGI collection cups were 
coated with 19.25% PEG200 in acetone, 4 mL for stage 1, and 2 mL for all other stages. 
The formulations were tested at 100 L/min for 2.5 seconds. After testing, the throat, all 
stages and the external filter paper were washed with 80% (v/v) water-methanol mixture. 
HPLC was used to quantify the amount of salbutamol deposited at each stage.  
4.2.8 Data Analysis 
Data obtained for each experiment were expressed as a mean ± standard deviation (SD) 
unless otherwise stated, n = 3. One-way Analysis of Variance (ANOVA) with a Shapiro-
Wilkins normality test was performed with a probability limit of 0.05 set to indicate 
significant differences. Graphs were created using Sigmaplot software (Sigmaplot 12.5, 
Systat Software, Inc) and error bars show SD. 
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In vitro deposition data were represented as a mass median aerodynamic diameter 
(MMAD), geometric standard deviation (GSD), emitted dose (ED), and fine particle fraction 
(FPF). 
The calculated average MMAD value for each formulation was compared to the average 
Volume mean diameter (VMD) using the following formulation: 
da=√ρpdv
2
/χ                                                                                     [ Equation 4.1] 
 
where: 
da = aerodynamic diameter, ρp = true density of the particle, dv = diameter of equivalent 
volume sphere, χ = dynamic shape factor.  
The ED of the formulation was calculated as the mass deposited in the throat and stages 
1-8 of the NGI as a percentage of the mean content of salbutamol found in the content 
uniformity analysis. The FPF was determined as the percentage of the ED that has a 
particle size less than 5 μm. MMAD and GSD were calculated from the inverse normal of 
the cumulative percentage under the stated aerodynamic diameter versus the log effective 
cut off diameter.   
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4.3 Results 
4.3.1 The effect of counter ions on the spray dried formulation 
Spray drying the salbutamol - counter ion formulations resulted in a white powder in at 
least 20% yield (table 4.2). There was no difference in the yield or size of the particle 
between the base and sulfate formulations (p > 0.05). However the gluconate, octanoate 
and phytate formulations all resulted in a significantly smaller particle size (p < 0.05) (table 
4.2). The yield of the spray drying process reduced as the particle size reduced.  
Table 4.2 - Spray drying and laser diffraction particle size results for formulations (base, sulfate, 
gluconate, octanoate, and phytate). X50 is the median particle volume diameter and VMD is the volume 
mean diameter. 
 
SEM pictures showed that the particles were smooth and spherical. The particles also 
appeared to be agglomerated. The particle size range in the SEM images was from 1 – 15 
μm. It is shown that the octanoate and gluconate formulations have slightly smaller 
particles on average, but they also seem to show more agglomeration (figure 4.1).  
 
Formulation Yield (%) x50 (μm) VMD (μm) 
Base 51 (±2.00) 3.68 (± 0.26) 3.96 (± 0.30) 
Sulfate 49 (± 9.02) 3.61 (± 0.28) 3.88 (± 0.25) 
Gluconate 20 (± 2.31) 2.57 (± 0.35) 2.82 (± 0.36) 
Octanoate 36 (± 1.53) 3.28 (± 0.06) 3.60 (± 0.06) 
Phytate 40 (± 6.43) 3.26 (± 0.27) 3.56 (± 0.28) 
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Figure 4.1 – Scanning electron microscopy images of salbutamol ion-pair formulations. Top left = base, 
top right = sulfate, middle left = gluconate, middle right = octanoate, bottom left = phytate) 
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To investigate the content uniformity of the spray dried powder five 10 mg samples were 
analyzed via HPLC. Powders were considered homogenous when no more than one of 
the samples fell outside of 85 – 115 % of the mean content, and no samples fell outside of 
75 – 125% of the mean (Pharmacopoeia, 2011). The salbutamol - counter ion formulations 
show that some of the drug was lost during the spray drying procedure, with around 75 – 
80% of the amount added in to the original feedstock being incorporated in to the final 
powder (table 4.3). All of the powders in these formulations were considered to be 
homogeneous. 
Table 4.3 – Percentage of salbutamol from spray drying feedstock that was incorporated in to the 
powder for formulations base, sulfate, gluconate, octanoate, and phytate 
Formulation Salbutamol content (%) 
Base 85.63 (± 7.27) 
Sulfate 77.04 (± 0.91) 
Gluconate 75.54 (± 4.52) 
Octanoate 84.79 (± 3.43) 
Phytate 79.78 (± 7.69) 
 
In vitro deposition of salbutamol was assessed using an NGI with a throat, stages 1 – 8 
and an external filter. The addition of the sulfate counter ion to the powder had no effect 
on the drug’s deposition within the system and as such the formulation had the same 
MMAD and FPF as the control (p > 0.05) (figure 4.2, table 4.4). The gluconate formulation 
which had a smaller particle size had a reduced deposition in stage 1 of the NGI, and a 
greater amount of the drug was deposited in to the later stages (p < 0.05) (figure 4.2). The 
changes in deposition resulted in a significantly smaller MMAD and higher FPF value for 
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this formulation (p < 0.05) (table 4.4). The octanoate and phytate formulations had a 
higher deposition of drug in the throat, and a much lower deposition in stage 1 when 
compared with the base formulation (p < 0.05). However this did not appear to have a 
detrimental effect on the deposition in the lower stages (figure 4.2). As these formulations 
appeared to have better deposition in to the later stages compared with the control, they 
also had a significantly smaller MMAD value (p <0.05) (table 4.4). There was no difference 
in the FPF values for the octanoate or phytate formulations in comparison with the base 











Figure 4.2 – Deposition of salbutamol on all stages of the Next Generation Impactor as a percentage of 
the total emitted dose for ion-pair formulations. Data shown represents the mean ± standard deviation 
(n=3) 
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Table 4.4 - Parameters derived from the stage by stage Next Generation Impactor deposition data for 
formulations base - phytate. Emitted dose (ED), mass median aerodynamic diameter (MMAD), 
geometric standard deviation (GSD), and fine particle fraction (FPF). 
 
Formulation ED (%) MMAD (μm) GSD (μm) FPF (%) 
Base 74.24 (± 2.14) 6.30 (± 0.71) 2.31 (± 0.04) 25.34 (± 4.08) 
Sulfate 74.28 (± 1.35) 6.24 (± 0.36) 2.20 (± 0.09) 25.14 (± 1.42) 
Gluconate 76.57 (± 1.71) 4.85 (± 0.35) 2.09 (± 0.01) 33.52 (± 3.24) 
Octanoate 79.00 (± 3.06) 4.85 (± 0.73) 2.39 (± 0.18) 27.83 (± 2.84) 
Phytate 71.38 (± 6.96) 4.93 (± 0.36) 2.16 (± 0.11) 26.96 (± 3.74) 
 
The calculated MMAD values for each formulation were compared to the VMD values 
found in particle sizing to assess how the aerosol performed using the equation shown in 
part 4.2.8. As the SEM pictures show that the particles are spherical a dynamic shape 
factor of 1 was used.  
For each formulation the calculated aerodynamic diameter (da) is lower than the calculated 
MMAD value, suggesting that the aerosolization of the powders was not complete. The 
octanoate and phytate formulations appear to be the ones that are better aerosolized 
(table 4.5).  
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Table 4.5 – Comparison of average mass median aerodynamic diameter (MMAD) from next generation 
impactor data, volume mean diameter (VMD) from laser diffraction, and aerodynamic diameter (da) 
calculated from laser diffraction VMD data for ion-pair formulations  
 
Formulation MMAD (μm) VMD (μm) Calculated da (μm) 
Base 6.30 (± 0.71) 3.96 (± 0.30) 4.88 
Sulfate 6.24 (± 0.36) 3.88 (± 0.25) 4.79 
Gluconate 4.85 (± 0.35) 2.82 (± 0.36) 3.48 
Octanoate 4.85 (± 0.73) 3.60 (± 0.06) 4.43 
Phytate 4.93 (± 0.36) 3.56 (± 0.28) 4.38 
 
4.3.2 The effect of PVP on performance and stability 
 PVP was added to the formulations as a stabilizing agent for the amorphous lactose. It 
was added as 0.5% of the overall powder weight and so the amount of lactose in the 
formulation was slightly lower than for the previous powders. The result of the addition of 
PVP was a slight increase in the yield of spray drying process. There was no significant 
difference in the size of the particles when compared with the equivalent formulation 
without PVP (p > 0.05). The octanoateP and phyateP had a significantly smaller particle 
size in comparison with the base formulation (p < 0.05) (table 4.6).   
Using Ion-pairs to Control Salbutamol Delivery to the Lungs 
 
 
Chapter 4 – Respirable Powder Formulations of Ion-paired Salbutamol 
139 









). X50 is the median particle volume diameter and VMD 
is the volume mean diameter. 
 
 The SEM pictures of the salbutamol ion-pair formulations with PVP showed that the 
addition of the PVP had an effect on the surface of the particles compared to the 
formulations without PVP. While the particles remain spherical, an uneven surface can be 







   
Formulation Yield (%) x50 (μm) VMD (μm) 
Base 51 (±2.00) 3.68 (± 0.26) 3.96 (± 0.30) 
SulfateP 59 (± 1.53) 3.92 (± 0.07) 4.14 (± 0.07) 
GluconateP 36 (± 6.66) 3.36 (± 0.13) 3.61 (± 0.29) 
OctanoateP 32 (± 6.11) 3.06 (± 0.12) 3.39 (± 0.12) 
PhytateP 35 (± 3.27) 3.23 (± 0.07) 3.46 (± 0.06) 
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Figure 4.3 – Scanning electron microscopy images of polyvinylpyrrolidone formulations (top left = 
sulfate
P
, top right = gluconate
P
, bottom left = octanoate
P




After the addition of PVP the spray dried formulations demonstrated 1 – 3 samples that fell 
outside the 75 – 125% of the mean uniformity range. The gluconateP formulation was the 
most homogeneous of the PVP formulations, with 1 sample having a result of 126% of the 
average, and the rest falling within 94 – 101% (table 4.7).  
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Table 4.7 – Percentage of salbutamol from spray drying feedstock that was incorporated in to the 









Formulation Salbutamol content (%) 
Salbutamol Base 85.63 (± 7.27) 
SulfateP 101.05 (± 25.38) 
GluconateP 85.36 (± 6.62) 
OctanoateP 88.41 (± 17.55) 
PhytateP 85.15 (± 13.57) 
 
The sulfateP and gluconateP had a much larger deposition of powder in the throat of the 
NGI compared with the sulfate and gluconate formulations (p < 0.05). As a result of this 
there is a significantly decreased amount of sulfateP and gluconateP powder deposited in 
stage 1 (p < 0.05); however the deposition in the later stages is very similar to the base 
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Figure 4.4 – Deposition of salbutamol on all stages of the Next generation impactor as a percentage of 









. Data shown represents the mean ± standard deviation (n=3) 
 
The results show that significantly less of the sulfateP and octanoateP formulations emitted 
from the inhaler (p < 0.05), even though both of these formulations have a lower MMAD 
value than their counter ion only equivalents (p < 0.05). The calculated FPF for gluconateP 
was almost 10% lower than the gluconate formulation. The FPF for the octanoateP 
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Table 4.8 - Parameters derived from the stage by stage Next Generation Impactor deposition data for 








. Emitted dose (ED), mass median 
aerodynamic diameter (MMAD), geometric standard deviation (GSD), and fine particle fraction (FPF). 
 
Formulation ED (%) MMAD (μm) GSD (μm) FPF (%) 
Base 74.24 (± 2.14) 6.30 (± 0.71) 2.31 (± 0.04) 25.34 (± 4.08) 
SulfateP 68.78 (± 2.41) 5.50 (± 0.11) 2.24 (± 0.03) 22.87 (± 3.41) 
GluconateP 73.91 (± 3.79) 5.15 (± 0.62) 2.30 (± 0.16) 25.74 (± 3.44) 
OctanoateP 64.10 (± 3.54) 4.41 (± 0.21) 2.30 (± 0.11) 36.23 (± 1.45) 
PhytateP 83.63 (± 5.07) 5.51 (± 0.40) 2.22 (± 0.02) 28.19 (± 1.01) 
 
For all PVP formulations the calculated aerodynamic diameter is lower than the 
experimental MMAD. Again the octanoateP formulation appears to be the best aerosolized 
of the PVP powders, with less than 0.25 μm difference between the two values (table 4.9). 
Table 4.9 – Comparison of average mass median aerodynamic diameter (MMAD) from next generation 
impactor data, volume mean diameter (VMD) from laser diffraction, and aerodynamic diameter (da) 
calculated from laser diffraction VMD data for ion-pair PVP formulations  
 
Formulation MMAD (μm) VMD (μm) Calculated da (μm) 
SulfateP 5.50 (± 0.11) 4.14 (± 0.07) 5.10 
GluconateP 5.15 (± 0.62) 3.61 (± 0.29) 4.45 
OctanoateP 4.41 (± 0.21) 3.39 (± 0.12) 4.18 
PhytateP 5.51 (± 0.40) 3.46 (± 0.06) 4.26 
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The stability of the powders with and without PVP was tested after storage for 1 month 
with dessicant, either at room temperature or 4oC. Repetition of the content uniformity 
study of the formulations containing only counter ion after this time suggested that these 
powders were unstable as samples fell outside 75 – 125% of the mean. Although there 
was no change in the mean drug concentration, there was a great increase in the 
variability of the results for all formulations (table 4.10). 
Table 4.10 – Comparison of the percentage of salbutamol from spray drying feedstock that was 
incorporated in to the powders for the salbutamol counter ion formulations prior to storage (T0)  and 




The in vitro drug deposition study of the base formulation after 4 weeks showed that there 
was a greater deposition of powder in the throat, and reduced deposition in stages 1 and 2 
(p < 0.05). The deposition in the later stages did not significantly differ, and there was no 
difference in the results between the two storage conditions (figure 4.5). The same 
deposition pattern was observed for the sulfate formulation after storage (figure 4.6). 
 
Formulation Salbutamol 
content at T0 (%) 
Salbutamol content at 
T28 after storage at 
RT (%) 
Salbutamol content at 
T28 after storage at 4oC 
(%) 
Base 85.63 (± 7.27) 104.24 (± 18.02) 97.36 (± 15.27) 
Sulfate 77.04 (± 0.91) 79.93 (± 14.88) 80.12 (± 11.14) 
Gluconate 75.54 (± 4.52) 83.56 (± 15.08) 78.71 (± 12.92) 
Octanoate 84.79 (± 3.43) 86.70 (± 9.55) 82.27 (± 9.69) 
Phytate 79.78 (± 7.69) 74.80 (± 11.72) 79.25 (± 11.08) 
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Sulfate T28 stored at RT











Figure 4.5 - Deposition of salbutamol in base formulation in next generation impactor (NGI) prior to 
storage (T0) and after 1 month storage (T28) after storage with dessicant at room temperature and 4
o
C. 








Figure 4.6 – Deposition of salbutamol in sulfate formulation in next generation impactor (NGI) prior to 
storage (T0) and after 1 month storage (T28) after storage with dessicant at room temperature and 4
o
C. 
Data represents a mean ± standard deviation (n=3) 
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There was no significant difference in the deposition of the gluconate or octanoate 








Figure 4.7 – Deposition of salbutamol in gluconate formulation in next generation impactor (NGI) prior 
to storage (T0) and after 1 month storage (T28) after storage with dessicant at room temperature and 
4
o
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Figure 4.8 – Deposition of salbutamol in octanoate formulation in next generation impactor (NGI) prior 
to storage (T0) and after 1 month storage (T28) after storage with dessicant at room temperature and 
4
o
C. Data represents a mean ± standard deviation (n=3) 
 
After 1 month the deposition of the phytate formulation showed an increased deposition in 
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Phytate T28 stored at RT











Figure 4.9 – Deposition of salbutamol in phytate formulation in next generation impactor (NGI) prior to 
storage (T0) and after 1 month storage (T28) after storage with dessicant at room temperature and 4
o
C. 
Data represents a mean ± standard deviation (n=3) 
 
The variance in the original content uniformity results for the PVP containing formulations 
was generally decreased after storage for 1 month, and formulations that initially failed the 
homogeneity criteria were found to pass. There was no significant difference in the 
salbutamol content for any of the PVP ion-pair formulations (p > 0.05). There was a 
significant increase in the variation of the results for the gluconateP powder that was stored 
at RT, suggesting that this formulation was more stable under the 4oC conditions (p < 
0.05) (table 4.11).  
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Table 4.11 – Comparison of the percentage of salbutamol from spray drying feedstock that was 
incorporated in to the powders for the salbutamol-counter ion-polyvinyl pyrrolidone formulations prior 





The sulfateP powder stored at RT displayed a significant decrease in deposition in the 
throat, as well as an increase in the powder found in stage 1 (p < 0.05) (figure 4.10). 
However, the powder stored at 4oC had the same deposition pattern as at the initial time 
point (p > 0.05) (figure 4.10). 
For the gluconateP formulation there was no difference in deposition between the powders 
from the 2 storage conditions (p > 0.05). For both, a decreased deposition in the throat 
and increased deposition in stages 1 and 2 were observed (p < 0.05) (figure 4.11). 
 
Formulation Salbutamol 
content at T0 (%) 
Salbutamol content at 
T28 after storage at 
RT (%) 
Salbutamol content at 
T28 after storage at 4oC 
(%) 
Base 85.63 (± 7.27) 104.24 (± 18.02) 97.36 (± 15.27) 
SulfateP 101.05 (± 25.38) 97.87 (± 11.04) 98.02 (± 16.05) 
GluconateP 85.36 (± 6.62) 70.35 (± 17.91) 73.75 (± 8.39) 
OctanoateP 88.41 (± 17.55) 84.23 (± 4.65) 85.70 (± 6.83) 
PhytateP 85.15 (± 13.57) 88.97 (± 11.24) 85.29 (± 9.77) 
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Figure 4.10 – Deposition of salbutamol in sulfate
P
 formulation in next generation impactor (NGI) prior 
to storage (T0) and after 1 month storage (T28) after storage with dessicant at room temperature and 
4
o








Figure 4.11 – Deposition of salbutamol in gluconate
P
 formulation in next generation impactor (NGI) 
prior to storage (T0) and after 1 month storage (T28) after storage with dessicant at room temperature 
and 4
o
C. Data represents a mean ± standard deviation (n=3) 
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The octanoateP powder that had been stored at RT showed an increased deposition in 
stage 1 of the NGI (p < 0.05). The powder that had been stored at 4oC showed an 








Figure 4.12 – Deposition of salbutamol in octanoate
P
 formulation in next generation impactor (NGI) 
prior to storage (T0) and after 1 month storage (T28) after storage with dessicant at room temperature 
and 4
o
C. Data represents a mean ± standard deviation (n=3) 
 
The phytateP formulation appeared to behave similarly after storage for 4 weeks under 
both conditions. An increase in deposition of the powder in the throat was seen, along with 
a decrease of deposition in stage 1 (p < 0.05) (figure 4.13). 































 T28 stored at RT
Octanoate
P
 T28 stored at 4
o
C
Using Ion-pairs to Control Salbutamol Delivery to the Lungs 
 
 








Figure 4.13 – Deposition of salbutamol in phytate
P
 formulation in next generation impactor (NGI) prior 
to storage (T0) and after 1 month storage (T28) after storage with dessicant at room temperature and 
4
o
C. Data represents a mean ± standard deviation (n=3) 
 
The ED, MMAD, GSD, and FPF information from each experiment was analyzed and 
compared against the values at T0 to determine if they remained stable after the 4 weeks 
for each formulation. FDA guidance states that a 10% change in the total mass of relevant 
fine particles would be considered significant (Drug, 1998). Therefore, formulations were 
determined to be unstable if the results after 4 weeks varied by over 10% for the ED and 
FPF values, more than 0.5 μm for the MMAD and more than 0.2 μm for the GSD. The 
overall formulation was deemed unstable if more than 1 of these failed the stability check 
or if the one that failed did so by double the acceptable limit (table 4.12 and 4.13). 
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Table 4.12 – Comparison of the calculated results for ED, MMAD, GSD, and FPF for formulations Base - Phytate
P 
after storage for 4 weeks at room 
temperature (RT). Powders passed the stability check if the emitted dose (ED) and fine particle fraction (FPF) did not vary by over 10% the geometric 
standard deviation (GSD) did not vary by over 0.2 μm, and the mass median aerodynamic diameter (MMAD) did not vary by over 0.5 μm from the values prior 











Formulation ED (%) MMAD (μm) GSD (μm) FPF (%) Stable? 
Base x x   x 
Sulfate x     
Gluconate x     
Octanoate x x   x 
Phytate x     
SulfateP x x   x 
GluconateP x x   x 
OctanoateP  x    
PhytateP      
Using Ion-pairs to Control Salbutamol Delivery to the Lungs 
 
 
Chapter 4 – Respirable Powder Formulations of Ion-paired Salbutamol 
154 
 
Table 4.13 – Comparison of the calculated results for ED, MMAD, GSD, and FPF for formulations Base - Phytate
P 
after storage for 4 weeks at 4
o
C. Powders 
passed the stability check if the emitted dose (ED) and fine particle fraction (FPF) did not vary by over 10% the geometric standard deviation (GSD) did not 
vary by over 0.2 μm, and the mass median aerodynamic diameter (MMAD) did not vary by over 0.5 μm from the values prior to storage. If 2 or more of these 








Formulation ED (%) MMAD (μm) GSD (μm) FPF (%) Stable? 
Base x    x 
Sulfate x    x 
Gluconate x    x 
Octanoate x    x 
Phytate x    x 
SulfateP x     
GluconateP  x    
OctanoateP      
PhytateP      
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4.3.3 The effect of l-leucine on aerosolisability 
The use of l-leucine in the formulation was to increase dispersity and therefore the amount 
of powder that would be inhaled. L-leucine was added as 5% of the total powder weight in 
the feed solution. The addition of the excipient further increased the yield of the powders 
(table 4.15). For all the formulations but the octanoate, the resultant powder was visibly 
much freer flowing. The particle size of the sulfatePL and gluconatePL formulations further 
increased from 3.92 and 3.36 μm, respectively, to give a size of 4.21 and 3.94 μm, 
respectively (p < 0.05) (table 4.15). Although the size of the octanoatePL significantly 
increased from the octanoateP (p < 0.05), there was no significant difference between that 
and the octanoate formulation (p > 0.05). There was also no significant change in the size 
of the particles in the phytatePL formulation (p > 0.05) (table 4.14).  
SEM pictures show that the l-leucine also affected the surface morphology of the spray 
dried particles. Fewer particles are seen to have the smooth appearance that was initially 
observed and there is an increase in uneven, “dimpled” looking particles and also broken 
particles (figure 4.14).   
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. X50 is the median particle volume diameter and VMD is the 




















Formulation Yield (%) x50 (μm) VMD (μm) 
Base 51 (±2.00) 3.68 (± 0.26) 3.96 (± 0.30) 
SulfatePL 65 (± 2.52) 4.21 (± 0.05) 4.43 (± 0.07) 
GluconatePL 68 (± 2.08) 3.94 (± 0.06) 4.17 (± 0.05) 
OctanoatePL 51 (± 1.53) 3.20 (± 0.04) 3.47 (± 0.04) 
PhytatePL 68 (± 1.53) 3.23 (± 0.07) 4.39 (± 0.02) 
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The content uniformity results for the sulfatePL and phytatePL formulations showed that 
almost the entirety of the drug that was in the feedstock for spray drying was incorporated 
in to the resultant powder, with averages of 90 and 95% respectively (table 4.15). All of 
these powders apart from the octanoatePL formulation were considered homogeneous 
according to the previously stated definition.  
 
Table 4.15 – Percentage of salbutamol from spray drying feedstock that was incorporated in to the 









Formulation Salbutamol content (%) 
Base 85.63 (± 7.27) 
SulfatePL 89.93 (± 5.56) 
GluconatePL 73.62 (± 11.82) 
OctanoatePL 79.88 (± 10.41) 
PhytatePL 94.85 (± 3.28) 
 
Addition of l-leucine in to the formulation was proposed to increase the dispersion 
efficiency of the powder; however this effect was only seen for sulfatePL which has 
increased deposition in stages 2 -7 when compared with the base (figure 4.15). The 
octanoatePL showed an increased MMAD value when compared to its PVP only 
equivalents (p < 0.05) (table 4.16). The phytatePL formulation showed a decreased MMAD 
value in comparison to the phytateP formulation (p < 0.05), but there was no difference 
when compared with the phytate formulation (p > 0.05). 
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Figure 4.15 – Deposition of salbutamol on all stages of the Next Generation Impactor as a percentage 









. Data shown represents the mean ± standard deviation (n=3) 
 
The addition of l-leucine did increase the amount of powder emitted from the inhaler for all 
formulations, with a maximum of almost 88 % being emitted for gluconatePL. As a result of 
this the FPF for each formulation except octanoatePL increased, being around 5 – 10 % 
higher than the PVP only formulations (table 4.16).  
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Table 4.16 - Parameters derived from the stage by stage Next Generation Impactor deposition data for 
formulations base, sulfate
PL
, gluconatePL, octanoatePL and phytate
PL
. Emitted dose (ED), mass 
median aerodynamic diameter (MMAD), geometric standard deviation (GSD), and fine particle fraction 
(FPF). 
 
Formulation ED (%) MMAD (μm) GSD (μm) FPF (%) 
Base 74.24 (± 2.14) 6.30 (± 0.71) 2.31 (± 0.04) 25.34 (± 4.08) 
SulfatePL 79.38 (± 1.12) 5.19 (± 0.15) 2.51 (± 0.03) 34.93 (± 3.36) 
GluconatePL 87.58 (± 2.74) 5.30 (± 0.26) 2.44 (± 0.22) 29.96 (± 5.08) 
OctanoatePL 84.42 (± 2.09) 5.09 (± 0.38) 2.56 (± 0.04) 33.39 (± 1.21) 
PhytatePL 80.44 (± 3.24) 4.99 (± 0.14) 2.48 (± 0.08) 32.01 (± 1.13) 
 
The calculated aerodynamic diameters for the sulfatePL and phytatePL powders were 
greater than the experimental MMAD, suggesting that the addition of l-leucine enhanced 
the aerosolization of these powders (table 4.17).  
Table 4.17 – Comparison of average mass median aerodynamic diameter (MMAD), volume mean 










Formulation MMAD (μm) VMD (μm) Calculated da (μm) 
SulfatePL 5.19 (± 0.15) 4.43 (± 0.07) 5.46 
GluconatePL 5.30 (± 0.26) 4.17 (± 0.05) 5.14 
OctanoatePL 5.09 (± 0.38) 3.47 (± 0.04) 4.27 
PhytatePL 4.99 (± 0.14) 4.39 (± 0.02) 5.41 
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The stability of the leucine formulations was tested in the same way as the PVP and 
counter ion formulations. 
The content uniformity results after 4 weeks of storage seem to indicate that the leucine 
formulations are more stable than the PVP and counter ion ones, especially when stored 
at RT. The results for each of the leucine powders stored at RT do not significantly differ 
from the initial results, and there is no significant increase in variability (p > 0.05). This is 
also true of the octanoatePL and phytatePL powders stored at 4oC (table 4.18). 
Table 4.18 – Comparison of the percentage of salbutamol from spray drying feedstock that was 
incorporated in to the powders for the salbutamol-counter ion-polyvinyl pyrrolidone-leucine 






content at T0 (%) 
Salbutamol content at 
T28 after storage at 
RT (%) 
Salbutamol content at 
T28 after storage at 4oC 
(%) 
Base 85.63 (± 7.27) 104.24 (± 18.02) 97.36 (± 15.27) 
SulfatePL 89.93 (± 5.56) 83.03 (± 8.83) 86.57 (± 13.11) 
GluconatePL 73.62 (± 11.82) 78.94 (± 6.70) 80.01 (± 11.08) 
OctanoatePL 79.88 (± 10.41) 76.67 (± 6.46) 80.66 (± 6.10) 
PhytatePL 94.85 (± 3.28) 91.82 (± 3.24) 90.42 (± 6.04) 
 
There was no change in the deposition profile of the sulfatePL or gluconatePL formulation 
after storage for 4 weeks under either condition (p > 0.05) (figure 4.16, 4.17). 
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Figure 4.16 – Deposition of salbutamol in sulfate
PL
 formulation in next generation impactor (NGI) prior 
to storage (T0) and after 1 month storage (T28) after storage with dessicant at room temperature and 
4
o








Figure 4.17 – Deposition of salbutamol in gluconate
PL
 formulation in next generation impactor (NGI) 
prior to storage (T0) and after 1 month storage (T28) after storage with dessicant at room temperature 
and 4
o
C. Data represents a mean ± standard deviation (n=3) 
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Although there was no significant difference in results between the 2 storage conditions, 
the deposition of the octanoatePL formulation after a month showed a significant increase 








Figure 4.18 – Deposition of salbutamol in octanoate
PL
 formulation in next generation impactor (NGI) 
prior to storage (T0) and after 1 month storage (T28) after storage with dessicant at room temperature 
and 4
o
C. Data represents a mean ± standard deviation (n=3) 
 
The phytatePL formulation also showed an increased salbutamol deposition in the throat (p 
< 0.05). However, there appeared to be no significant change in the deposition of the other 
stages of the NGI (p > 0.05) (figure 4.19).  
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Figure 4.19 – Deposition of salbutamol in phytate
PL
 formulation in next generation impactor (NGI) prior 
to storage (T0) and after 1 month storage (T28) after storage with dessicant at room temperature and 
4
o
C. Data represents a mean ± standard deviation (n=3) 
 
The ED, MMAD, GSD and FPF results were analyzed for stability using the same criteria 
as previously mentioned (table 4.19 and 4.20). 
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 formulations after 
storage for 4 weeks at room temperature (RT). Powders passed the stability check if the emitted dose (ED) and fine particle fraction (FPF) did not vary by 
over 10% the geometric standard deviation (GSD) did not vary by over 0.2 μm, and the mass median aerodynamic diameter (MMAD) did not vary by over 0.5 















 formulations after 
storage for 4 weeks at 4
o
C. Powders passed the stability check if the emitted dose (ED) and fine particle fraction (FPF) did not vary by over 10% the 
geometric standard deviation (GSD) did not vary by over 0.2 μm, and the mass median aerodynamic diameter (MMAD) did not vary by over 0.5 μm from the 
values prior to storage. If 2 or more of these parameters failed, or one failed by over double the acceptable limit the powder was deemed unstable. 
 
Formulation ED (%) MMAD (μm) GSD (μm) FPF (%) Stable? 
SulfatePL      
GluconatePL      
OctanoatePL      
PhytatePL      
Formulation ED (%) MMAD (μm) GSD (μm) FPF (%) Stable? 
SulfatePL x     
GluconatePL x     
OctanoatePL      
PhytatePL      
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4.4 Discussion 
A spray drying method for lactose and salbutamol ion-pairs was developed that generated 
particles below 5 μm in diameter with uniform drug content in an acceptable yield. The 
method was optimized for this size range as it is generally accepted that particles below 5 
μm in diameter are inhalable (Elversson et al., 2003). Furthermore, the SEM pictures of all 
formulations showed that the particles were spherical, which indicates that they were 
probably amorphous (Wu et al., 2014). This was expected as it is well known that the 
spray drying procedure tends to generate amorphous powders (Rabbani and Seville, 
2005). 
 Confirmation of the amorphous nature of the powders was attempted using differential 
scanning calorimetry (DSC) (results not shown). DSC is a technique frequently used to 
analyze the physical and chemical properties of a drug or formulation and how those 
properties change with change in temperature (Knopp et al., 2016). The recrystallization 
peak of lactose, the bulk of the formulations generated, is known to occur around 170oC 
(GombÁs et al., 2002), however this could not be seen in the drug-lactose mixtures due to 
a chemical reaction between the two components. The Maillard reaction is the reaction of 
a reducing sugar, such as lactose, and amines such as salbutamol (Wirth et al., 1998). 
Unfortunately, this meant that the glass transition of lactose, occurring at around 115oC in 
the base formulation was the only indicator of the physical properties of the powder. Glass 
transitions could not be accurately observed for any of the formulations; however the 
absence of noticeable Tg does not indicate that these powders are crystalline. There are 
drawbacks to the DSC technique when using complex mixtures in that the thermal events 
may overlap and weak transitions can be lost (Knopp et al., 2016). In the thermograms 
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acquired for this study it is possible that the Tg of lactose overlaps with the peak 
associated with the loss of water from the sample, and as such the Tg could not be 
identified. To overcome this in future experiments a powder X-ray Diffraction technique 
could be employed.  
The addition of the sulfate counter ion in to the formulation had no significant effect on the 
particle size or aerosolisability of the spray dried powder. The addition of the gluconate, 
octanoate and phytate counter ions all resulted in a significantly lower particle size by laser 
diffraction. It is well documented that surfactants, such as sodium octanoate, adsorb to an 
air-liquid or oil-liquid interface, arranging themselves such that the hydrophilic head is in 
the water phase and hydrophobic tail in the non-aqueous phase (Adhikari et al., 2009, 
Pugnaloni et al., 2004). Low molecular weight surfactants are particularly capable of this 
due to their increased mobility leading to a reduction of surface tension (Pugnaloni et al., 
2004). In spray-drying a reduced surface tension leads to reduced droplet size, which can 
explain the smaller particles size found in the octanoate formulation (Patel et al., 2009b). 
Similarly, in order to reduce particle size the gluconate and phytate molecules must have 
an effect on the properties of the feed stock solution. A reduction in surface tension, 
viscosity or density would all result in a smaller droplet, and therefore particle, size (Patel 
et al., 2009b). It has been found in studies that low molecular weight aliphatic acids, much 
like gluconic acid, reduce the surface tension of water (Mahiuddin et al., 2008).  
The emitted dose for the base, sulfate, gluconate, octanoate and phytate formulations all 
ranged between 70 – 80%, showing none of the counter ions significantly affected this 
which could suggest that there was not a significant difference in the surface electrical 
charge of the particles in each of these powders (Wong et al., 2014). The MMAD value for 
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each of these formulations falls in to the aerosolisable range, which is up to around 7 μm 
for lung deposition (Maa et al., 1997, Labiris and Dolovich, 2003c). However the reduced 
particle size of the gluconate, octanoate and phytate powders meant these formulations 
also had a significantly reduced aerodynamic diameter (4.85, 4.85, 4.93 μm vs. 6.30 μm 
for gluconate, octanoate, phytate and base, respectively). The fine particle fractions 
ranged from 25 – 34%. These values are similar to the values in commercial drug – 
lactose mixtures without further excipients, which typically range from 20 – 30% (Hassoun 
et al., 2015).  
Formulations were created containing PVP, as it is known to have a stabilizing effect on 
amorphous lactose. Although the use of amorphous materials in pharmaceutical 
formulations has its advantages, such as increasing the bioavailability of the active 
ingredient, they are inherently unstable (Mahlin et al., 2006, Berggren and Alderborn, 
2003a).  Amorphous powders can undergo spontaneous recrystallization, changing the 
physical properties of a drug formulation, and ultimately leading to a short shelf life 
(Berggren and Alderborn, 2003a). Incorporation of PVP in to the ion-pair formulations 
resulted in an increase in particle size for the sulfateP and gluconateP formulations. This 
was expected as the polymer would increase the viscosity of the feed stock solution, 
leading to larger droplets (Mahlin et al., 2006). Conversely, the octanoateP particle size 
was significantly lower than the octanoate formulation. It has been shown previously that 
spray dried PVP enriches a particle surface and so perhaps the mixture and arrangement 
of octanoate and PVP molecules at the surface of the particle causes this decrease in size 
(Mahlin et al., 2006). There was no change in the size of the phytateP particles. The SEM 
pictures show that the inclusion of PVP causes a dimpled appearance to some particles, 
this effect can also be attributed to the increase in viscosity of the feed solution containing 
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the polymer affecting the drying pattern of the droplets (Elversson et al., 2003). The 
octanoateP formulation appeared to contain fewer irregularities in the surface of the 
particles, which might be explained by the surfactants presence at the surface of the 
particle (Maa et al., 1997). There was a reduction in the emitted dose and fine particle 
fraction of the sulfateP and gluconateP formulations caused by their greater particle size, 
although the sulfateP powder had a greatly reduced MMAD in comparison to the sulfate 
powder. The reduction in emitted dose might also contributed to by a difference in the 
electrical charge of particles that have surface PVP compared with the surface 
composition of the none PVP particles (Wong et al., 2014). The reduction in particle size of 
the octanoateP formulation resulted in a reduced MMAD and an increased FPF, but the 
formulation also suffered from a significantly reduced emitted dose which could be caused 
by the increased surface area and therefore contact between the particles, or a change in 
the charge of the surface of particles. There was an increase in the MMAD of the phytateP 
particles, but also a significant increase in the emitted dose (83.63% phytateP vs 71.38% 
phytate). This increase could be explained by the irregular surface of the particles 
increasing flowability by reducing the contact between particles (Vehring, 2008).  
Both the ion-pair formulations and PVP formulations were kept with a dessicant at either 
room temperature or 4oC for 4 weeks to test their stability over this time. Repetition of the 
content uniformity test showed a significant increase in the variability of salbutamol content 
in the ion-pair powders without PVP and therefore each of those formulations failed the 
homogeneity test after the storage period under either condition. Although some of the 
PVP formulations initially failed the homogeneity test, after one month storage the 
variability in salbutamol content was greatly reduced with many of the formulations now 
passing the test. The gluconateP formulation appeared to be the least stable as under both 
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conditions a significant drop in salbutamol content was found (85.36% ±6.62 at T0, 
70.35% ±17.91 at T28 RT, 73.75% ±8.39 at T28 4oC). This formulation appeared 
particularly unstable after storage at room temperature as the variability in salbutamol 
content results was almost 20%.  
The in vitro deposition experiments were also repeated after the storage period. All 
calculated values from this data were given an allowed variance (10% for ED and FPF, 0.5 
μm for MMAD and 0.2 μm for GSD) and if results for a formulation fell outside of these 
limits they would fail. If a formulation failed in 2 or more of the 4 criteria it was deemed 
unstable. Of the ion-pair formulations, the sulfate, gluconate and phytate powders were the 
most stable as they passed the stability check after storage at room temperature. The 
base and octanoate powders failed the check under both of the storage conditions. The 
octanoateP and phytateP passed the stability check after storage at room temperature. It 
has been suggested that for stable storage of amorphous materials a temperature of at 
least 50oC below the Tg should be used, and the Tg is reduced by any absorbed water in 
the material (Berggren and Alderborn, 2004). PVP is known to inhibit crystallization but the 
effect is increased with increasing polymer concentration and molecular weight (Berggren 
and Alderborn, 2003a) therefore it is possible that the concentration and molecular weight 
of PVP used for these formulations was not sufficient to inhibit recrystallization over 4 
weeks at room temperature. However all of the ion-pair/PVP formulations passed the 
stability check after storage at 4oC. The stabilizing action of PVP is thought to be as a 
result of it forming hydrogen bonds with other substances as it contains a hydrogen bond 
donating group (Berggren and Alderborn, 2003b, Crowley and Zografi, 2003, Taylor and 
Zografi, 1998).  
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Formulations for each ion-pair were generated containing PVP and l-leucine to assess 
whether a powder with improved aerosolisability could be created. The addition of l-leucine 
in to the spray drying feedstock greatly increased the yield of powder, with a 68% recovery 
for the gluconatePL and phytatePL formulations. It has been shown in many studies that the 
incorporation of l-leucine in to a spray dried powder for inhalation can improve the 
powder’s dispersibility and aerodynamic performance (Rabbani and Seville, 2005, Li et al., 
2005, Najafabadi et al., 2004). It is thought that this improved dispersibility is due to the 
formation of an l-leucine shell during the spray drying process. Studies have shown that 
pure spray dried l-leucine creates hollow crystalline leucine particles and so the amino acid 
has the potential to encapsulate other spray dried material in a crystalline shell (Vehring, 
2008). The appearance of the generated sulfatePL, gluconatePL and phytatePL powders 
were visibly freer flowing than the powders without l-leucine. This was not true for the 
octanoatePL formulation which could be due to the octanoate molecule precipitating before 
l-leucine and therefore inhibiting its ability to crystallize (Vehring, 2008). This can also be 
seen in the SEM pictures. The sulfatePL, gluconatePL and phytatePL all display a wrinkled 
appearance that has been previously seen with particles containing l-leucine (Vehring, 
2008, Najafabadi et al., 2004), however the octanoatePL formulation appears to contain 
less of these and more smooth spherical particles.  
The dose emitted from an inhaler for each of the leucine containing formulations increased 
up to 10% in comparison with the ion-pair only formulations which could be as a result of 
the irregular morphology of the particles preventing excessive aggregation (Chen et al., 
2012). It is thought that leucine travels to the surface of droplets in the spray-drying 
procedure, causing a leucine shell to form on drying. This shell causes the particle to have 
an irregular surface morphology, which in turn significantly decreases the contact area 
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between particles (Chen et al., 2016, Mangal et al., 2015). There was a significant 
decrease in the MMAD value for the sulfatePL in comparison with the sulfate formulation 
(5.19 μm vs. 6.24 μm) and also a significant increase in the FPF (34.93% vs. 25.14%). 
However no significant difference was observed for the gluconatePL, octanoatePL or 
phytatePL powders. Although the FPF value for each of the leucine formulations was higher 
than those without, that range was only 30 – 35% which is not significantly improved on 
what can be expected of simple drug – lactose powders. Previous studies have shown that 
incorporation of leucine in to a powder can result in respirable fractions of up to 80% of the 
delivered dose (Rabbani and Seville, 2005). However, these studies used initial leucine 
fractions of up to 10%, compared to the 5% used in this study. In addition the improved 
dispersion effect of leucine can be enhanced by spray drying from an ethanol-water 
mixture, leucine is less soluble in ethanol than water and adjusting its solubility with a co-
solvent system can provide the high saturation of the molecule needed to form the 
crystalline shell (Rabbani and Seville, 2005, Vehring, 2008). Alternatively di- or tri-
peptides, such as trileucine, can be employed to enhance aerosolisability. Trileucine is 
less soluble than leucine in water and such a smaller fraction is needed to improve 
dispersibility than the equivalent leucine formulation (Vehring, 2008). 
The stability of the leucine formulations was also tested after 4 weeks storage with 
dessicant at either room temperature or 4oC. There was no significant difference between 
T0 and T28 content uniformity results for any of the formulations stored at room 
temperature, suggesting that these powders were more stable in amorphous form than the 
formulations with PVP alone. This would suggest that l-leucine itself has a stabilizing effect 
on the amorphous bulk of the powder, inhibiting recrystallization of amorphous materials, 
as has been theorized previously (Sou et al., 2013). This stabilizing effect was also seen in 
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the repeated drug deposition data, with each of the leucine formulations meeting the set 
criteria for the stability check after storage under both conditions. This would indicate that 
with further investigation in to the concentration of l-leucine used or spray drying conditions 
employed to generate the powder an inhalable ion-pair formulation with high FPF that is 
stable over a long period of time could be created.  
4.5 Conclusion 
Dry powder formulations containing salbutamol ion-pairs were generated via a spray 
drying technique that was optimized for salbutamol and lactose. These formulations were 
presumed to be amorphous in nature due to being spherical and demonstrated an 
acceptable respirable fraction. Further ion-pair formulations were generated containing the 
polymer PVP. The stabilizing effects of PVP on amorphous solids are well documented 
and so its effect of the ion-pair formulations was investigated. It was found that the addition 
of PVP increased the particle size of the sulfateP, gluconateP formulations, thought to be 
caused by an increase in viscosity of the spray drying feed solution. The polymer also 
caused the previously spherical particles to take on a “dimpled” appearance. Conversely, 
the particle size of the octanoateP formulation was significantly reduced, and as a result 
this formulation exhibited improved aerosol performance. The sulfateP, octanoateP and 
phytateP formulations showed no significant change in deposition results after 4 weeks in 
storage at 4oC, suggesting that the inclusion of PVP in to the formulation had inhibited 
recrystallization at this temperature. The addition of the amino acid l-leucine in to the 
formulations was also investigated due to its well-known ability to improve the dispersibility 
of powders. The generated leucine powders also had a wrinkled appearance, and 
displayed an amplified respirable fraction and emitted dose. L-leucine also appeared to 
Using Ion-pairs to Control Salbutamol Delivery to the Lungs 
 
 
Chapter 4 – Respirable Powder Formulations of Ion-paired Salbutamol 
173 
convey an amount of protection from recrystallization on to the powders as testing after 
one month showed no difference in the content uniformity or deposition results after 
storage at either room temperature or 4oC. It was concluded that further work could 
improve the aerosolisability of the powders further, minimizing the particle size and 
therefore MMAD values to maximize lung deposition, but that the powders generated in 
this Chapter would be suitable to be used in the planned in vivo testing in Chapter 5. The 
specific counter ion powders that will be used in the in vivo work will be chosen dependent 
on their ability to modify salbutamol’s dissolution and absorption profile which will also be 
explored in Chapter 5.  
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5.1 Introduction 
Upon deposition in the lung, an ion-pair dry powder formulation must undergo several 
processes that will determine its biopharmaceutical characteristics. Given what has been 
shown in the previous chapters of this thesis it would be anticipated that ion-pair formation 
would alter the way the therapeutic agent interacts with the lung environment. The ion-pair 
could modify drug dissolution, tissue absorption or retention, or modify the clearance of the 
drug. 
 Ion-pair formation could modify both the drug solid state or its lipophilicity, hence it can 
influence dissolution. Depending on the size of the aerosolized ion-pair, the amount of 
lung fluid that is present for dissolution could vary from ~0.1 μm in the alveolar region to a 
maximum of 100 μm in the upper airways (Olsson et al., 2011, Widdicombe and 
Widdicombe, 1995). Therefore, it is possible that an inhaled particle will be deposited in 
lung fluid that has less depth than the diameter of the particle depending on where it is 
deposited (Olsson et al., 2011). It is generally accepted that a poorly soluble drug can 
show a prolonged period of therapeutic action in the lungs due to its slow dissolution 
(Olsson et al., 2011, Wang et al., 2014).  This is due to the slow rate of dissolution 
preventing rapid absorption of the drug molecule, and therefore clearance in to the blood. 
However, undissolved particles are subject to removal from the airways via the mucociliary 
escalator or phagocytosis, which could greatly reduce the retention time of the therapeutic 
agent within the lungs (Wang et al., 2014). Thus, the use of an ion-pair strategy to limit 
dissolution could increase lung retention time by limiting the amount of drug that is 
available to be absorbed across the epithelium. On the other hand, modification of 
dissolution could be inappropriate for some drug molecules depending on their intended 
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site of action as it could lead to more efficient removal of the agent and a reduced lung 
retention time.  
Alternatively, the ion-pair could directly modulate the absorption of the therapeutic agent 
across the lung epithelial cells. Absorption mechanisms can be passive or active. Passive 
mechanisms include the diffusion of small molecular weight lipophilic compounds through 
the epithelial cell, transcellular transport, or the travel of hydrophilic compounds through 
the intercellular space, paracellular transport (Liu et al., 2013). In vivo data has shown that 
lipophilic drugs are absorbed much more rapidly than hydrophilic drugs, so an ion-pairing 
strategy could be employed to create a complex with increased hydrophilicity to reduce the 
rate of transport into the epithelium (Olsson et al., 2011). Conversely, there have been 
several studies that have shown that rapidly dissolving hydrophobic molecules, such as 
tacrolimus, display prolonged drug action due to the molecule remaining in the epithelial 
cells rather than absorbing in to the systemic circulation, so creating a more hydrophobic 
complex could increase tissue retention (Watts et al., 2010, Thorsson et al., 2001). Finally, 
the rate of absorption of a compound could be altered by increasing its molecular weight. 
Ion-pairing with a high molecular weight counter ion could limit drug transport across the 
respiratory epithelium as transport rates have been shown to be inversely proportional to 
molecular weight (Grainger et al., 2006).  
The aim of this Chapter was to investigate the effect of ion-pairing on the in vitro and in 
vivo behavior of salbutamol. The biocompatibility of the counter ions and excipients used 
in previous chapters was analyzed and the transport of salbutamol base across an airway 
cell monolayer assessed.  The effect of the sulfate, gluconate, octanoate and phytate 
counter ions on the transport of salbutamol was then investigated. Following this, suitable 
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ion-pairs were chosen to be tested in an animal model. Dissolution studies were performed 
for the spray dried powders of the chosen ion-pairs containing PVP. Although the previous 
chapter indicated that the l-leucine containing powders appeared to be the most stable it 
was decided against using these powders in this study. This was as a result of l-leucines 
zwitterionic nature at physiological pH, which could potentially break down the salbutamol 
ion – pair. The bronchoprotective properties of salbutamol base and the phytate ion-pair 
against a histamine challenge were studied in vivo.  
The culture of epithelial cells and cell layers is widely used and accepted in the 
pharmaceutical industry as a method to study the transport of inhaled medicines as well as 
their biocompatibility. In particular, the bronchial epithelial cell line Calu-3 has been shown 
to grow in to layers of columnar epithelial cells with tight junctions, making it ideal to study 
the transport of molecules (Forbes, 2000, Forbes and Ehrhardt, 2005). Consequently, the 
Calu-3 cell line was chosen as a model of the airway epithelium for use in the work in this 
Chapter.   
This in vitro cell model can also be used to assess the biocompatibility of the excipients 
and counter ions used in the dry powder formulation. The counter ions in an ion-pair 
formulation are present in excess to promote the formation of the ion-pair species; as a 
result it is very important that they are well tolerated. For this work the effect of counter ion 
on cell viability using the 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide 
(MTT) assay was investigated. The MTT assay measures cell viability resulting from their 
mitochondrial activity (van Meerloo et al., 2011). Functioning mitochondria of the cells 
convert the yellow MTT compound into purple formazan crystals, and therefore the extent 
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to which the compound is converted can be used as a reflection of cell viability (van 
Meerloo et al., 2011).  
Although in vitro cell culture models can reveal a large amount of information regarding the 
mechanisms and kinetics of pulmonary drug transport, animal models are still required to 
gain insight into the pharmacokinetic and pharmacodynamic properties of the formulation 
following inhalation. Ideally, the study of pulmonary medicines would be performed on 
humans, however the use of small animal models has many advantages including the 
small amount of drug sample required for experiments (Sakagami, 2006). Of the small 
rodents, guinea pigs are ideal models for an inhaled medicine because the guinea pig has 
a similar respiratory physiology to humans (Cryan et al., 2007) and the airway smooth 
muscle of guinea pigs is functionally similar to that of humans (Cryan et al., 2007, Canning 
and Chou, 2008). The use of ion-pairs to create an inhaled salbutamol formulation could 
lead to a prolonged duration of bronchodilation in vivo, or create a prolonged period of 
protection against bronchoconstriction. For this reason, guinea pigs were chosen as a 
suitable animal model to investigate the pharmacokinetic behavior of the ion-pair 
formulations.  
5.2 Materials and Methods 
5.2.1  Materials 
Reagents for cell culture use were obtained from Sigma Aldrich (Dorset, UK), these 
included: Dulbecco’s Modified Eagle’s Medium/Nutrient F-12 Ham’s 50/50, fetal bovine 
serum (FBS), non-essential amino acids, L-glutamine, gentamicin, trypsin-EDTA (0.25% 
trypsin, 0.05% EDTA), trypan blue, PBS, HBSS, MTT, dimethylformamide (DMF), and 
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Triton X. Calu-3 human bronchial cells were from ATCC (Rockville, USA). Sodium dodecyl 
sulfate (SDS) solution (20% w/v) was purchased from Fisher Scientific (Leicestershire, UK) 
and Transwell® inserts (polyester membrane, 0.4 μm pore size, 0.33 cm2 growth surface 
area) were obtained from Corning Limited (Flintshire, UK). Salbutamol base (BN. H80619) 
was from Cipla Ltd (India) and used without further purification. Sodium sulfate was 
purchased from Alfa Aesar (Lancashire, UK). Sodium octanoate was obtained from Sigma 
Aldrich (Dorset, UK). Sodium gluconate and dipotassium phytate were purchased from 
Santa Cruz Biotechnology (USA). Orthophosphoric acid, HPLC grade water and 
acetonitrile were from Fisher Scientific (Leicestershire, UK). 
5.2.2 Calu-3 cell culture 
Calu-3 human bronchial cells were used between passage 10 and 50 and were kept in a 
humidified 5% CO2/95% atmospheric air incubator at 37
oC. Cell culture media was made 
up of 50:50 Dulbecco’s modified Eagle’s medium F-12 Ham’s (500 mL), FBS (50 mL), non-
essential amino acid solution (5 mL), L-glutamine (200 mM, 5 mL), and gentamicin (0.5 
mL). Medium was exchanged every 2 – 3 days and cells were passaged when they 
reached 80% confluency with trypsin-EDTA at a 1:3 split ratio. All cell culture work was 
carried out in a Class II safety cabinet.  
Cells were harvested for use in experiments when they reached 80% confluency using the 
trypsin-EDTA solution. An aliquot of cell suspension was diluted with an equal volume of 
trypan blue and positioned on a haemocytometer for cell counting under a light 
microscope. Cells were counted from the 4 large corner squares of the haemocytometer 
and averaged to give a concentration of cells per mL of suspension. Non-viable cells were 
detected by the internalization of trypan blue and were not included in the count. The cell 
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suspension was diluted with the appropriate volume of cell culture medium to give the 
required cell seeding concentration for the experiment.  
5.2.3 Biocompatibility assay 
Biocompatibility of counter ions and formulation excipients was assessed using an MTT 
cell viability assay. Calu-3 cells were seeded at a density of 1 x 104 cells/well in a 96 well 
plate and cultured for 24 hours in cell culture medium (100 μL) with a reduced FBS 
concentration (2% v/v). All test samples were prepared in warmed cell culture medium (2% 
FBS) before use. Cells were either exposed to the test sample, cell culture medium as a 
negative control or 1% triton-X solution as a positive control and the cells were cultured for 
24 hours. After this time the medium was removed from the cells and replaced with fresh 
cell culture medium (2% FBS, 200 μL) and MTT solution (5 mg/mL in PBS, 50 μL). The 
cells were incubated at 37oC for 4 hours before the medium was removed and replaced 
with an SDS solution (10% w/v in 50:50 DMF:water, 100 μL). The cells were incubated 
with this solution for 16 hours to solubilize any formazan crystals present. Absorbance 
from each well was measured using a UV spectrophotometer (SpectraMax 190, Molecular 
Devices, USA) at 570 nm and corrected for a background reading performed at 650 nm. 
For each test well the absorbance value of a cell free well was subtracted and the 
remaining absorbance was used to determine cell viability by comparison to the positive 
and negative control values using the following equation: 
𝐕𝐢𝐚𝐛𝐢𝐥𝐢𝐭𝐲 (%) =  
𝐀𝐭𝐞𝐬𝐭 − 𝐀𝐩𝐨𝐬𝐢𝐭𝐢𝐯𝐞
𝐀𝐧𝐞𝐠𝐚𝐭𝐢𝐯𝐞−𝐀𝐩𝐨𝐬𝐢𝐭𝐢𝐯𝐞
𝐱 𝟏𝟎𝟎                                                  [Equation 5.1] 
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Where Atest is the absorbance of the cell treated with sample, Apositive is the absorbance 
of the cell treated with the positive control and Anegative is the absorbance of the negative 
control (cell culture medium). 
This assay was performed on the following compounds: sodium sulfate, sodium gluconate, 
sodium glucoheptonate, sodium fumarate, sodium maleate, sodium benzoate, sodium 
octanoate, dipotassium phytate, lactose, PVP.  
5.2.4 Transport study 
Cells were seeded on to Transwell® inserts at a density of 1.65 x 105 cells/well in cell 
culture medium in the apical (100 μL) and basolateral (500 μL) side. The cells were 
cultured at air liquid interface by removal of the apical medium on day 2 of culturing. The 
basolateral medium was replaced every 2 – 3 days. Cells were used on days 9 – 13 after 
seeding when cell layer barrier function is stable (Grainger et al., 2006). Transepithelial 
electrical resistance (TER) was measured prior to the transport assay. Cell culture medium 
(100 μL) was placed in the apical chamber of the well and the cells were incubated for at 
least 30 minutes before the TER was measured using chopstick electrodes with an EVOM 
voltohmmeter (STX-2 and EVOM G, World Precision Instruments, Stevenage, UK). TER 
was calculated by subtracting the resistance value of a cell free insert (140 Ω) and 
correcting for the surface area of the insert (0.33 cm2). Cells were deemed fit for use if 
their TER value was over 300 Ωcm2. Cell culture medium was removed from the apical 
chamber of fit for use wells and the cells were washed twice with warm HBSS (100 μL). 
The Transwell® insert was moved to a new well containing fresh, warm HBSS (600 μL) 
and HBSS was placed in the apical chamber (100 μL) before the cells were incubated for 2 
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hours to allow for equilibration. Test samples (salbutamol base (500 μg/mL), 20:1 
salbutamol sulfate, 20:1 salbutamol gluconate, 20:1 salbutamol octanoate and 1:1 
salbutamol phytate) were made up in warm HBSS before use.  
At the beginning of the experiment the HBSS was removed from the apical chamber by 
aspiration and replaced with test solution (200 μL), a sample (100 μL) was taken 
immediately to verify concentration. Samples (100 μL) were removed from the basolateral 
chamber every 20 minutes for 2 hours and replaced with fresh warm HBSS. At 120 
minutes the TER was measured again and a sample (100 μL) was also taken from the 
apical chamber. All samples were diluted with HBSS (1:9 dilution for apical samples, 1:2 
dilution for basolateral samples) and analyzed for salbutamol concentration by HPLC. 
5.2.5 High Performance Liquid Chromatography 
An HPLC system consisting of a Dionex P680 pump, Dionex ASI- 100 autosampler and 
Dionex PDA-100 photodiode array detector (Dionex Corporation, CA, USA) was used to 
determine salbutamol concentration. Separation was achieved using a Gemini® (250 x 4.6 
mm, particle size: 5 μm) column (Phenomenex® Ltd., Cheshire, UK). The mobile phase 
used for analysis was 96.5% water, 3% acetonitrile, 0.5% orthophosphoric acid that had 
been filtered through a 0.2 μm nylon membrane and degassed by sonication. The run time 
was set at 15 minutes with a flow rate of 1 mL/min and 2 injections of 100 μL per vial. The 
UV detection was set at 226 nm. The amount of salbutamol in the samples was 
determined by comparison with a calibration curve. To generate a calibration curve an 
aliquot of 10 mg salbutamol was weighed out and added to a 100 mL volumetric flask and 
made up to volume with PBS to give a 100 μgmL-1 solution. A set of serial dilutions was 
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performed using glass pipettes and volumetric flasks to prepare 6 standards for 
comparison with the basolateral samples (150, 100, 80, 50, 30, 20 ngmL-1) and 6 
standards for comparison with the apical samples (100, 80, 50, 30, 20, 10 μg/mL). 
5.2.6 Spray drying 
Spray dried powders containing 1% salbutamol, 0.5% PVP, 98.5% lactose and 20:1 ratio 
of counter ion - drug were prepared as described in Chapter 2. The counter ions used 
were sodium octanoate and dipotassium phytate. 
5.2.7 Dissolution study 
Type 3 gelatin capsules were filled with 12.5 mg (± 0.5) of powders generated by spray 
drying. A total of 5 capsules were actuated per experiment to deliver powder on to the 
surface of a 0.45 μm pore Transwell insert (pre wetted with HBSS) using a Twin-Stage 
Impinger, as described by Grainger et al. (Grainger et al., 2012). The Transwell was 
transferred to a 24-well plate containing 600 μL of HBSS and at intervals was moved to a 
new well. The amount of salbutamol in the well at each time point was analyzed by HPLC.  
5.2.8 Animals 
Experiments were conducted under a project license issued by the United Kingdom Home 
Office in accordance with the United Kingdom Animal Scientific Procedures Act, 1986. 
Protocols were approved by the Local Ethical Review Committee of King’s College 
London. All in vivo experiments were conducted on male Dunkin-Hartley guinea pigs (400- 
450 g, Charles River). Guinea pigs were housed in animal holding facilities maintained at 
18 – 19 oC with a standard 12 h light cycle. A maximum of 6 guinea pigs were housed in 
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the same cage. The cages contained sawdust and hay, with cardboard tunnels to provide 
enrichment. Animals were fed ad libitum on an FD1 guinea pig diet (Special Diets 
Services, Essex, UK) with free access to water.  
5.2.9 In vivo Bronchoprotection study 
Guinea pigs (400 g) were anaesthetized (7 mL/kg of 25% w/v urethane in sterile saline 
over 4 doses) and intratracheal intubation was performed before the animals were 
connected to a pneumotachograph and pressure transducer. Changes in airflow were 
measured using a lung function recording system and were displayed in real time on a 
personal computer. The flow signal was integrated to give a measure of tidal volume. A 
cannula was inserted into the thoracic cavity between the third and fifth ribs and connected 
to the negative side of the pressure transducer. The positive side of the pressure 
transducer was connected to the side of the pneumotachograph proximal to the animal. 
The difference in mouth and thoracic pressure was used as a measure of transpulmonary 
pressure. The lung function parameter, total airway resistance (RL; cm of water per L per 
s), was derived from each measure of flow, tidal volume, and transpulmonary pressure by 
integration. Histamine (1, 2, 4 μg/kg) was injected intravenously and 10 minutes later the 
salbutamol base or ion-pair was administered as a nebulized solution in saline with an 
Aeroneb Pro device (Aerogen, Galway, Ireland). Spray dried powders were dissolved in 
saline to give a 1 mg/mL concentration, 1 mL was put in to the nebulizer which was 
actuated for 10 seconds to give a salbutamol dose of 1.5 μg/kg concentration. The 
Aeroneb Pro has an average flow rate of 0.4 mL/min and gives droplets in the size range 
of 1 – 5 μm as measured on an Andersen Cascade Impactor (average 3.1 μm) (Aerogen).  
Histamine was intravenously injected at 30, 60, 120 and 180 minutes post drug exposure.  
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5.2.10 Lung Cell Count 
At the end of the bronchoprotection study a lavage was performed with 5 mL of 
bronchoalveolar lavage fluid. The total number of cells was counted on a Neubauer 
haemocytometer (Fisher Scientific, Loughborough, UK). 
5.2.11 Data analysis 
Data for the dissolution study was obtained from 3 experiments and was expressed as a 
mean ± standard deviation. The data was fitted to the following dissolution curves: first 
order; Baker and Londsdale; Peppas; Hixon and Crowell; and Higuchi in SigmaPlot. Data 
from cell culture experiments was obtained from 3 experiments, with 3 test wells per 
experiment, and was expressed as a mean ± standard error. Sigmoidal curves were fitted 
to the binding data in SigmaPlot and the value at 50% was taken as the IC50 value in the 
MTT assay. One-way Analysis of Variance (ANOVA) with a Shapiro-Wilkins normality test 
was performed with a probability limit of 0.05 set to indicate significant differences.  
5.3  Results 
5.3.1 The biocompatibility excipients used in an ion-pair 
formulation 
A sigmoidal relationship between the concentration of each of the counter ions and 
excipients tested in the MTT assay and cell viability was observed (figure 5.1 – 5.3). 
Following 24 hour exposure, sodium octanoate was found to have the lowest half maximal 
inhibitory concentration (IC50) with a value of 1.7 mg/mL (table 5.1).  The counter ion with 
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the greatest IC50 concentration was sodium gluconate with a value of 38.1 mg/mL. The 
lactose and PVP excipients were shown to be well tolerated by Calu-3 cells, with IC50 












Figure 5.1 - Relationship between concentration and cell viability after 24 hour exposure for sodium 
sulfate (black circle), sodium fumarate (red triangle) and sodium benzoate (green square). Data is 
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Figure 5.2 - Relationship between concentration and cell viability after 24 hour exposure for 
dipotassium phytate (black circle), sodium maleate (red triangle) and sodium octanoate (green square). 









Figure 5.3 - Relationship between concentration and cell viability after 24 hour exposure for sodium 
gluconate (black circle), lactose (red triangle), PVP (green square) and sodium glucoheptonate (yellow 
diamond). Data is expressed as a mean ± standard error (n=3 experiments, with 3 replicates per 
experiment) 
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Table 5.1 – Half maximal inhibitory concentration (IC50) values for each excipient after 24 hour 











5.3.2 Transport of salbutamol ion-pairs across the respiratory 
epithelium model 
To be able to accurately quantify the salbutamol concentrations that had been transported 
through a cell monolayer, a more sensitive HPLC method compared to what was used in 
previous chapters was developed using 96.5% water, 3% acetonitrile and 0.5% 
orthophosphoric acid mobile phase and UV detection at 226 nm. This method gave a 
linear relationship between salbutamol concentration and UV absorption over a wide range 
of salbutamol values (0.02 – 100 μg/mL), with an R2 value of 0.9998. The calculated limit 
Excipient IC50 (mg/mL) 
Sodium sulfate 14.5 ± 3.6 
Sodium gluconate 38.1 ± 3.2 
Sodium glucoheptonate 27.8 ± 6.9 
Sodium octanoate 1.7 ± 0.3 
Sodium benzoate 11.7 ± 1.7 
Sodium fumarate 14.6 ± 3.0 
Sodium maleate 5.1 ± 0.9 
Dipotassium phytate 6.6 ± 0.5 
Lactose 88.6 ± 19.6 
PVP 41.4 ± 0.8 
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of detection value was 9.4 ng/mL and the limit of quantification was 28 ng/mL (figure 5.4, 
5.5). The calculated coefficient of variation remained low, with a maximum value of 3.9% 










Figure 5.4 - Relationship between salbutamol concentration and UV absorption in HPLC analysis over 
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Figure 5.5 - Relationship between salbutamol concentration and UV absorption in HPLC analysis over 





In order to establish a suitable concentration of salbutamol to apply to cells to investigate 
its transport a range of concentrations (0.2 – 20 mg/mL) were tested. A linear relationship 
between the salbutamol concentration across the range tested and the rate of transport 
was observed (figure 5.6).  A suitable concentration would be as close to an expected 
physiological concentration of salbutamol following inhalation as possible whilst also 
allowing for accurate analysis of the drug by HPLC. A starting concentration of 0.5 mg/mL 
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Figure 5.6  - Relationship between salbutamol concentrations applied to the apical side of Calu-3 
monolayer and the rate of transport of the drug to the basolateral compartment. Data represents a 








Figure 5.7 -  Transport of salbutamol base (0.5 mg/mL) across a Calu-3 cell monolayer over 60 minutes 
(n = 1) 
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The rate of transport of salbutamol base (0.5 mg/mL), 20:1 salbutamol sulfate, 20:1 
salbutamol gluconate, 20:1 salbutamol octanoate and 1:1 salbutamol phytate from the 
apical chamber of a Calu-3 monolayer grown at air-liquid interface to the basolateral 
chamber was therefore tested. It was found that the salbutamol sulfate, gluconate and 
phytate ion-pairs had a significantly lower rate of transport in comparison with the base (p 
< 0.05). The calculated apparent permeability coefficient (Papp) was 8.50 nm/s for 
salbutamol base and 4.38, 4.06, 4.32 nm/s for the sulfate, gluconate and phytate ion-pairs, 
respectively (figure 5.8). There was no significant difference in the rate of transport of the 










Figure 5.8 – Representative graph of the transport of salbutamol across a Calu-3 monolayer over 2 
hours for salbutamol base (black circle), salbutamol sulfate (red inverted triangle), salbutamol 
gluconate (green square), salbutamol octanoate (yellow diamond) and salbutamol phytate (blue 
triangle). Data shown is expressed as a mean ± standard deviation (n=3) 
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Figure 5.9 - Calculated apparent permeability coefficient (Papp) values for salbutamol base, salbutamol 
sulfate, salbutamol gluconate, salbutamol octanoate and salbutamol phytate across an air-liquid 
interface grown Calu-3 monolayer. Data is expressed as a mean ± standard error (n=6 experiments, 
with 3 replicates per experiment). * denotes a significant difference from salbutamol base. 
 
5.3.3 Dissolution of salbutamol ion-pair spray dried powders 
Salbutamol phytate and octanoate ion-pairs were chosen to take forward in to further 
studies to investigate whether these could be used to prolong the action of salbutamol 
based on the cell culture results. The dissolution profile of particles that were deposited on 
to a Transwell® insert in the lower chamber of a twin stage impinger was investigated. It 
was found that each of the powders had a rapid dissolution. A total of 31% (± 16) of 
salbutamol in the salbutamol base formulation, 38% (± 8) of salbutamol in the salbutamol 
octanoate formulation and 43% (± 3) of salbutamol in the salbutamol phytate formulation 
were dissolved within the first minute.  There was no significant difference in the 
dissolution of the salbutamol base or salbutamol phytate powder (p > 0.05) (figure 5.10). 
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There was no significant difference in the dissolution of the salbutamol base and 
salbutamol octanoate powders in the first 15 minutes (p > 0.05). However there was a 
significant increase in the dissolution of the salbutamol octanoate powder at the 30, 45, 
and 60 minute time points in comparison with salbutamol base (p < 0.05) (figure 5.10). The 
salbutamol base spray dried powder reached a maximum of 77% of the total salbutamol 
dissolved at 60 minutes, this value was 82% for the salbutamol phytate powder and 92% 









Figure 5.10 - Dissolution profile of spray dried salbutamol base, salbutamol octanoate and salbutamol 
phytate powders with PVP after deposition on to a Transwell insert. Data is expressed as a mean ± 
standard deviation (n=3). * denotes a significant difference. 
 
The dissolution profiles were fitted with the following curves to ascertain which model best 
described the data: first order; Baker and Londsdale; Peppas; Hixon and Crowell; and 
Higuchi (figure 5.11, 5.12, 5.13). It was found that for each of the spray dried powders the 
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Peppas model best fit the dissolution data with R2 values of 0.9942, 0.9927, and 0.9678 








Figure 5.11 - Salbutamol base spray dried powder dissolution in PBS over 60 minutes. Data is 
expressed as a mean ± standard deviation (n = 3). Data is fitted with the following curves: Baker and 
Londsdale (black solid line, R
2
 = 0.3772), Peppas (red long dashed line, R
2
 = 0.9942), Hixon and Crowell 
(green short dashed line, R
2
 = -1.408), Higuchi (blue dotted line, R
2
 = -0.091), first order (pink dashed 
and dotted line, R
2
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Figure 5.12 - Salbutamol octanoate spray dried powder dissolution in PBS over 60 minutes. Data is 
expressed as a mean ± standard deviation (n = 3). Data is fitted with the following curves: Baker and 
Londsdale (black solid line, R
2
 = 0.704), Peppas (red long dashed line, R
2
 = 0.9927), Hixon and Crowell 
(green short dashed line, R
2
 = -0.3822), Higuchi (blue dotted line, R
2
 = -0.2294), first order (pink dashed 
and dotted line, R
2








Figure 5.13 - Salbutamol phytate spray dried powder dissolution in PBS over 60 minutes. Data is 
expressed as a mean ± standard deviation (n = 3). Data is fitted with the following curves: Baker and 
Londsdale (black solid line, R
2
 = -0.5313), Peppas (red long dashed line, R
2
 = 0.9678), Hixon and 
Crowell (green short dashed line, R
2
 = -3.7538), Higuchi (blue dotted line, R
2
 = -2.9204), first order (pink 
dashed and dotted line, R
2
 = -1.9782). 
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5.3.4 In vivo bronchoprotection efficacy of salbutamol ion-pairs 
A bronchoprotection study for salbutamol base/PVP and salbutamol phytate/PVP spray 
dried powders as well a control of lactose/PVP/dipotassium phytate using 3 animals for 
each test condition. The difference in the percentage increase in maximum lung resistance 
was measured after a histamine challenge before administration of the test substance and 
then at 30, 60, 120 and 180 minutes post administration. The variation in response of each 
animal to the histamine challenge, as well as the test and control substances was 
extremely high and so statistical differences between the test substances could not be 
found (figure 5.14 – 5.16). As the administration of a 4 μg/kg dose of histamine gave a 
sufficient change in resistance for each animal before the administration of any test 
substances, the response to this dose for each animal was compared (table 5.2). It was 
found that there was a significant difference in the increase in resistance at 30, 60 and 120 
minutes post salbutamol base administration when compared with the control response (p 
< 0.05, figure 5.18). The administration of salbutamol phytate resulted in a significant 
difference in the response to histamine challenge at 60 and 120 minutes (p < 0.05, figure 
5.18). Response to the phytate control resulted in some animals having a higher response 
to histamine than at the control at 30 and 120 minutes (figure 5.18). One of the animals 
given the phytate control did not survive to 180 minutes.  
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Figure 5.14 - Resistance traces for Animal 1 for salbutamol phytate. Top left = control (dose of 1, 2, 4 
μg/kg histamine and nebulized dose of salbutamol base). Top right = 30 mins. Middle left = 60 mins. 
Middle right = 120 mins. Bottom left = 180 mins. 1, 2, and 4 markers show administration of 1, 2, and 4 
μg/kg histamine. 
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Figure 5.15 - Resistance traces for Animal 2 for salbutamol phytate. Top left = control (dose of 1, 2, 4 
μg/kg histamine and nebulized dose of salbutamol base). Top right = 30 mins. Middle left = 60 mins. 
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Figure 5.16 - Resistance traces for Animal 3 for salbutamol phytate. Top left = control (dose of 1, 2, 4 
μg/kg histamine and nebulized dose of salbutamol base). Top right = 30 mins. Middle left = 60 mins. 
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Figure 5.17 - Resistance traces after administration of dipotassium phytate control (n = 1) Top left = 
control (dose of 1, 2, 4 μg/kg histamine and nebulized dose of salbutamol base). Top right = 30 mins. 
Middle left = 60 mins. Middle right = 120 mins. Bottom left = 180 mins. 1, 2, and 4 markers show 
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Table 5.2 – Increase in lung resistance after administration of 4 μg/kg histamine at 5 min prior to and 30, 60, 120 and 180 minutes post 
administration of salbutamol base, salbutamol phytate or phytate control. NA is shown where there is no reading due to animal death.
  Percentage increase in total airway 
resistance (%) 
Percentage increase in resistance 
normalized to same animal histamine 
control (%) 
Test Substance Animal Time (mins) Time (mins) 
  -5 30 60 120 180 -5 30 60 120 180 










40.22 7.093 41.40 75.18 
 2 57.90 12.76 26.83 38.89 127.11 100.00 22.04 46.34 67.17 219.53 
 3 101.30 10.83 3.87 41.69 33.44 100.00 10.69 3.82 41.15 33.01 
Salbutamol phytate 
spray dried powder 
1 169.09 28.87 8.95 25.02 30.60 100.00 17.07 5.29 14.80 18.10 
 2 121.03 152.40 63.13 59.41 82.13 100.00 125.92 52.16 49.09 67.86 
 3 34.69 6.50 4.77 20.18 36.07 100.00 18.74 13.75 58.17 103.98 
Phytate control 1 43.15 13.90 49.10 93.89 2.77 100.00 32.21 113.79 217.59 NA 
 2 26.99 83.63 19.50 163.44 14.60 100.00 309.86 72.25 605.56 54.09 
 3 47.93 28.81 20.63 27.10 37.43 100.00 60.11 43.04 56.54 78.09 
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Figure 5.18 – Percentage increase in lung resistance after administration of histamine (4 μg/kg) 30, 60, 
120 and 180 minutes after administration of salbutamol base (solid black bar), salbutamol phytate (red 
striped bar) and phytate control (green crossed bar) relative to the increase prior to administration 
(histamine control). Data is expressed as a mean ± standard error (n=3). Dotted line shows baseline 
response to histamine, * denotes a statistically significant difference to histamine control, # denotes n 
= 2.  
 
The total number of cells present in the lung was counted after the experiment was 
concluded, although this was only performed for a small number of animals it did not 
indicate any differences in the total number of cells present in the lung after administration 
of any of the test solutions (table 5.3).  
Table 5.3 – Total cell count in bronchoalveolar lavage post bronchoprotection study for salbutamol 
base (n = 1), salbutamol phytate (n = 2) and phytate control (n = 2).  
Formulation Cell count (x 104 cells/mL) 
Salbutamol base 90 
Salbutamol phytate 85.88 (± 12.9) 
Phytate control 81.07 (± 5.5) 
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5.4 Discussion 
The biocompatibility of excipients used in the spray dried formulations was assessed as a 
function of mitochondrial activity in Calu-3 cells. The desired effect of the formulations is 
prolonged drug action, so a 24 hour exposure to the test molecules was performed in an 
attempt to model an extreme situation. Lactose was extremely well tolerated in the assay 
with an IC50 value of 88.6 mg/mL, previous studies have also shown that lactose is well 
tolerated by the Calu-3 cell line (Scherließ, 2011). PVP was also well tolerated with an IC50 
of 41.4 mg/mL. The counter ions showed a wide range of biocompatibility, the least 
tolerated was the hydrophobic octanoate counter ion (IC50 = 1.7 mg/mL), the most 
tolerated was the hydrophilic gluconate counter ion (IC50 = 38.1). Several studies have 
found that there is a negative correlation between lipophilicity of molecules and their 
toxicity (Chen et al., 2008, Moridani et al., 2003, Smith et al., 2002). This is thought to be 
because more lipophilic molecules can cross biological membranes more easily and 
interact with biological macromolecules such as enzymes (Chen et al., 2008). Although in 
general the MTT results in this chapter showed that more lipophilic compounds were less 
well tolerated by the Calu-3 cells, there was not a linear correlation between logP and IC50 
values.  
In order to assess whether the tested excipients are suitable for use in a powder 
formulation for inhalation it is important to put the biocompatibility results in to perspective. 
To gain maximum therapeutic efficacy salbutamol should be deposited in the middle and 
small airways (Tena and Clarà, 2012). A 20 mg dose of the spray dried salbutamol 
octanoate powder would contain: 0.18 mg salbutamol; 0.09 mg of PVP; 2.50 mg of sodium 
octanoate (used in this example as it has the lowest IC50 value); and 17.22 mg of lactose. 
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If this was delivered with 100% efficiency to the bronchiolar region of the lungs 
(generations 9 – 15) and distributed uniformly in this region the concentration of each 
excipient would be 3.76 x 10-5  mg/cm2 for PVP, 1.04 x 10-3 mg/cm2 for sodium octanoate 
and 7.18 x 10-3 mg/cm2 for lactose (Valentin, 2002, ICRP, 1994). The experimental IC50 
values for these excipients are 41.4 mg/mL, 1.7 mg/mL and 88.6 mg/mL for PVP, sodium 
octanoate and lactose, respectively, which are the equivalent of 12.94 mg/cm2, 0.53 
mg/cm2 and 27.69 mg/cm2, respectively, when corrected for the volume of liquid applied 
and surface area of the well. The theoretical deposition concentrations based on a uniform 
distribution are much lower than the experimental IC50 values. This however, is not a 
totally realistic view of deposition. Deposition in the lungs does not happen uniformly and 
instead there will be regions of higher deposition, for example at lung bifurcations where 
the air rapidly changes direction. The toxicity data shows that at least a 500 fold increase 
is needed in the concentration of sodium octanoate to reach its IC50 value, still presuming 
100% of the dose was deposited in the bronchiolar region. It is also important to remember 
that toxicity assays performed in cell culture models are likely to be more sensitive than in 
vivo tissue, and so the tolerated levels in tissue would be higher (Korting et al., 1994). For 
these reasons each of the counter ions and excipients tested in the MTT assay were 
deemed suitable for use in an inhaled formulation.  
The transport of salbutamol base showed a linear relationship between flux of transport 
and initial salbutamol concentration over a concentration range of 0.2 – 20 mg/mL. This 
would suggest that salbutamol base is passively transported across the Calu-3 monolayer 
as there appeared to be no saturation of transporters at higher concentrations. There is 
some discussion in the literature as to whether this is the case. Studies have shown that 
there is a strong correlation of the transport of salbutamol across a monolayer of 
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16HBE14o- cells with the transport of the paracellular marker mannitol, which suggests 
that salbutamol is transported via the paracellular route also (Forbes, 2000, Unwalla et al., 
2012). However, contradicting studies have hypothesized that salbutamol is transported 
actively via an organic cation transporter (OCT) (Ehrhardt et al., 2005, Haghi et al., 2012). 
These studies have shown that transport of salbutamol across 16HBE14o- and Calu-3 
cells, grown at both liquid-liquid interface and air-liquid interface, can be limited by an 
excess of another organic cation such as tetraethylammonium (TEA) (Ehrhardt et al., 
2005, Haghi et al., 2012). Ehrhardt et al. used salbutamol concentrations of 100 μM and 5 
mM and saw a significant decrease in apparent permeability coefficient at the higher 
concentration. This corresponds to concentrations of 24 μg/mL and 1.2 mg/mL. It is 
therefore possible that over the concentration range used in this study (0.2 – 20 mg/mL) 
that active transport due to OCT was already saturated.   
The rate of transport of salbutamol across a Calu-3 monolayer was significantly reduced 
for the sulfate, gluconate and phytate ion-pairs. Previous studies have shown that the 
transport rate of salbutamol sulfate through Calu-3 cells is around half that of salbutamol 
base, however it was hypothesized that this was due to the difference in partition 
coefficients of the 2 species (Haghi et al., 2012). Partitioning studies for the salbutamol 
sulfate, gluconate and phytate ion-pairs in Chapters 2 and 3 show that there was no 
significant difference in the partition coefficient compared with the base and so this could 
not be the reason for the difference in transport rates. If the transport of salbutamol and 
the ion-pair is assumed to be passive and paracellular as indicated by the results in this 
chapter and literature then there may be other mechanisms that cause the reduction in 
transport rate. The ion-paired complex will have a high molecular weight than salbutamol 
base alone, however these complexes will still remain under 1000 Daltons in weight, and 
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so the contribution of molecular weight on transport rate is thought to be negligible (Tronde 
et al., 2008).  
Other factors that have been shown to be extremely important to drug absorption in rat 
lung are the polar surface area and hydrogen bonding potential of compounds (Tronde et 
al., 2008). Permeability decreases with increased hydrogen bond potential due to an 
increase in the desolvation energy required to break hydrogen bonds with water (Conradi 
et al., 1996). Also in the lung the percentage polar surface area of the total molecular 
surface area (%PSA) has been shown to be an important factor in drug absorption. The 
lung has been shown to be more permeable than other biological membranes to 
molecules with a high polar surface area, but %PSA has still been shown to correlate to 
permeability (Tronde, 2002). Each of the sulfate, gluconate, and phytate counter ions have 
a high polar surface area and numerous sites that can form hydrogen bonds with water, 
and so this could be the cause of the reduced rate of ion-pair transport. The transport rate 
of the octanoate ion-pair did not significantly differ from that of salbutamol base even 
though the octanoate ion-pair did have a significantly increase logD7.4 value in the 
partitioning studies in Chapter 2 (-1.386 for salbutamol base vs. -0.630 for salbutamol 
octanoate). Studies have shown that there appears to be a linear correlation between the 
log apparent partition coefficients of molecules and their absorption rate in the lung 
(Taylor, 1990) (figure 5.19). When comparing the partition coefficient values from Chapter 
2 with the correlated compounds it is possible that although the increase in logD7.4 is 
statistically significant, it may not be enough of an increase to see a significant difference 
in drug transport. 
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Figure 5.19 - Relationship between log apparent partition coefficient (log Papp) and drug absorption (ka) 
from the lung for 21 compounds. Taken from (Taylor, 1990) 
 
The dissolution of each of the salbutamol base, octanoate and phytate powders showed 
rapid dissolution with around 40% of the total powder being dissolved in the first minute. 
This could be as a result of the apparent amorphous nature of the powders. Amorphous 
powders have a higher Gibbs free energy, and therefore a higher dissolution and solubility 
than the crystalline form of the same powder (Kanaujia et al., 2015, Khadka et al., 2014). 
As the salbutamol octanoate had a significantly higher logD7.4 than salbutamol base (-
0.630 vs. -1.386, respectively) it was expected that the octanoate formulation might have a 
slower rate of dissolution, however this was not the case. The dissolution of the octanoate 
formulation was the same as for the base until 30 minutes, when significantly more of the 
total salbutamol was found in solution for the octanoate formulation. This could also be 
attributed to the apparent amorphous nature of the powders and might suggest that a 
more dramatic change in lipophilicity would be required to significantly alter dissolution of a 
Using Ion-pairs to Control Salbutamol Delivery to the Lungs 
 
 
Chapter 5 – The Effect of Ion-pairing on the In vitro and In vivo Behavior of Salbutamol 
209 
spray dried ion-pair formulation. Each of the powders adhered to the Korsmeyer-Peppas 
model (R2 values = 0.9942, 0.9927 and 0.9678 for salbutamol base, octanoate, and 
phytate formulations, respectively). The Korsmeyer-Peppas model is given by the following 
equation: 
Mt/M∞ = Kt
n                                                                                                                                       [Equation 5.2] 
 
Where Mt/M∞ is the fraction of drug released at time t, K is the release rate constant, and n 
is the release exponent. 
When dissolution data up to 60% dissolution is fitted to this equation the release exponent 
describes the mechanism of release (Dash et al., 2010, Carbinatto et al., 2014). For 
spherical particles a release exponent of less than 0.43 describes Fickian diffusion, 0.43 – 
0.85 describes anomalous transport and greater than 0.85 is Case II transport (Carbinatto 
et al., 2014). The calculated release rate constants were 32.1034, 39.5820, and 44.7649 
for salbutamol base, octanoate, and phytate, respectively. The release exponents were 
0.2036, 0.2438 and 0.1949 for salbutamol base, octanoate and phytate, respectively, so 
each of the powders dissolved according to Fickian diffusion. Fickian diffusion can be 
described by a single parameter: the diffusion coefficient (Ritger and Peppas, 1987).  
The variability in the in vivo results was unexpected. Previous studies have shown that 
there is significant variability in the guinea pig’s response to histamine induced bronchial 
reactivity (DOUGLAS et al., 1973), however the use of each animal as its own control 
should minimize this variability in results. Therefore the variability observed in the results 
of this study may be due to external factors, such as changing room temperature, and 
therefore animal body temperature over the 3 hour experiment time. 
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In the animal model, administration of salbutamol base spray dried powder (1.5 μg/kg) via 
nebulization resulted in a diminished response to histamine at 30, 60 and 120 minutes. 
The protective effect of salbutamol appeared to be most pronounced at 60 minutes post 
administration, which would be expected as the bronchodilation effects of salbutamol 
following inhalation are known to peak at around 1 – 2 hours (Imboden and Imanidis, 
1999). After administration of the salbutamol phytate solution there was a significant 
decrease in response to histamine at 60 and 120 minutes, whereas the response to 
histamine challenge after administration of the phytate control solution appeared to be 
greater than the control at 30 and 120 minutes. At 120 minutes post phytate control 
administration 2 of the 3 animals tested exhibited a percentage increase in lung resistance 
of over double what was seen prior to nebulization which would suggest that phytate is 
having a negative effect on the guinea pig’s response to histamine. This may be caused by 
the action of phytic acid on other cells present in the lung as phytic acid has been shown 
to play a role in the respiratory burst of neutrophils (Eggleton et al., 1991). Respiratory 
burst is the production of reactive oxygen species that are strongly antimicrobial, but can 
also cause damage to surrounding lung tissue and causing the cell death of other immune 
cells (Dahlgren and Karlsson, 1999). Previous work has shown that although incubation of 
human neutrophils with phytic acid alone had no effect on the production of reactive 
oxygen intermediates, it caused an increased response to subsequent stimulus (Eggleton 
et al., 1991). Furthermore, high concentrations of histamine have been shown to act as a 
stimulus, causing equine neutrophils to generate the reactive oxygen species which in turn 
causes histamine release (Benbarek et al., 1999). It therefore might be the case that the 
level of histamine present in the lungs of animals that were given phytate could be higher 
than those who weren’t, which could explain why there was no difference in the response 
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to histamine at 30 minutes post salbutamol phytate administration. Further testing could be 
completed to assess whether this is the cause of the increased response to histamine in 
the phytate control animals. If this was the case, it could be beneficial to use a metabolite 
of phytic acid as a counter ion in ion-pairing, as the smaller inositol phosphates had a 
greatly reduced effect on respiratory burst (Eggleton et al., 1991). 
5.5 Conclusion 
In conclusion, all 8 counter ions, lactose, and PVP were shown to be well tolerated by 
Calu-3 human bronchial cells at concentrations they might be found at after powder 
inhalation. The salbutamol sulfate, gluconate and phytate ion-pairs were shown to 
significantly reduce the rate of salbutamol transport through an air-liquid interface grown 
Calu-3 monolayer. There was no significant difference in the dissolution of the salbutamol 
octanoate or phytate spray dried powders when compared with the base and there was no 
significant difference in the bronchoprotective effect of salbutamol base or salbutamol 
phytate over a 3 hour time period. The results in this chapter indicate that ion-pairing could 
be used as a strategy to prolong drug action for salbutamol, but that the choice of counter 
ion is crucial. 
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The respiratory system provides an attractive route of drug administration for both locally 
and systemically acting medicines. Therapeutics agents that work in the lung benefit from 
rapid onset of action, and high local concentrations which can minimize systemic side 
effects. Furthermore the large surface area and extensive network of blood vessels that 
serve the alveolar region allow for absorption of small molecules and macromolecules in to 
the systemic circulation at a therapeutically relevant concentration (Patton and Byron, 
2007). With the added advantage of pulmonary drug delivery being non-invasive, the 
benefits of designing a medicine to be inhaled are obvious. However, there are also some 
challenges associated with pulmonary drug delivery. Most notably, many inhaled drug 
molecules suffer from a very short duration of action due to the rapid absorption and 
clearance from the lung tissue (Labiris and Dolovich, 2003a). The result of this is that 
these medicines need to be taken frequently, leading to poor patient compliance (Patton 
and Byron, 2007). Therefore an inhaled formulation which could avoid, but not harm, the 
lung’s clearance mechanisms could improve the delivery of many current inhaled therapies 
by prolonging drug action and make the pulmonary route viable for other drug molecules.  
The use of ion-pairs in an inhaled formulation is one strategy that has the potential to 
extend a drug’s residence time in the lung. The main benefit of using an ion-pair is that the 
physical and biopharmaceutical properties of a drug can be altered without having to 
chemically modify the structure of the molecule. There have been many studies that have 
used ion-pairing to alter the properties of drugs given via the transdermal, ocular and oral 
routes; however there has been very little study of how this strategy might be used in an 
inhaled formulation (Song et al., 2012, Li et al., 2017, Patel et al., 2016). Furthermore, the 
lungs could be an ideal site for an ion-pairing strategy to work as any inhaled particles 
would contact with a relatively small volume of liquid, which would encourage the 2 ions in 
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the formulation to remain as a complex. When designing an ion-pair formulation for inhaled 
drug therapy there are some considerations that need to be taken in to account. Firstly, the 
charged drug molecule needs to bind to a counter ion with enough strength that it would 
not immediately dissociate when diluted in the fluid lining the lung. The chosen counter ion 
in the formulation needs to be highly biocompatible as it would be present in the 
formulation in an excess to promote the formation of the ion-pair. The ion-pair complex 
would need to be able to be incorporated in to a formulation that could deliver it to the 
correct site in the lungs, and it would need to alter the properties of the drug molecule in a 
way that could prolong its residence time in the lung.  
The aim of the work presented in this thesis was to investigate the potential of ion-pairs to 
prolong drug action in the lungs. To achieve this salbutamol was chosen as the model 
drug, as it is known to be positively charged at physiological pH. The major findings of this 
work were that salbutamol formed an ion-pair with a range of hydrophilic and hydrophobic 
counter ions, the ion-pair complexes could be incorporated in to a dry powder formulation 
without adverse effects on the aerosolization of the powders, and the ion-pair complexes 
could alter the transport of salbutamol through an epithelial cell monolayer.     
In Chapter 2, salbutamol was shown to bind to several different counter ions via 2 methods 
of analysis. The 7 counter ions that were analyzed were chosen as they had all been 
previously used in medical formulations, and they had a range of logP values, as well as 
differing numbers of sites capable of hydrogen bonding. Association constants were 
calculated from both the FTIR and HPLC methods of analyzing the ion-pair complex. It 
was found that weaker ion-pair complexes were formed between salbutamol and the small 
sulfate ion (pKa = 1.57 and 2.37 for FTIR and HPLC, respectively) in comparison with 
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molecules that had greater potential for hydrogen bonding, such as the gluconate counter 
ion (pKa = 2.27 and 2.62 for FTIR and HPLC, respectively), and the more lipophilic 
octanoate counter ion (pKa = 2.56 and 3.40 for FTIR and HPLC, respectively). The 2 
methods of characterizing the ion-pairs gave different absolute values for association 
constants, but seemed to show the same trend. In future work the binding of salbutamol 
and these counter ions could be further investigated using NMR (Nie et al., 2015, 
Dezhampanah and Chokami, 2014). The use of multiple techniques to study an ion-pair 
complex could give more information on how the 2 ions bind together and how they 
interact with their environment.  
Speciation software predicted that at a drug concentration of 0.00209 M and using 20:1 
counter ion – drug ratios that at least 90% of the salbutamol would be found in ion-pair 
form for each of the counter ions. Under these conditions over 99% of salbutamol was 
predicted to be in ion-pair form for the glucoheptonate, benzoate and fumarate ion-pairs. 
Consequently, this ratio of drug to counter ion was chosen to assess the influence of the 
ion-pairs on the partitioning of salbutamol across a water-octanol interface. It was found 
that the LogD7.4 value of salbutamol base was -1.386, indicating that at physiological pH 
the majority of the drug is found in the aqueous compartment. There was no significant 
difference in the LogD7.4 value of the salbutamol sulfate ion-pair (-1.405) compared to 
salbutamol. This was unexpected as previous studies in to the difference in cell transport 
of salbutamol base and sulfate have found that the rate of sulfate transport is significantly 
lower and this has previously been attributed to the difference in lipophilicity (Haghi et al., 
2012). There was also no significant difference in the partitioning of the gluconate ion-pair 
compared to the salbutamol parent molecule (LogD7.4 = -1.241). The glucoheptonate ion-
pair had a significantly lower LogD7.4 (-1.845) and the octanoate ion-pair had a significantly 
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higher value (-0.630). It was therefore predicted that the glucoheptonate ion-pair would 
have a lower rate of transport than salbutamol and the octanoate ion-pair would have a 
higher rate of transport.  
The presence of micelles in the salbutamol octanoate solution was investigated due to the 
surfactant nature of the counter ion. The concentrations of the counter ions used in the 
partitioning study, and in any potential formulation, were below the literature CMC value of 
300 mM (Stanley et al., 2009), however it was unknown whether the ion-pairing might 
affect this. PCS was used to assess the difference in light intensity in comparison with a 
salbutamol sulfate control. There were no differences found, and so it was assumed that 
any octanoate would be free and available to bind to the salbutamol.  
The work in Chapter 3 examined the suitability of phytic acid and its derivatives for ion-
pairing with salbutamol. Phytic acid is a natural compound found in many cereals, legumes 
and nuts, so its potential for biocompatibility are high (Graf et al., 1987). Furthermore, it is 
known to be able to strongly bind to positively charged metals such as zinc (Hurrell, 2003). 
These properties make it an extremely interesting compound for use in an ion-pairing 
strategy, as it may be able to form functional ion-pairs with drug molecules. A potential 
method by which ion-pairing with phytic acid could decrease the rate of transport of a 
molecule is by increasing the molecular weight of the complex as phytic acid has a 
relatively high molecular weight (MW 660.04 g/mol). Enzymatic derivatives of phytic acid, 
such as IP3, are smaller inositol phosphates, which should retain their chelating ability. 
Therefore IP3 was chosen alongside phytic acid to compare their binding with salbutamol 
and how this might affect drug transport.  
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IP3 is a commercially available molecule, however it is extremely expensive. Therefore in 
order to properly assess its binding with salbutamol, and if it were to be incorporated in to 
an inhaled formulation, a method of producing adequate quantities of the compound 
needed to be established. Synthesis of IP3 from a myo-inositol starting material was 
attempted. Unfortunately, a clean sample of the IP3 end product was not generated as the 
final step in the synthesis failed. Future work could look into different conditions to succeed 
in this final synthetic step, or another route of synthesis altogether. It might also be 
possible to generate IP3 via an enzymatic degradation of phytic acid, although preliminary 
work suggested that chemical synthesis may have the highest potential for yielding a 
larger quantity of clean material.  
FTIR and HPLC binding analysis of salbutamol phytate showed that the binding of 
salbutamol and phytate was much stronger than with any of the counter ions that had been 
investigated in Chapter 2 as 100% binding occurred at around a 10x lower counter ion 
concentration. 100% of salbutamol in salbutamol phytate was bound at 0.005 M phytate 
concentration, whereas 100% of salbutamol in salbutamol octanoate bound was at 0.05 M 
octanoate concentration by FTIR analysis. The calculated association constants (4.15 and 
5.38 for FTIR and HPLC analysis, respectively) were also much higher than any calculated 
for the counter ions analyzed in Chapter 2. Therefore speciation software predicted that 
almost 100% of salbutamol would be found in ion-pair form for even a 10:1 counter ion – 
drug ratio.  
The partitioning of the salbutamol phytate ion-pair did not significantly differ from 
salbutamol base alone (-1.211 vs. -1.386 for salbutamol phytate and base, respectively), 
therefore it was hypothesized that any change in the transport of salbutamol in the phytate 
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ion-pair would be due to the difference in size of the complex or its hydrogen bonding 
potential (Ma and Hadzija, 2012, Tronde et al., 2008).  
The sulfate, gluconate, octanoate and phytate ion-pairs were incorporated in to a spray 
dried powder formulation with lactose (Chapter 4) and the generated particles were 
spherical and under 4 μm in size. The gluconate, octanoate and phytate ion-pair powders 
all had a significantly smaller particle size by laser diffraction (2.57, 3.28 and 3.26 μm, 
respectively) than the base alone or sulfate ion-pairs (3.68 and 3.61 μm respectively), 
which resulted in them having a smaller MMAD value and therefore being better 
aerosolized (MMAD values: base = 6.30, sulfate = 6.24, gluconate = 4.85, octanoate = 
4.85, phytate = 4.93 μm). Furthermore all powders were homogenous in terms of 
salbutamol content. This suggested that a dry powder formulation could be a suitable way 
to deliver ion-pairs to the lung as the excess of ion present in the powder did not 
detrimentally affect the aerosolization or cause an increased retention of the powder in the 
inhaler (Wong et al., 2014). The spherical nature of the particles suggested that they are 
amorphous, however this could not be confirmed by DSC due to the complexity of the 
powders (Knopp et al., 2016). In future work this could be overcome by use of techniques 
such as powder x-ray diffraction (PXRD) to confirm whether the powder is amorphous or 
not.  
Addition of PVP in to the spray dried solution resulted in significantly smaller particles for 
the salbutamol octanoate and phytate formulations; it also resulted in a dimpled 
appearance to the particles.  The sulfateP and octanoateP formulations had a significantly 
lower MMAD value than their counter ion only powders, but also had a lot more powder 
retained in the inhaler. The stability of the powders after one month was improved by the 
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addition of PVP for the octanoate and phytate powders stored at RT and for all the counter 
ion powders stored at 4oC. This work showed that successful storage, at least short-term, 
can be achieved for spray dried ion-pair powders. Future work could assess the use of 
other polymers and the optimal concentration at which they can be incorporated in to the 
powder for maximum stability, as well as testing the stability of the powder over 3, 6 and 
12 months. 
Inclusion of l-leucine in the formulations brought about a significant decrease in the MMAD 
and increase in FPF for the sulfate ion-pair formulation (5.19 μm and 34.93%, 
respectively). Unexpectedly there was no improvement in aerosolization for the gluconate, 
octanoate or phytate formulations. This could be as a result of leucine not presenting on 
the surface of the particle as has been found in other studies (Mangal et al., 2015, Chen et 
al., 2012). The addition of leucine also resulted in the generation of chemically stable 
formulations for all counter ions after 1 month at both room temperature and 4oC which 
would indicate that its addition in to an ion-pair inhaled formulation could be beneficial 
even if it did not improve the aerosols dispersion.    
In Chapter 5 the Calu-3 human bronchial cell line was used as a model of the pulmonary 
epithelium to assess the compatibility and transport of the ion-pairs (Grainger et al., 2006).  
Due to the counter ions being present in a great excess in the powder formulations, it was 
thought to be very important that they are biocompatible with the lung epithelium. All 
counter ions were found to be well tolerated in the study, with IC50 values ranging from 
38.1 mg/mL for sodium gluconate to 1.7 mg/mL for sodium octanoate. The excipients were 
also very well tolerated with IC50 values of 41.4 mg/mL for PVP and 88.6 mg/mL for 
lactose. These data indicated that a 500 fold increase in concentration is needed to reach 
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the IC50 value of sodium octanoate based on the even distribution of a 20 mg dose of 
powder in the bronchiolar region. All of the counter ions and excipients tested were 
therefore tolerated well over the concentration that they might be found in the lung, 
especially considering that the toxicity test performed on discrete cells would be much 
more sensitive than whole tissue (Korting et al., 1994).  
The sulfate, gluconate and phytate ion-pairs all significantly reduced the rate of transport 
of salbutamol across an air-liquid grown Calu-3 monolayer which indicated that these 
counter ions could be used to create a system for salbutamol that limits the transport of the 
drug to prevent rapid clearance whilst prolonging drug action (Patton and Byron, 2007). As 
none of these ion-pairs altered the partitioning of salbutamol between octanol and water 
(Chapter 2) it was thought that the reduction in rate of transport was due to a change in the 
percentage polar surface area or hydrogen bonding capability of the complex compared 
with the drug alone (Tronde et al., 2008). Although the octanoate ion-pair did alter the 
partitioning of salbutamol it did not significantly change the transport of salbutamol.  
Another method of prolonging the action of salbutamol would be to limit the rate of 
dissolution (Borghardt et al., 2015). As the octanoate ion-pair was more hydrophobic in the 
partitioning study and the phytate ion-pair altered the transport and had the highest 
association constant of any of the ion-pairs these were chosen to assess the dissolution. 
There was no difference in the dissolution of these powders when compared with the 
salbutamol base powder.  This might be expected as all the powders appear to be 
amorphous, and amorphous powders rapidly dissolve due to their increased Gibbs free 
energy (Kanaujia et al., 2015). These data could indicate that spray drying might not be an 
ideal method to create an inhalable powder if alteration of the dissolution of the powder is 
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desired as it often produces amorphous powders (Singh and Van den Mooter, 2016). The 
production of a crystalline inhalable ion-pair powder that could limit the rate of dissolution 
of a drug could be achieved by using supercritical fluid precipitation techniques or a 
mechanofusion process (Begat et al., 2009). 
The phytate ion-pair was tested in vivo in a guinea pig model after administration as a 
nebulized solution in Chapter 5. Due to experimental limitations the formulations were not 
given as a dry powder. At the dose given (1.5 μg/kg salbutamol) salbutamol base gave a 
significantly lower response to histamine challenge at 30, 60 and 120 minutes after drug 
administration when compared with their response prior to the drug being given. 
Salbutamol phytate gave a significantly lower response at 60 and 120 minutes post drug 
administration. A solution of dipotassium phytate, lactose and PVP appeared to give an 
increased response to histamine at 30 and 120 minutes, which could have been due to a 
priming effect of phytate on neutrophils leading to a respiratory burst (Eggleton et al., 
1991). This demonstrates the importance of counter ion choice in an ion-pairing 
formulation and also the importance of in vivo testing to know how formulations affect 
whole systems rather than just specific cell lines. Furthermore there was a lot of variability 
between animals for all 3 of the test solutions (salbutamol base, salbutamol phytate and 
phytate control). Because of this statistical testing for differences was difficult and further 
testing would be required to be able to definitively state whether there were significant 
differences between the test solutions or not. Future work would also administer the ion-
pairs as a dry powder to the animals to fully investigate whether the high local 
concentration achieved by this method could affect the duration of drug action.
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Figure 6.1 - Schematic of main findings of current work. 1. Salbutamol forms ion-pairs with negatively charged counter ions at physiological pH. 
2. All the counter ions tested had suitable tolerability levels by epithelial cells. 3. Ion-pairs were incorporated in to a dry powder formulation that 
was in the inhalable range and stable over 4 weeks. 4. Ion-pairs can modify drug transport through an epithelial cell monolayer
3. Ion-pairs were 
successfully 
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6.1 Future work 
The immediate area of work in this thesis that should be expanded is the in vivo study. The 
small number of animals used in the work in Chapter 5 meant that statistical differences 
could not be found. This was expected as there can be large inter animal variations in 
response to compounds, salbutamol and histamine, the challenge, and so a larger sample 
set is needed to fully understand the effect that the ion-pair formulation has in comparison 
to salbutamol base alone. Furthermore it is important to understand the increased 
response to histamine seen in some animals given the phytate control solution. 
Establishing whether this is a real reaction, perhaps due to an allergy, is essential to 
determining whether phytic acid is a safe and suitable compound to be used in an inhaled 
formulation. Furthermore, delivery of the ion-pair formulations to animals as a dry powder 
should be investigated. Although the work in Chapter 5 suggests that there are no 
differences in dissolution of the ion-pair powders when compared to the base, 
administration of the ion-pairs in powder form could mean that there is an increased 
concentration at the site of deposition and so salbutamol and the counter ion would be 
more likely to be found in ion-pair complex form which could accentuate any prolonged 
effect the ion-pair has. 
In terms of the ion-pair powders, further optimization of the spray drying method could 
decrease the resulting particle size of the formulations which could augment the fraction of 
the powder that reaches the lung when inhaled. It would also be beneficial to test the 
powders using XRPD to confirm their amorphous nature, and stability studies carried out 
over 12 months could determine the effect of an excess concentration of ions in a powder 
intended for inhalation over a prolonged period of time. The results in Chapter 4 of this 
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thesis indicate that the inclusion of l-leucine in the spray dried formulation resulted in an 
increased stability and better powder flow for many of the ion-pairs tested, however it was 
excluded from the powders that were tested in vivo due to its zwitterionic nature at 
physiological pH. Further work could examine whether its inclusion in a dry powder 
formulation would have a deleterious effect on the action of an ion-pair, or perhaps an 
amino acid could be employed in an ion-pair formulation as both the counter ion for an ion-
pair complex and to improve the aerosolisability of the powder.  
Finally, the effect of ion-pairing on other inhaled medicines could be tested. In this study 
salbutamol was used as a model drug as it is a well-documented molecule with a short 
duration of action. However, one of the draws of an ion-pairing formulation is that 
physicochemical properties of drug molecules can be altered without the need to change 
the chemical structure, and taking that further there is a potential to find a counter ion that 
prolongs the duration of action of multiple different inhaled medicines. Investigation in to 
the ion-pairing of other inhaled medicines could establish whether the strategy can be 
used for useful for other molecules and whether there is one counter ion that can bind to 
and cause the prolonged action of numerous APIs. 
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6.2 Conclusion 
Overall the work in this thesis has shown that ion-pairing charged drug molecules with 
counter ions have potential for creating a formulation that prolongs drug action in the 
lungs. Ion-pairs can be formed with a range of small molecules which are well tolerated by 
lung epithelial cells. These ion-pairs have the potential to alter physicochemical properties 
of drug molecules such as logD7.4 and transport across an epithelial barrier. Ion-pairs can 
be incorporated in to a dry powder formulation for delivery to the lungs with no negative 
effects on the aerosolization of the powder. The data in this thesis has also highlighted the 
importance of counter ion choice, as each ion-pair complex will interact with the lung 
environment differently and some may not bring about the necessary changes to prolong 
the duration of drug action. Using ion-pairs is a promising method of prolonging drug 
action in the lungs and further work in a whole lung or animal model is needed to fully 
realize this.  
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